



LUPUS & KCR 2023

www.lupus-kcr2023.org

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium

May 17 (Wed) - 20 (Sat), 2023 | Coex, Seoul, Korea

Program Book



Hosted by

Korean Society of Systemic Lupus
Erythematosus Research



대한류마티스학회
Korean College of Rheumatology

Supported by



KOREA
TOURISM
ORGANIZATION



SEOUL METROPOLITAN
GOVERNMENT



Welcome Address 04

Program at a Glance 08

LUPUS & KCR 2023 Highlight 12

Floor Plan 14

Invited Faculty 18

Scientific Program

Day 1: May 17 (Wed) 28

Day 2: May 18 (Thu) 34

Day 3: May 19 (Fri) 50

Day 4: May 20 (Sat) 68

Short Oral Presentation 82

E-poster Presentation 94

Organizing Committee 118

Sponsorship 124



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



Welcome Address of Congress Chair



Dear colleagues and friends,

On behalf of the Organizing Committee, it is my great pleasure and honor to invite you to the 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023). It will be held in Seoul, Korea from May 17th to 20th, 2023, co-hosted by Korean Society of Systemic Lupus Erythematosus Research (KSSR) and the Korean College of Rheumatology (KCR).

It is the first time that Korea has been given the honor of hosting this prestigious event and the fifth time the event has been hosted in the Asia-Pacific region after Singapore, Israel, China, and Australia.

“Stairway to the End of the War” is the theme of LUPUS & KCR 2023. It has multiple meanings, one of which is aiming to end the war on rheumatic diseases including SLE. We are hoping that it will also mean the end of war on COVID19 through which the participants could attend the meeting in person. It will gather a huge audience of more than 2,000 participants of rheumatologists from all over the world and world-renowned experts in rheumatic diseases on basic and clinical science.

KSSR is a professional membership organization composed of Korean rheumatologists who have a particular interest in SLE under the KCR. We have been managing most Korean SLE patients and actively performing both basic and clinical research. With over 1,000 members in Korea, KCR is an organization that represents health professionals and scientific societies related to the field of rheumatology. It has contributed to the advancement and promotion of rheumatology in Korea since 1981 and has successfully hosted the annual KCR international symposium since 2006 to strengthen collaboration on rheumatology both domestically and internationally.

This joint meeting of LUPUS & KCR 2023 will expand the scope of programs and topics encompassing and maximizing impacts and synergies. It will be the perfect meeting where you can present your products, discuss with world renowned basic and clinical researchers specialized in rheumatic diseases so that you can connect and collaborate with experts.

I look forward to welcoming you in Seoul in 2023.

With warmest regards

Sang-Cheol Bae, MD, PhD, MPH

Congress Chair, LUPUS & KCR 2023

President, 15th International Congress on Systemic Lupus Erythematosus

President, Korean College of Rheumatology

Welcome Address of Chairman of the Board of Directors



Dear colleagues and friends,

On behalf of the Organizing Committee, it is my great honor to invite you to the 15th International Congress on Systemic Lupus Erythematosus and the 43rd Korean College of Rheumatology Annual Scientific Meeting & 17th International Symposium (LUPUS & KCR 2023).

Since 1981, members of KCR have been dedicated to the treatment and research of rheumatic diseases through clinical, basic, and translational research. In May of 2022, KCR successfully organized its annual congress in a hybrid format. Despite the unpredictable circumstances, 922 participants from 35 countries engaged and exchanged their knowledge and experience in KCR 2022.

As we host this joint congress with the International Congress on Systemic Lupus Erythematosus (SLE), which is the leading international meeting on SLE, we believe this collaboration could generate significant academic synergy.

We hope you actively engage in various sessions filled with valuable lectures by world-renowned speakers. Especially, we have organized a series of sessions : Plenary Session, Keynote Lectures, Joint Symposium, and International Symposium. I look forward to these sessions that will help you update knowledge and catch up with the latest trends in the field of rheumatology.

The organizing committee is filled with anticipation that we will hold the first in-person congress after an outbreak of a pandemic. As much as we are excited to see the speakers and audiences in person, we also promise to provide wholehearted support for organizing a safe and convenient congress.

I am looking forward to welcoming all of you face-to-face, in Seoul, in 2023.

My warmest regards,

Shin-Seok Lee, MD, PhD

Chairman of the Board of Directors,
Korean College of Rheumatology

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



Program at a Glance













DAY 1. | May 17 (Wed)

(*) Marked session provides the ENG-KOR simultaneous interpretation.

LUPUS								
Time	Auditorium (3F)	Grand Ballroom 101 (1F)	Grand Ballroom 102 (1F)	Grand Ballroom 103 (1F)	Grand Ballroom 104 (1F)	Grand Ballroom 105 (1F)	Conference Room 205 (2F)	Conference Room 209 (2F)
08:00 - 08:30								
08:30 - 09:00								
09:00 - 09:30								
09:30 - 10:00								
10:00 - 10:30								
10:30 - 11:00								
11:00 - 11:30								
11:30 - 12:00								
12:00 - 12:30								
12:30 - 13:00								
13:00 - 13:30								
13:30 - 14:00								
14:00 - 14:30								
14:30 - 15:00								
15:00 - 15:30				APLAR - LUPUS Joint Symposium Emerging Issue in Asia-Pacific Region : Infections and Lupus		Pre-conference Workshop T2T: Defining LDA and Remission	Pre-conference Workshop Disease Activity and Damage Measures in Clinical Practice	
15:30 - 16:00								
16:00 - 16:30								
16:30 - 17:00								
17:00 - 17:30	Opening Session & Key Note Lecture * "The FoUr"							
17:30 - 18:00								
18:00 - 18:30								
18:30 - 19:00	Welcome Reception							
19:00 ~								









DAY 2. | May 18 (Thu)

(*) Marked session provides the ENG-KOR simultaneous interpretation.










LUPUS					KCR									
Time	Auditorium (3F)	Grand Ballroom 101 (1F)	Grand Ballroom 102 (1F)	Conference Room 205 (2F)	Grand Ballroom 103 (1F)	Grand Ballroom 104 (1F)	Grand Ballroom 105 (1F)	Conference Room 209 (2F)						
08:00 - 08:30		Breakfast Symposium 1 			Breakfast Symposium 2 	Breakfast Symposium 3 	Breakfast Symposium 4 							
08:30 - 09:00					Presidential Plenary Session *									
09:00 - 09:30		Meet the Professor 1 B Cell Therapy for Difficult Lupus Cases	Meet the Professor 2 Cutaneous Lupus	Meet the Professor 3 Antiphospholipid Syndrome										
09:30 - 10:00														
10:00 - 10:30	Coffee Break													
10:30 - 11:00	Plenary Session 1 SLE: Year in Review				Year in Review (Clinical)	Year in Review (Basic)		Musculoskeletal US Workshop I - Advanced Course						
11:00 - 11:30														
11:30 - 12:00														
12:00 - 12:30		Luncheon Symposium 1 			Luncheon Symposium 2 	Luncheon Symposium 3 	Luncheon Symposium 4 							
12:30 - 13:00					APLAR-KCR Joint Symposium Career Development of Young Rheumatologists in the APLAR Region	COVID-19 in Health and Autoimmunity	KCR Research Foundation Session							
13:00 - 13:30		Concurrent Session 1 Global Challenges	Concurrent Session 2 Biomarkers from Bench to Bedside						Alliance Session 1 * Improving Lupus Outcomes through Patient Education					
13:30 - 14:00														
14:00 - 14:30														
14:30 - 15:00	Poster Viewing & Coffee Break Short Oral Presentation: Grand Ballroom 101, 102, Conference Room 206 A+B Auditorium Meeting Room A, B, C			Meet the Mentor 1 Room 205B	Poster Viewing & Coffee Break									
15:00 - 15:30														
15:30 - 16:00	Plenary Session 2 Disease Mechanism				International Symposium 1 For Better Management of Systemic Sclerosis		Basic Research Workshop for Rheumatologist Translational Research of Rheumatic Diseases	Musculoskeletal US Workshop II - Basic Course						
16:00 - 16:30							Clinical Research Workshop for Rheumatologist Finding Biomarkers							
16:30 - 17:00					International Symposium 2 Management of Systemic Vasculitis									
17:00 - 17:30	Concurrent Session 3 Management Recommendations	Concurrent Session 4 Cytokines and Cell Signaling	Alliance Session 2 * Rheumatic Diseases Around the World	Patient Session 1 * Best Practice in the Management of SLE										
17:30 - 18:00														
18:00 - 18:30										Evening Symposium 1 				
18:30 - 19:00	Satellite Symposia Harmony Ballroom in InterContinental Seoul Coex Hotel 	Evening Symposium 2 *												
19:00 - 19:30														
19:30 - 20:00														
20:00 - 20:30														
20:30 - 21:00														

DAY 3. | May 19 (Fri)

(*) Marked session provides the ENG-KOR simultaneous interpretation.

LUPUS					KCR				
Time	Auditorium (3F)	Grand Ballroom 101 (1F)	Grand Ballroom 102 (1F)	Conference Room 205 (2F)	Grand Ballroom 103 (1F)	Grand Ballroom 104 (1F)	Grand Ballroom 105 (1F)	Conference Room 209 (2F)	
08:00 - 08:30		Breakfast Symposium 5 			Breakfast Symposium 6 	Breakfast Symposium 7 	Breakfast Symposium 8 		
08:30 - 09:00					KCR Keynote Lecture I *				
09:00 - 09:30									
09:30 - 10:00		Meet the Professor 4 SLE and Infection	Meet the Professor 5 Precision Medicine						Meet the Professor 6 Managing Lupus Pregnancy
10:00 - 10:30	Coffee Break								
10:30 - 11:00	Plenary Session 3 Novel Treatments and Strategy		Special Lecture COVID-19 and LUPUS		International Symposium 3 Rheumatoid Arthritis-Associated Interstitial Lung Disease	Free Paper Session 1 Osteoarthritis & Orthopedics	Free Paper Session 2 Vasculitis & Metabolic Bone Disease		
11:00 - 11:30									
11:30 - 12:00									
12:00 - 12:30		Luncheon Symposium 5 			Luncheon Symposium 6 	Luncheon Symposium 7 	Luncheon Symposium 8 		
12:30 - 13:00									
13:00 - 13:30	Concurrent Session 5 Comorbidities	Concurrent Session 6 New Treatments	Alliance Session 3 * Global Collaboration to Overcome Health Care Disparities		International Symposium 4 Urate-Lowering Benefits and Risks on Comorbidities	Free Paper Session 3 Spondyloarthritis	Free Paper Session 4 Epidemiology & Health Service Research		
13:30 - 14:00									
14:00 - 14:30									
14:30 - 15:00	Poster Viewing & Coffee Break Short Oral Presentation: Room 205 A, B, Room 206 A+B Auditorium Meeting Room A, B, C				Poster Viewing & Coffee Break			Meet the Mentor 2 Room 209A	Meet the Mentor 3 Room 209B
15:00 - 15:30									
15:30 - 16:00	Plenary Session 4 Practical Treatment Issues				International Symposium 5 Stratification of Patients with Primary Sjögren's Syndrome	Free Paper Session 5 Rheumatoid Arthritis – Clinical Research I	Medical Humanities Program		
16:00 - 16:30						Free Paper Session 6 Rheumatoid Arthritis – Clinical Research II			
16:30 - 17:00									
17:00 - 17:30	Concurrent Session 7 Pregnancy and Reproductive Issues	Concurrent Session 8 Omics and Breakthrough Technology	Alliance Session 4 Grants and Funding for SLE Research	Patient Session 2 * Living and Coping with Lupus	Academic Awards				
17:30 - 18:00									
18:00 - 18:30					General Assembly				
18:30 - 19:00									
19:00 ~	Gala Dinner								

DAY 4. | May 20 (Sat)

LUPUS					KCR				
Time	Auditorium (3F)	Grand Ballroom 101 (1F)	Grand Ballroom 102 (1F)	Conference Room 205 (2F)	Grand Ballroom 103 (1F)	Grand Ballroom 104 (1F)	Grand Ballroom 105 (1F)	Conference Room 209 (2F)	
08:00 - 08:30		Breakfast Symposium 9 			Breakfast Symposium 10 	Breakfast Symposium 11 	Breakfast Symposium 12 		
08:30 - 09:00					KCR Keynote Lecture II				
09:00 - 09:30									
09:30 - 10:00		Meet the Professor 7 Musculoskeletal Diseases in SLE	Meet the Professor 8 Lupus Nephritis	Meet the Professor 9 Pulmonary Hypertension					
10:00 - 10:30	Coffee Break								
10:30 - 11:00	Plenary Session 5 Clinical Challenges : Diagnosis and Outcome Measures				International Symposium 6 The Evolution of Fibromyalgia, its Concepts, and Treatment	Free Paper Session 7 Basic and Translational Research	Free Paper Session 8 Miscellaneous Rheumatic Disease and Inflammatory Disease		
11:00 - 11:30						Luncheon Symposium 10 	Luncheon Symposium 11 		Luncheon Symposium 12 
11:30 - 12:00									
12:00 - 12:30		Luncheon Symposium 9  			International Symposium 7 Chondrocyte Metabolism and Osteoarthritis	Free Paper Session 9 COVID-19 infection in Autoimmune Rheumatic Diseases	Free Paper Session 10 Sjögren's Syndrome, Systemic Sclerosis & Inflammatory Myositis		
12:30 - 13:00									
13:00 - 13:30	Concurrent Session 9 Targeting Organs	Concurrent Session 10 Immune Cells	Concurrent Session 11 Antiphospholipid Syndrome						
13:30 - 14:00									
14:00 - 14:30									
14:30 - 15:00	Poster Viewing & Coffee Break Short Oral Presentation: Room 205 A, B, Room 206 A+B Auditorium Meeting Room A, B				Poster Viewing & Coffee Break			Meet the Mentor 4 Room 209A	
15:00 - 15:30									
15:30 - 16:00	LUPUS 2023 Congress Highlights				International Symposium 8 Managing Spondyloarthritis: Where are We Now	Editorial Committee Workshop	Coding and Insurance Guideline in Rheumatic Disease		
16:00 - 16:30									
16:30 - 17:00									
17:00 - 17:30	Closing Session & Awards				KCR Presentation Awards & Closing				
17:30 - 18:00									

Scan Here!



Visit our official web platform to
explore and connect with
LUPUS & KCR 2023!

Scan the QR code and visit our official web platform
where you can explore our program & speakers,
search and like e-posters, and make connections!

You can log-in with the same ID and password
information of our website.



Don't miss out on
LUPUS & KCR 2023
official giveaways!

You may receive the conference bag and the USB
card with the official artwork and the logo when you
claim your name badge at the registration desk.



Get all stamps from our sponsors'
exhibition booths and
get a special gift!

Visit all of our sponsors' exhibition booths, located on
the 1st floor lobby in front of the Grand Ballroom and
the 2nd floor exhibition area, and gather the stamps!

When you complete the stamp tour, visit the Kit Desk
on the 1st floor and a special gift is awaiting.



Visit E-poster Zone on the 2nd floor
and push "Like" on
your favorite one!

For the most liked E-posters, there will be a prize!
Go on and check out LUPUS & KCR 2023 E-posters
and "Like" your favorite ones.

You can also "Like" the E-posters on our
official web platform.

평점 관련 유의사항

1. LUPUS & KCR 2023은 대면 학술대회로, 현장에 참석하신 경우에만 평점이 인정됩니다.
2. 학술대회 평점은 최초 입장 시간과 최종 퇴장 시간을 기준으로 산출됩니다.
학술대회에 참석하셨더라도 평점 단말기에 바코드를 태그하신 기록이 없으면 평점이 부여되지 않을 수 있습니다.
3. 휴식시간은 평점 이수 시간 산출에 포함되지 않습니다.
4. 평점 확인은 학술대회 종료 후 결과보고가 완료되면 대한의사협회 연수교육 홈페이지 (<http://edu.kma.org>)로 로그인 후 마이페이지에서 '연수교육 이수확인서'를 출력하실 수 있습니다.

학술대회 평점

	5월 17일(수)	5월 18일(목)	5월 19일(금)	5월 20일(토)
대한의사협회 평점	2평점	6평점	6평점 (필수평점 2점 포함)	6평점
전공의 평점	학술대회 기간동안 6시간 이수하면 2평점			


관절초음파 워크숍

- 초음파 지도전문의 교육 : 대한내과학회 초음파지도전문의 연수 평점 **3평점 부여**
- 초음파 전공의 교육 : 대한내과학회 전공의 초음파 연수 **15건 인정**


학술대회 평점 인정 기준

연수교육 이수시간	인정 평점
1시간 미만	평점 인정 불가
1시간 이상 2시간 미만	1평점 인정
2시간 이상 3시간 미만	2평점 인정
3시간 이상 4시간 미만	3평점 인정
4시간 이상 5시간 미만	4평점 인정
5시간 이상 6시간 미만	5평점 인정
6시간 이상	6평점 인정


1F



2F



3F



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



Invited Faculty



 [Opening Session]


Sang-Cheol Bae
Hanyang Univ.
Korea



Shin-Seok Lee
Chonnam Nat'l Univ.
Korea



Seung Cheol Shim
Chungnam Nat'l Univ.
Korea




Jeewoo Yang
Pianist
Korea



David McCann
Harvard Univ.
USA



Hyunjoon Yoo
Hyunjoon Yoo Architects
Korea



Soo Hyun Ro
Lupus Patient & Singer
Korea

 [LUPUS 2023 Congress Highlights]


Seung Cheol Shim
Chungnam Nat'l Univ.
Korea



Sung Hwan Park
The Catholic Univ. of Korea
Korea

 [Plenary Session 1]
- SLE: Year in Review


Mary Crow
Hosp. for Special Surgery
USA



Paul Fortin
Université Laval
Canada

 [Plenary Session 2]
- Disease Mechanism


Joe Craft
Yale Univ.
USA



George Tsokos
Harvard Medical School
USA

 [Plenary Session 3]
- Novel Treatments and Strategies


Andrea Doria
Univ. of Padua
Italy



Brad Rovin
The Ohio State Univ.
USA

 [Plenary Session 4]
- Practical Treatment Issues


Chi-Chiu Mok
Tuen Mun Hosp.
Hong Kong



Ian Bruce
The Univ. of Manchester
UK

 [Plenary Session 5]
- Clinical Challenges: Diagnosis and Outcome Measures


Eric Morand
Monash Univ.
Australia



David Isenberg
Univ. College London
UK

**[Concurrent Session 1]**

- Global Challenges



Rosalind Ramsey-Goldman
Northwestern Univ.
USA



Lai Shan Tam
The Chinese Univ. of
Hong Kong
Hong Kong



Sang-Cheol Bae
Hanyang Univ.
Korea

**[Concurrent Session 2]**

- Biomarkers from Bench to Bedside



Yoshiya Tanaka
Univ. of Occupational and
Environmental Health
Japan



Chandra Mohan
Univ. of Houston
USA



Kyunggon Kim
Univ. of Ulsan
Korea

**[Concurrent Session 7]**

- Pregnancy and Reproductive Issues



Ian Bruce
The Univ. of
Manchester
UK



Angela Tincani
ASST-Spedali Civili
and Univ. of Brescia
Italy



Jisoo Lee
Ewha Womans Univ.
Korea

**[Concurrent Session 8]**

- Omics and Breakthrough Technology



John Harley
Cincinnati Education
and Research for
Veterans Foundation
USA



Peter E. Lipsky
AMPEL BioSolutions
USA



Betty Diamond
The Feinstein
Institutes for Medical
Research
USA

**[Concurrent Session 3]**

- Management Recommendations



Elisabet Svenungsson
Karolinska Institutet and
Karolinska Univ. Hosp.
Sweden



Chi-Chiu Mok
Tuen Mun Hosp.
Hong Kong



Thomas Dörner
Charité
Universitätsmedizin
Berlin
Germany

**[Concurrent Session 4]**

- Cytokines and Cell Signaling



Lothar Hennighausen
Nat'l Institutes
of Health
USA



Marina Botto
Imperial College
London
UK



Boris Reizis
NYU Grossman
School of Medicine
USA

**[Concurrent Session 9]**

- Targeting Organs



Yong Cui
China-Japan
Friendship Hosp.
China



Mengtao Li
Peking Union Medical
College Hosp.
China



Anselm Mak
National Univ. of
Singapore
Singapore

**[Concurrent Session 10]**

- Immune Cells



Seungki Kwok
The Catholic Univ. of
Korea
Korea



Ignacio Sanz
Emory Univ.
USA



Mariana Kaplan
Nat'l Institute
of Arthritis and
Musculoskeletal and
Skin Diseases
USA

**[Concurrent Session 5]**

- Comorbidities



Michelle Petri
Johns Hopkins Univ.
USA



Sasha Bernatsky
Research Institute
of the McGill Univ.
Health Centre
Canada



Chang-Hee Suh
Ajou Univ.
Korea

**[Concurrent Session 6]**

- New Treatments



Joan Merrill
Oklahoma
Medical Research
Foundation
USA



Ronald Van Vollenhoven
Amsterdam UMC
Netherlands



Richard Furie
Northwell Health
USA

**[Concurrent Session 11]**

- Antiphospholipid Syndrome



Munther Khamashta
Kings College London
UK



Michelle Petri
Johns Hopkins Univ.
USA



Nathalie Costedoat-Chalumeau
Cochin Hosp.
France

**[Special Lecture]**

- Presidential Plenary Session



Dae Hyun Yoo
Hanyang Univ.
Korea



Sang-Cheol Bae
Hanyang Univ.
Korea



Josef S. Smolen
Medical Univ. of
Vienna
Austria



Byung-Kwan Cho
KAIST
Korea

**[Meet the Mentor 1-4]**

George Tsokos
Harvard
Medical School
USA



Ho-Youn Kim
Ho Youn Kim's
Clinics for Arthritis
Rheumatism
Korea



Mary Crow
Hosp. for Special
Surgery
USA



SeongYoon Kim
KIMSEONGYOON
Clinic
Korea

**[APLAR-KCR Joint Symposium]**

Debashish Danda
Christian Medical
College Hosp.
India



Tsutomu
Takeuchi
Keio Univ.
Japan



Kichul Shin
Seoul Nat'l Univ.
Korea

**[Keynote Lecture 1 & 2]****[International Symposium 1]**

- For Better Management of Systemic Sclerosis



Dinesh Khanna
Univ. of Michigan
USA



Tae Hee Lee
Soonchunhyang Univ.
Korea

**[International Symposium 3]**- Rheumatoid Arthritis-Associated
Interstitial Lung Disease

Jeffrey A. Sparks
Brigham and Women's Hosp.
USA



Eun Young Lee
Seoul Nat'l Univ.
Korea

**[International Symposium 5]**- Stratification of Patients with Primary
Sjögren's Syndrome

Benjamin Fisher
Univ. of Birmingham
UK



Hong Ki Min
Konkuk Univ.
Korea

**[International Symposium 7]**

- Chondrocyte Metabolism and Osteoarthritis



Ali Mobasheri
Univ. of Oulu
Finland



Seungwoo Han
Kyungpook Nat'l Univ.
Korea

**[International Symposium 2]**

- Management of Systemic Vasculitis



Peter A. Merkel
Univ. of Pennsylvania
USA



Sung Soo Ahn
Yonsei Univ.
Korea

**[International Symposium 4]**- Urate-Lowering Benefits and Risks on
Comorbidities

Eun Ha Kang
Seoul Nat'l Univ.
Korea



Daniel I. Feig
Univ. of Alabama
USA

**[International Symposium 6]**- The Evolution of Fibromyalgia, its Concepts,
and Treatment

Manuel
Martinez-Lavin
Nat'l Institute of
Cardiology Mexico
Mexico



Jeeyoung Oh
Konkuk Univ.
Korea



Jiwon Hwang
Sungkyunkwan Univ.
Korea

**[International Symposium 8]**

- Managing Spondyloarthritis: Where are We Now



Uta Kiltz
Rheumazentrum Ruhrgebiet
Germany



Seong R. Kwon
Inha Univ.
Korea

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



Scientific Program



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



DAY 01

Program

 May 17 (Wed)

🕒 13:30-15:00 [Study Group Session] Grand Ballroom 101	
LUPUS Chinese SLE Treatment and Research Group (CSTAR) Study Group Session E	
Chairs	Xiaofeng Zeng (Peking Union Medical College, China) Mengtao Li (Peking Union Medical College Hosp., China)
13:30-13:50	15-year outcome of Chinese patients with SLE: Data from CSTAR Xinping Tian (Peking Union Medical College, China)
13:50-14:10	Treatment of neuropsychiatric systemic lupus erythematosus: Clinical challenges and future perspectives Pingting Yang (China Medical Univ., China)
14:10-14:30	2022 Chinese guideline for the management of pregnancy and reproduction in systemic lupus erythematosus Jiuliang Zhao (Peking Union Medical College, China)
14:30-15:00	Q & A

🕒 13:30-15:00 [Study Group Session] Grand Ballroom 102	
LUPUS The Systemic Lupus Erythematosus International Collaborating Clinics Group (SLICC) Study Group Session E	
Chair	Paul Fortin (Université Laval, Canada)
13:30-13:50	HCQ issue Nathalie Costedoat-Chalumeau (Cochin Hosp., France)
13:50-14:10	Pregnancy Evelyne Vinet (McGill Univ. Health Centre, Canada)
14:10-14:30	NPSLE Alexandra Legge (Dalhousie Univ., Canada)
14:30-15:00	Q & A

🕒 13:30-15:00 [Study Group Session] Grand Ballroom 105	
LUPUS Asia Pacific Lupus Collaboration (APLC) Study Group Session E	
Chair	Chak-sing Lau (Univ. of Hong Kong, Hong Kong)
13:30-13:50	Establishment of the Asia Pacific Lupus Collaboration - Challenges and opportunities Rangi Kandane-Rathnayake (Monash Univ., Australia)
13:50-14:10	Scientific outcomes from the Asia Pacific Lupus Collaboration - From endpoint validation to survival factors Eric Morand (Monash Univ., Australia)
14:10-14:30	Treat to target studies in SLE - Using real world data to strengthen study design Mandana Nikpour (The Univ. of Melbourne, Australia)
14:30-15:00	Q & A

🕒 15:00 – 16:00 [Pre-conference Workshop] Room 205 A+B	
LUPUS T2T: Defining LDA and Remission E	
Chair	Hye-Soon Lee (Hanyang Univ., Korea)
15:00-15:30	T2T Ronald Van Vollenhoven (Amsterdam UMC, Netherlands)
15:30-16:00	Q & A

🕒 15:00 – 16:30 [APLAR-LUPUS Joint Symposium] Grand Ballroom 104	
LUPUS Emerging Issue in Asia-Pacific region: Infections and lupus E	
Chairs	Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan) Seung Cheol Shim (Chungnam Nat'l Univ., Korea)
15:00-15:12	Introduction: Infection in SLE Chi-Chiu Mok (Tuen Mun Hosp., Hong Kong)
15:12-15:24	Tuberculosis and non tuberculosis mycobacterium in SLE Laniyati Hamijoyo (Univ. of Padjadjaran, Indonesia)
15:24-15:36	Pneumocystis pneumonia and rheumatology - Current understanding and approach to better practice Koshiro Sonomoto (Univ. of Occupational and Environmental Health, Japan)
15:36-15:48	Viral infections (except for COVID-19) Kenji Oku (Kitasato Univ., Japan)
15:48-16:00	COVID-19 Lai Shan Tam (The Chinese Univ. of Hong Kong, Hong Kong)
16:00-16:30	Q & A

🕒 15:00 – 16:00 [Pre-conference Workshop] Room 209 A+B	
LUPUS Disease Activity and Damage Measures in Clinical Practice E	
Chair	So-Young Bang (Hanyang Univ., Korea)
15:00-15:30	Disease activity and damage index Matthias Schneider (Heinrich-Heine-Universität Düsseldorf, Germany)
15:30-16:00	Q & A

17:00-18:30 [Opening Session] Auditorium	
LUPUS KCR Opening Session	
17:00-17:05	Welcome address Sang-Cheol Bae (Hanyang Univ, Korea)
17:05-17:10	Congratulatory address Shin-Seok Lee (Chonnam Nat'l Univ, Korea)
17:10-17:20	Overview of LUPUS & KCR 2023 Sang-Cheol Bae (Hanyang Univ, Korea)
17:20-17:25	Congratulatory address Se-hoon Oh (Mayor of Seoul)
17:25-17:30	Teaser of the FoUr Seung Cheol Shim (Chungnam Nat'l Univ, Korea)
Key Note lecture: The FoUr	
Chairs Sang-Cheol Bae (Hanyang Univ, Korea) Seung Cheol Shim (Chungnam Nat'l Univ, Korea)	
17:30-17:40	The Light Jeewoo Yang (Pianist, Korea)
17:40-18:00	The Words David McCann (Harvard Univ, USA)
18:00-18:20	The Height Hyunjoon Yoo (Hyunjoon Yoo Architects, Korea)
18:20-18:30	The Barrier Soo Hyun Ro (Lupus Patient & Singer, Korea)
18:30-21:00 [Social Program] Auditorium Lobby	
LUPUS KCR Welcome Reception	



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



DAY 02

Program

 May 18 (Thu)

08:00-09:00 [Breakfast Symposium 1 - Celltrion] Grand Ballroom 101+102	
LUPUS KCR Biobetter: A New Therapeutic Option in Rheumatic Diseases E	
Chair	Sang-Hyon Kim (Keimyung Univ., Korea)
08:00-08:40	Redefining subcutaneous infliximab in rheumatic disease Jae Hyun Jung (Korea Univ., Korea)

08:00-09:00 [Breakfast Symposium 2 - AbbVie] Grand Ballroom 103	
LUPUS KCR Optimizing Care to Resolve Issues in Rheumatoid Arthritis E	
Chair	Seung Cheol Shim (Chungnam Nat'l Univ., Korea)
08:00-08:40	Value of remission in rheumatoid arthritis patients and the benefit-risk profile of upadacitinib Lai Shan Tam (The Chinese Univ. of Hong Kong, Hong Kong)

08:00-09:00 [Breakfast Symposium 3 - Astellas] Grand Ballroom 104	
LUPUS KCR Rheumatoid Arthritis with Tacrolimus K	
Chair	Dae Hyun Yoo (Hanyang Univ., Korea)
08:00-08:40	Efficacy and safety of tacrolimus for rheumatoid arthritis Seulkee Lee (Sungkyunkwan Univ, Korea)

08:00-09:00 [Breakfast Symposium 4 - Janssen] Grand Ballroom 105	
LUPUS KCR Redefine TNF-α in Rheumatoid Arthritis E	
Chair	Sang-Heon Lee (Konkuk Univ., Korea)
08:00-08:40	The role and expectations of Golimumab 100mg mono in rheumatoid arthritis: Japanese experience with Golimumab Tsutomu Takeuchi (Keio Univ., Japan)

09:00-10:00 [Special Lecture] Grand Ballroom 103+104+105	
KCR Presidential Plenary Session A가 K	
Chairs	Shin-Seok Lee (Chonnam Nat'l Univ., Korea) Sang-Cheol Bae (Hanyang Univ., Korea)
09:00-09:30	The path I have taken for Korean Society of Rheumatology Dae Hyun Yoo (Hanyang Univ., Korea)
09:30-10:00	Towards precision medicine in rheumatology: My career & decision Sang-Cheol Bae (Hanyang Univ., Korea)

09:00-12:00 [Workshop] Room 209A+B	
KCR Musculoskeletal US Workshop 1 - Advanced Course K	
Chairs	Chong-Hyeon Yoon (The Catholic Univ. of Korea, Korea) Sang-Hoon Lee (Kyung Hee Univ., Korea)
09:00-09:30	Proper setting of ultrasound equipment Jae Hoon Kim (Korea Univ., Korea)
09:30-10:00	Utilization of doppler test in rheumatology Joa Kim (Chosun Univ., Korea)
10:00-10:30	Evaluation of bones, cartilage, tendons and enthesitis using US Hyun Ok Kim (Gyeongsang Nat'l Univ., Korea)
10:30-11:00	Utilization of US in Sjögren's syndrome and vasculitis Hong Ki Min (Konkuk Univ., Korea)
11:00-11:30	US use in spinal disease and neurological disease: Guided injection Chang Hoon Lee (Wonkwang Univ., Korea)
11:30-12:00	Intra-articular US-guided Injection Chong Hyuk Chung (Wonkwang Univ., Korea)

09:15-10:00 [Meet the Professor 1] Grand Ballroom 101	
LUPUS B cell Therapy for Difficult Lupus Cases E	
Facilitator	Seung-Ki Kwok (The Catholic Univ. of Korea, Korea)
09:15-09:45	B cell therapy for difficult lupus cases David Isenberg (Univ. College London, UK)
09:45-10:00	Q&A

09:15-10:00 [Meet the Professor 2] Grand Ballroom 102	
LUPUS Cutaneous Lupus E	
Facilitator	Joo Yeon Ko (Hanyang Univ., Korea)
09:15-09:45	Cutaneous lupus Victoria Werth (Univ. of Pennsylvania, USA)
09:45-10:00	Q&A

09:15-10:00 [Meet the Professor 3] Room 205A+B	
LUPUS Antiphospholipid Syndrome E	
Facilitator	Sang-Won Lee (Yonsei Univ., Korea)
09:15-09:45	Antiphospholipid syndrome Tatsuya Atsumi (Hokkaido Univ., Japan)
09:45-10:00	Q&A

10:30-12:00 [Plenary Session 1] Auditorium	
LUPUS SLE: Year in Review E	
Chairs Sang-Cheol Bae (Hanyang Univ., Korea) Shin-Seok Lee (Chonnam Nat’l Univ., Korea)	
10:30-11:00	Basic science Mary Crow (Hosp. for Special Surgery, USA)
11:00-11:30	Clinical science Paul Fortin (Université Laval, Canada)

10:30-12:00 [Symposium] Grand Ballroom 103	
KCR Year in Review (Clinical) K	
Chairs Chan Hong Jeon (Soonchunhyang Univ., Korea) Sang-Heon Lee (Konkuk Univ., Korea)	
10:30-11:00	Emerging new diagnostic and therapeutic options in systemic sclerosis Hyun-Sook Kim (Soonchunhyang Univ., Korea)
11:00-11:30	Advances in therapeutic and diagnostic options for ANCA-associated vasculitis Chan-Bum Choi (Hanyang Univ., Korea)
11:30-12:00	Latest advances in the management of rheumatoid arthritis Hae-Rim Kim (Konkuk Univ., Korea)

10:30-12:00 [Symposium] Grand Ballroom 104+105	
KCR Year in Review (Basic) K	
Chairs Dae Hyun Yoo (Hanyang Univ., Korea) Jason Jungsik Song (Yonsei Univ., Korea)	
10:30-11:00	Interaction between stromal cells and immune cells: Past, present, and future Sang-il Lee (Gyeongsang Nat’l Univ., Korea)
11:00-11:30	Pain in musculoskeletal diseases, friend or foe Hyun Ah Kim (Hallym Univ., Korea)
11:30-12:00	Proteomics for the discovery of rheumatic diseases Yong-Gil Kim (Univ. of Ulsan, Korea)

12:00-13:00 [Luncheon Symposium 1 - GSK] Grand Ballroom 101+102	
LUPUS KCR Changing the Course of the Disease in SLE : When is the Window of Opportunity? E	
Chair Matthias Schneider (Heinrich-Heine-Universität Düsseldorf, Germany)	
12:00-12:40	Taking advantage of the window of opportunity: Using targeted therapy in SLE Andrea Doria (Univ. of Padua, Italy)

12:00-13:00 [Luncheon Symposium 2 - BMS] Grand Ballroom 103	
LUPUS KCR Impact of Autoantibodies in RA Treatment Outcomes and RA Associated Co-morbidities E	
Chair Won Park (Inha Univ., Korea)	
12:00-12:40	Impact of autoantibodies in RA treatment outcomes and RA associated co-morbidities Ronald Van Vollenhoven (Amsterdam UMC, Netherlands)

12:00-13:00 [Luncheon Symposium 3 - Yuhan] Grand Ballroom 104	
LUPUS KCR Emerging Trends in Rheumatic Disease : The Changing Landscape of Biosimilars in Korea K	
Chair Jung-Yoon Choe (Daegu Catholic Univ., Korea)	
12:00-13:00	Extension of rheumatic disease treatment area: Biosimilar’s role & position Bon San Koo (Inje Univ., Korea)

12:00-13:00 [Luncheon Symposium 4 - Viatris] Grand Ballroom 105	
LUPUS KCR A Well-balanced NSAID for Rheumatoid Arthritis K	
Chair Seong-Ho Kim (Inje Univ., Korea)	
12:00-12:40	The paradigm shift to selective COX-2 Inhibitor : How PRECISION trial and sub-analysis impact on NSAIDs treatment Min Wook So (Pusan Nat’l Univ., Korea)

13:00-14:30 [Concurrent Session 1] Auditorium	
LUPUS Global Challenges E	
Chairs Laurent Arnaud (Strasbourg Univ., France) Eun Ha Kang (Seoul Nat’l Univ., Korea)	
13:00-13:20	Global epidemiology of SLE: Do we need more than just counts? Rosalind Ramsey-Goldman (Northwestern Univ., USA)
13:20-13:40	SLE disease burden from a patient perspective Lai Shan Tam (The Chinese Univ. of Hong Kong, Hong Kong)
13:40-14:00	Access to health care Sang-Cheol Bae (Hanyang Univ., Korea)
LO-001	Socioeconomic trends in outcomes of tertiary prevention among patients with systemic connective tissue disorders in Germany Patrick Brzoska (Witten/Herdecke Univ., Germany)
LO-002	“Skin-Deep Resilience” in the black women’s experiences living with lupus (BeWELL) Study Kara W Chung (Tulane School of Public Health and Tropical Medicine, USA)
LO-003	Prevalence of remission according to physician and patient and level of agreement in a real-world multicenter lupus registry José María Pego reigosa (Hosp. Meixoeiro, Spain)

13:00-14:30 [Concurrent Session 2] Grand Ballroom 101	
LUPUS Biomarkers from Bench to Bedside E	
Chairs	Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan) Yong-Gil Kim (Univ. of Ulsan, Korea)
13:00-13:20	Immune phenotype and its therapeutic application in SLE Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan)
13:20-13:40	The quest for end organ focused biomarkers in SLE Chandra Mohan (Univ. of Houston, USA)
13:40-14:00	Proteomics for urine biomarkers Kyunggon Kim (Univ. of Ulsan, Korea)
LO-004	Frequency and determinants of flare and persistently active disease in a large multinational prospective lupus cohort Yanjie Hao (The Univ. of Melbourne, Australia)
LO-005	Urinary L-selectin reflects clinical and histological renal disease activity and treatment response in lupus nephritis across multiple ethnicities Huihua Ding (Shanghai Jiao Tong Univ., China)
LO-006	Change in urinary biomarkers at three months predicts 1-year treatment response of lupus nephritis better than proteinuria Andrea Fava (Johns Hopkins Univ., USA)

13:00-14:30 [Alliance Session 1] Grand Ballroom 102	
LUPUS Improving Lupus Outcomes through Patient Education A가 E K	
Chairs	Sandra Navarra (Univ. of Santo Tomas, Philippines) Seung Cheol Shim (Chungnam Nat'l Univ., Korea)
13:00-13:20	Lupus education for physicians and patients in a resource-limited setting Sandra Navarra (Univ. of Santo Tomas, Philippines)
13:20-13:40	Shared decision making: Empowering patients through education Yoon-Kyoung Sung (Hanyang Univ., Korea)
13:40-14:00	Patient perspectives on education using digital resources Seung Min Jung (The Catholic Univ. of Korea, Korea)
14:00-14:30	Panel Discussion

13:00-14:30 [APLAR-KCR Joint Symposium] Grand Ballroom 103	
KCR Career Development of Young Rheumatologists in the APLAR Region E	
Chairs	Debashish Danda (Christian Medical College Hosp., India) Shin-Seok Lee (Chonnam Nat'l Univ., Korea)
13:00-13:30	New initiatives of APLAR (APLAR Academy) Debashish Danda (Christian Medical College Hosp., India)
13:30-14:00	Lessons learned from the Japan College of Rheumatology International School Tsutomu Takeuchi (Keio Univ., Japan)
14:00-14:30	KCR's future directives for YRs Kichul Shin (Seoul Nat'l Univ., Korea)

13:00-14:30 [Symposium] Grand Ballroom 104	
KCR COVID-19 in Health and Autoimmunity E K	
Chairs	Sung-Hwan Park (The Catholic Univ. of Korea, Korea) Young Mo Kang (Kyungpook Nat'l Univ. Korea)
13:00-13:30	Clinical Aspect of COVID-19 infection in patients with systemic autoimmune diseases Su-Jin Moon (The Catholic Univ. of Korea, Korea)
13:30-14:00	Alliance of T and innate immune cells via cytokine receptors in health and autoimmunity Insoo Kang (Yale Univ., USA)
14:00-14:30	T cell immune responses against SARS-CoV-2 Eui-Cheol Shin (KAIST, Korea)

13:00-14:30 [Symposium] Grand Ballroom 105	
KCR KCR Research Foundation Session K	
Chairs	Jung-Yoon Choe (Daegu Catholic Univ, Korea) Won Tae Chung (Dong-A Univ., Korea)
13:00-13:20	Effect of complement factor H-related protein 5 in murine arthritis models Chang-Nam Son (Eulji Univ., Korea)
13:20-13:40	The microbiome of the upper respiratory track in rheumatoid arthritis Young Bin Joo (Hanyang Univ., Korea)
13:40-14:00	Glucocorticoid and infectious complication in rheumatic disease Jun Won Park (Seoul Nat'l Univ., Korea)
14:00-14:30	Korean diagnosis-related groups (DRGs) payment system in rheumatic and musculoskeletal diseases Byoong Yong Choi (Seoul Medical Center; Korea)

14:30-15:30 [Meet the Mentor] Conference Room 205B	
KCR Meet the Mentor 1 E	
Facilitator	Seung-Ki Kwok (The Catholic Univ. of Korea, Korea)
14:30-15:30	Meet the Mentor 1 - Prof. George Tsokos George Tsokos (Harvard Medical School, USA)




<div><div><div>🕒</div><div>14:30-15:30</div></div><div><div>LUPUS</div></div></div> <div>[Short Oral Prsentation]</div> <div>Grand Ballroom 101</div> <div><div>E</div></div>	
Chair <div>Seung-Geun Lee (Pusan Nat’l Univ., Korea, Korea)</div>	
LSO-025	Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide Porntip Intapiboon (Prince of Songkla univ., Thailand)
LSO-026	Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis : Results from a real-world CSTAR cohort study Wei Bai (Peking Union Medical College Hosp., China)
LSO-027	Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis : A prospective cohort study Jung-Min Shin (Eulji Univ., Korea)
LSO-028	Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab Ioannis Parodis (Karolinska Institutet, Sweden)
LSO-029	Predictors of renal relapse in Korean patients with lupus nephritis : Over a 35-year period at a single center Howook Jeon (Uijeongbu St. Mary’s Hosp., Korea)
LSO-030	Predictors of renal flares in systemic lupus erythematosus : A post-hoc analysis of four phase III clinical trials of belimumab Alvaro Gomez (Karolinska Institutet, Sweden)
LSO-100	Does early complete remission preclude adverse outcomes in lupus nephritis? Dafna Gladman (Univ. of Toronto, Canada)


<div><div><div>🕒</div><div>14:30-15:30</div></div><div><div>LUPUS</div></div></div> <div>[Short Oral Prsentation]</div> <div>Grand Ball Room 102</div> <div><div>E</div></div>	
Chair <div>Chang-Nam Son (Eulji Univ., Korea)</div>	
LSO-031	Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort Yanjie Hao (The Univ. of Melbourne, Australia)
LSO-032	Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients Bernardo A. Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)
LSO-033	Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus Alexandra Legge (Dalhousie Univ., Canada)
LSO-034	Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erythematosus- a prospective observational study Gayathri Ms (Jawaharlal Institute of Postgraduate Medical Education and Research, India)
LSO-035	Withdrawn
LSO-036	Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE) Shirley Chiu Wai Chan (Univ. of Hong Kong, Hong Kong)



<div><div><div>🕒</div><div>15:30-17:00</div></div><div><div>LUPUS</div></div></div> <div>[Plenary Session 2]</div> <div>Auditorium</div> <div><div>E</div></div>	
Chairs <div>Mary Crow (Hosp. for Special Surgery, USA) Sung-Hwan Park (The Catholic Univ. of Korea, Korea)</div>	
15:30-16:00	T cell immunity in SLE Joe Craft (Yale Univ., USA)
16:00-16:30	Lupus nephritis: Mechanisms of kidney damage George Tsokos (Harvard Medical School, USA)
LO-007	EZH2 deficiency in B cells impairs plasmablast differentiation and ameliorates lupus-like disease in mice Amr Sawalha (Univ. of Pittsburgh, USA)
LO-008	MEF2D (Mef2d) expression in CD4 T cells influences humoral autoimmunity by regulating follicular helper T cell differentiation and function Ye-Ji Kim (Seoul Nat’l Univ., Korea)
LO-042	High genetic risk load for systemic lupus erythematosus in antinuclear antibody-positive individuals at the preclinical stage Sehwan Chun (Kyung Hee Univ., Korea)





<div><div><div>🕒</div><div>15:30-17:00</div></div><div><div>KCR</div></div></div> <div>[International Symposium 1]</div> <div>Grand Ballroom 103</div> <div><div>E</div></div>	
Chairs <div>Eun Bong Lee (Seoul Nat’l Univ., Korea) Jae-Bum Jun (Hanyang Univ., Korea)</div>	
15:30-16:00	Management of early systemic sclerosis Dinesh Khanna (Univ. of Michigan, USA)
16:00-16:30	Optimal management of G-I involvements in systemic sclerosis Tae Hee Lee (Soonchunhyang Univ., Korea)
KIO-001	Risk of new-onset depression in patients with systemic sclerosis : A nationwide population-based study Su-Jin Moon (The Catholic Univ. of Korea, Korea)
16:40-16:55	Systemic sclerosis in Korea Eun Bong Lee (Seoul Nat’l Univ., Korea)





<div><div><div>🕒</div><div>15:30-17:00</div></div><div><div>KCR</div></div></div> <div>[Workshop]</div> <div>Grand Ballroom 105</div> <div><div>K</div></div>	
Chairs <div>Yong-Gil Kim (Univ. of Ulsan, Korea) Sang Youn Jung (CHA Univ., Korea)</div>	
15:30-16:00	Autoimmune diseases experimental models for development and validation of therapeutic target between the immune system and joints Mi-La Cho (The Catholic Univ. of Korea, Korea)
16:00-16:30	Immune cell analysis for rheumatic diseases Seokchan Hong (Univ. of Ulsan, Korea)
16:30-17:00	Proteomics for autoimmune disease Ho Chul Kang (Ajou Univ., Korea)

<div>  15:30-18:30 </div> <div>  </div>	<div> [Workshop] </div> <div> Musculoskeletal US Workshop 2 - Basic Course </div>	<div> Room 209A+B </div> <div>  </div>
Chairs	<div> Geun-Tae Kim <i>(Kosin Univ., Korea)</i> Hyun Ok Kim <i>(Gyeongsang Nat'l Univ., Korea)</i> </div>	
15:30-16:00	<div> Ultrasound of the upper extremities Kyung-Ann Lee <i>(Soonchunhyang Univ., Korea)</i> </div>	
16:00-16:30	<div> Ultrasound of the low extremities Jae Hyun Jung <i>(Korea Univ., Korea)</i> </div>	
16:30-17:30	<div> Hands on courses of upper extremities - Shoulder Yune Jung <i>(The Catholic Univ. of Korea, Korea)</i>, Soo Min Ahn <i>(Univ. of Ulsan, Korea)</i> </div>	
	<div> Hands on courses of upper extremities - Wrist, Elbow Bo Young Kim <i>(Univ. of Ulsan , Korea)</i>, Youngjae Park <i>(The Catholic Univ. of Korea, Korea)</i> </div>	
17:30-18:30	<div> Hands on courses of low extremities - Knee Bora Nam <i>(Hanyang Univ., Korea)</i>, Chang Hoon Lee <i>(Wonkwang Univ., Korea)</i> </div>	
	<div> Hands on courses of low extremities - Ankle, Foot Young Sun Suh <i>(Gyeongsang Nat'l Univ., Korea)</i>, Jung Hee Koh <i>(The Catholic Univ. of Korea, Korea)</i> </div>	

 17:00-18:30 <div>LUPUS</div>	[Concurrent Session 3] Management Recommendations	Auditorium <div>E</div>
Chairs	Thomas Dörner (<i>Charité –Universitätsmedizin Berlin und Deutsches, Germany</i>) Chang Keun Lee (<i>Univ. of Ulsan, Korea</i>)	
17:00-17:20	EULAR recommendations for management of SLE Elisabet Svenungsson (<i>Karolinska Institutet and Karolinska Univ. Hosp., Sweden</i>)	
17:20-17:40	Treatment of SLE and lupus nephritis: Comparison of Asian and Western guidelines Chi-Chiu Mok (<i>Tuen Mun Hosp., Hong Kong</i>)	
17:40-18:00	Cardiovascular disease risk management in SLE/APS Thomas Dörner (<i>Charite Universitätsmedizin Berlin, Germany</i>)	
LO-009	Responsiveness of the CLASI to alopecia and mucous membrane involvement : A retrospective study of prospectively collected data Victoria Werth (<i>Univ. of Pennsylvania, USA</i>)	
LO-010	Relationship between the EULAR/ACR classification criteria and organ damage in systemic lupus erythematosus Chi-Chiu Mok (<i>Tuen Mun Hosp., Hong Kong</i>)	
LO-011	Withdrawal of maintenance glucocorticoid versus other immunosuppressants among patients with Systemic Lupus Erythematosus in long term clinical remission: Interim analysis of a non-inferiority randomised controlled trial Aishwarya Gopal (<i>Jawaharlal Institute of Postgraduate Medical Education and Research, India</i>)	

 17:00-18:30	[Concurrent Session 4]	Grand Ballroom 101
	Cytokines and Cell Signaling	
Chairs	Marina Botto (<i>Imperial College London, UK</i>) Yong-wook Park (<i>Chonnam Nat'l Univ., Korea</i>)	
17:00-17:20	Deconvoluting JAK/STAT building blocks in development and disease Lothar Hennighausen (<i>Nat'l Institutes of Health, USA</i>)	
17:20-17:40	Type I IFN and T cell metabolism in SLE Marina Botto (<i>Imperial College London, UK</i>)	
17:40-18:00	Extracellular DNA and DNases in SLE Boris Reizis (<i>NYU Grossman School of Medicine, USA</i>)	
LO-012	The innate immune checkpoint NLRP12 represses IFN signatures and attenuates the progression of lupus nephritis. Szu-Ting Chen (<i>Nat'l Yang Ming Chiao Tung Univ., Taiwan</i>)	
LO-013	Novel pathogenetic mechanisms mediated by dysregulation of TRIM21-STING-type I interferon axis in lupus Youngjae Park (<i>The Catholic Univ. of Korea, Korea</i>)	
LO-014	Mechanistic interrogation of STAT1 gain-of-function syndrome provides new insights into human lupus pathogenesis Shaun Jackson (<i>Seattle Children's Research Institute, USA</i>)	

 17:00-18:30	<div data-bbox="1863 1043 2041 1056">[Alliance Session 2]</div> <div data-bbox="2656 1043 2843 1056">Grand Ballroom 102</div> <div data-bbox="1656 1064 1733 1092">LUPUS</div> <div data-bbox="1863 1064 2368 1096">Rheumatic Diseases Around the World</div> <div data-bbox="2742 1064 2843 1096">    </div>
Chairs	<div data-bbox="1863 1142 2585 1161">Bernardo A. Pons-Estel <i>(Regional Center for Autoimmune and Rheumatic Diseases, Argentina)</i></div> <div data-bbox="1863 1171 2211 1192">Yoon-Kyoung Sung <i>(Hanyang Univ., Korea)</i></div>
17:00-17:20	<div data-bbox="1863 1232 2285 1253">Lupus in Africans - The past and the present</div> <div data-bbox="1863 1264 2291 1283">Olufemi Adelowo <i>(Lagos State Univ. Teaching Hosp., Nigeria)</i></div>
17:20-17:40	<div data-bbox="1863 1304 2546 1325">Overcoming the challenges of rheumatic diseases in Asian Pacific region</div> <div data-bbox="1863 1335 2128 1354">Tsutomu Takeuchi <i>(Keio Univ., Japan)</i></div>
17:40-18:00	<div data-bbox="1863 1375 2677 1396">Global collaborations on clinical trial, practice, and education in pediatric rheumatology</div> <div data-bbox="1863 1407 2226 1425">Angelo Ravelli <i>(IRCCS Istituto Giannina Gaslini, Italy)</i></div>
18:00-18:30	Panel Discussion

 17:00-18:30	[Patient Session 1]	Room 205A+B
	Best Practice in the Management of SLE	 

<div><div><div>🕒</div><div>17:00-18:30</div></div><div><div>KCR</div></div></div> <div>[International Symposium 2]</div> <div>Grand Ballroom 103</div> <div><div>E</div></div>	
<div>Management of Systemic Vasculitis</div>	
<div>Chairs<div>Chan-Bum Choi <i>(Hanyang Univ., Korea)</i></div><div>Sang-Won Lee <i>(Yonsei Univ., Korea)</i></div></div>	
17:00-17:30	<div>Recent advances in the treatment of ANCA-associated vasculitis</div> <div>Peter A. Merkel <i>(Univ. of Pennsylvania, USA)</i></div>
17:30-18:00	<div>Application of the 2022 ACR/EULAR classification criteria for MPA, GPA, and EGPA to Korean patients with AAV</div> <div>Sung Soo Ahn <i>(Yonsei Univ., Korea)</i></div>
KIO-002	<div>Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to the 2022 ACR/EULAR classification criteria</div> <div>Jangwoo Ha <i>(Severance Hosp., Korea)</i></div>
18:10-18:25	<div>Metabolic syndrome in ANCA-associated vasculitis</div> <div>Pil Gyu Park <i>(Nat'l Health Insurance Service Ilsan Hosp., Korea)</i></div>

<div><div><div>🕒</div><div>17:00-18:30</div></div><div><div>KCR</div></div></div> <div>[Workshop]</div> <div>Grand Ballroom 105</div> <div><div>K</div></div>	
<div>Clinical Research Workshop for Rheumatologist: Finding Biomarkers</div>	
<div>Chairs<div>Kichul Shin <i>(Seoul Nat'l Univ., Korea)</i></div><div>Tae-Jong Kim <i>(Chonnam Nat'l Univ., Korea)</i></div></div>	
17:00-17:30	<div>Meta-analysis for biomarker discovery</div> <div>Young Ho Lee <i>(Korea Univ., Korea)</i></div>
17:30-18:00	<div>Statistical methods for biomarker discovery</div> <div>Seo Young Park <i>(Korea Nat'l Open Univ., Korea)</i></div>
18:00-18:30	<div>EMR data for biomarker discovery</div> <div>Jonggi Choi <i>(Univ. of Ulsan, Korea)</i></div>

<div><div><div>🕒</div><div>18:30-19:30</div></div><div><div>LUPUS</div><div>KCR</div></div></div> <div>[Evening Symposium 1 - AstraZeneca]</div> <div>Grand Ballroom 101+102</div> <div><div>E</div></div>	
<div>Turning the Page in Lupus Management</div>	
<div>Chair<div>Mandana Nikpour <i>(The Univ. of Melbourne, Australia)</i></div></div>	
18:30-19:10	<div>A new chapter in lupus care: How can we improve long-term outcomes for patients?</div> <div>Masato Okada <i>(St. Luke's Int'l Hosp., Japan)</i></div>

<div><div><div>🕒</div><div>18:30-19:30</div></div><div><div>LUPUS</div><div>KCR</div></div></div> <div>[Evening Symposium 2 - JW Pharmaceutical]</div> <div>Grand Ballroom 103</div> <div><div><div>A</div><div>가</div></div><div><div>K</div></div></div>	
<div>Update on Treatment of Systemic Vasculitis</div>	
<div>Chair<div>Chan-Bum Choi <i>(Hanyang Univ., Korea)</i></div></div>	
18:30-19:10	<div>Tocilizumab for the treatment of systemic vasculitis</div> <div>Sang-Won Lee <i>(Yonsei Univ., Korea)</i></div>

<div><div><div>🕒</div><div>19:00-21:00</div></div><div><div>LUPUS</div><div>KCR</div></div></div> <div>[Satellite Symposia - Samsung Bioepis]</div> <div>InterContinental Seoul COEX Harmony Ballroom</div> <div><div>E</div></div>	
<div>Samsung Bioepis Satellite Symposium</div>	
<div>Chair<div>Josef S. Smolen <i>(Medical Univ. of Vienna, Austria)</i></div></div>	
19:00-20:00	<div>The economics of Anti-TNF biosimilar: Regulatory pathway to uptake and systemwide savings</div> <div>Aslam H. Anis <i>(The Univ. of British Columbia, Canada)</i></div>
20:00-21:00	<div>What rheumatology should know about biosimilar before prescription</div> <div>Jonathan Kay <i>(UMass Chan Medical School, USA)</i></div>

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



DAY 03

Program

 May 19 (Fri)

🕒

08:00-09:00

[Breakfast Symposium 5 - Yuhan]

Grand Ballroom 101+102

LUPUS

KCR

Exploring the Medical Strategies for Management of Rheumatic Disease in the USA

E

Chair	Jae Joon Lee (Sungkyunkwan Univ., Korea)
08:00-08:40	Current approach to treatment of rheumatoid arthritis and axial spondyloarthritis in the United States Jonathan Kay (UMass Chan Medical School, USA)

🕒

08:00-09:00

[Breakfast Symposium 6 - Eisai]

Grand Ballroom 103

LUPUS

KCR

Introducing Jyseleca (Filgotinib): JAK1-preferential Inhibitor

E

Chair	Chang Keun Lee (Univ. of Ulsan, Korea)
08:00-08:40	The efficacy and safety of Jyseleca in RA: Based on clinical trials and real world experience in Japan Yuko Kaneko (Keio Univ. Hosp., Japan)

🕒

08:00-09:00

[Breakfast Symposium 7 - GSK]

Grand Ballroom 104

LUPUS

KCR

Planning for Tomorrow Today: How Can We Improve Prognosis in SLE?

E

Chair	Mandana Nikpour (The Univ. of Melbourne, Australia)
08:00-08:40	Acting now to minimize the impacts of organ damage and infection in SLE Yasuhiro Katsumata (Tokyo Women's Medical Univ., Japan)

🕒

08:00-09:00

[Breakfast Symposium 8 - Pfizer]

Grand Ballroom 105

LUPUS

KCR

Practical Review of RA Management with Etanercept

K

Chair	Chang Hee Suh (Ajou Univ., Korea)
08:00-08:40	Long-established clinical value of Enbrel in RA patients Yune Jung Park (The Catholic Univ. of Korea, Korea)

🕒

09:00-10:00

[Special Lecture]

Grand Ballroom 103+104+105

KCR

Keynote Lecture 1

A가

E

Chairs	Shin-Seok Lee (Chonnam Nat'l Univ., Korea)
09:00-09:50	Update on the management of rheumatoid arthritis : Current insights and a look into the future Josef S. Smolen (Medical Univ. of Vienna, Austria)

🕒

09:15-10:00

[Meet the Professor 4]

Grand Ballroom 101

LUPUS

SLE and Infection

E

Facilitator	Yeon-Ah Lee (Kyung Hee Univ., Korea)
09:15-09:45	SLE and infection Masayoshi Harigai (Tokyo Women's Medical Univ., Japan)
09:45-10:00	Q&A

🕒

09:15-10:00

[Meet the Professor 5]

Grand Ballroom 102

LUPUS

Precision Medicine

E

Facilitator	Hye-Soon Lee (Hanyang Univ., Korea)
09:15-09:45	Precision medicine Tim Vyse (King's College London, UK)
09:45-10:00	Q&A

🕒

09:15-10:00

[Meet the Professor 6]

Room 205A+B

LUPUS

Managing Lupus Pregnancy

E

Facilitator	Jisoo Lee (Ewha Womans Univ., Korea)
09:15-09:45	Managing lupus pregnancy Evelyne Vinet (McGill Univ. Health Centre, Canada)
09:45-10:00	Q&A

🕒

10:30-12:00

[Plenary Session 3]

Auditorium

LUPUS

Novel Treatments and Strategies

E

Chairs	Eric Morand (Monash Univ., Australia) Chang-Hee Suh (Ajou Univ., Korea)
10:30-11:00	Overview of new SLE treatments and defining the targets Andrea Doria (Univ. of Padua, Italy)
11:00-11:30	Calcineurin inhibitors: New & old Brad Rovin (The Ohio State Univ., USA)
LO-015	Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks Richard Furie (Northwell Health, USA)
LO-016	The multifaceted immunomodulatory properties of cenerimod, a selective S1P1 receptor modulator, target three key aspects of SLE pathogenesis Marianne M. Martinic (Idorsia Pharmaceuticals, Switzerland)
LO-017	Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: Results from the open-label Phase 1b/2 MISSION study Brad Rovin (The Ohio State Univ., USA)

<div><div><div>🕒</div><div>10:30-12:00</div></div><div><div>KCR</div></div></div> <div>[International Symposium 3]</div> <div>Grand Ballroom 103</div> <div><div>E</div></div>	
<div>Chairs</div> <div>Seungwoo Han <i>(Kyungpook Nat'l Univ., Korea)</i> Sang-il Lee <i>(Gyeongsang Nat'l Univ., Korea)</i></div>	
10:30-11:00	<div>Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease</div> <div>Jeffrey A. Sparks <i>(Brigham and Women's Hosp., USA)</i></div>
11:00-11:30	<div>Approach and management of rheumatoid arthritis with interstitial lung disease</div> <div>Eun Young Lee <i>(Seoul Nat'l Univ., Korea)</i></div>
KIO-003	<div>Risk factors for mortality in patients with rheumatoid arthritis-associated interstitial lung disease : A single-center prospective cohort study</div> <div>Yeo-Jin Song <i>(Hanyang Univ., Korea)</i></div>
KIO-004	<div>Shortened telomere length is associated with usual interstitial pneumonia in rheumatoid arthritis</div> <div>Young Bin Joo <i>(Hanyang Univ., Korea)</i></div>
KIO-005	<div>Serum KL-6 levels in patients with rheumatoid arthritis-associated interstitial lung disease</div> <div>Sung Hae Chang <i>(Soonchunhyang Univ., Korea)</i></div>

<div><div><div>🕒</div><div>10:30-12:00</div></div><div><div>KCR</div></div></div> <div>[Free Paper Session 1]</div> <div>Grand Ballroom 104</div> <div><div>E</div><div>K</div></div>	
<div>Chairs</div> <div>Ji Hyeon Ju <i>(The Catholic Univ. of Korea, Korea)</i> Hyun Sik Gong <i>(Seoul Nat'l Univ., Korea)</i></div>	
KO-001	<div>Association of healthy lifestyles with all-cause and cause-specific mortality among individuals with osteoarthritis: A prospective cohort study of the UK biobank</div> <div>Tianxiang Fan <i>(Southern Medical Univ., China)</i></div>
KO-002	<div>Association between trajectory of metabolic syndrome and knee pain over 11 years in middle-aged adults</div> <div>Amrishi Singh <i>(Univ. of Tasmania, Australia)</i></div>
KO-003	<div>The intervention of osteoarthritis and comorbid depressive disorder by a selective combination of pro/prebiotic treatment.</div> <div>Hee-Jeong Im Sampen <i>(Univ. of Illinois, USA)</i></div>
KO-004	<div>Subchondral bone density distribution in elbows with early and advanced osteoarthritis in association with elbow alignment</div> <div>Ji Sup Hwang <i>(Seoul Nat'l Univ., Korea)</i></div>
KO-005	<div>Low serum adiponectin levels were associated with radiographic progression of hand osteoarthritis in a 6-year follow-up of the Dong-gu study</div> <div>Sung-Eun Choi <i>(Chonnam Nat'l Univ., Korea)</i></div>
KO-006	<div>A single intraarticular injection of nanotechnology-based drug formulation as a safe osteoarthritis disease-modifying drug</div> <div>Hee-Jeong Im Sampen <i>(Univ. of Illinois, USA)</i></div>
KO-007	<div>Serial administration of recombinant human bone morphogenetic protein-2 and osteoprotegerin-Fc enhances the differentiation of osteoblasts</div> <div>Chang-Nam Son <i>(Eulji Univ., Korea)</i></div>
KO-008	<div>Osteoporosis gene therapy using non - viral minicircle vector inserted osteoprotegerin and PTHrP(1-34+107-139) gene</div> <div>Ye Ji Eom <i>(The Catholic Univ. of Korea, Korea)</i></div>

<div><div><div>🕒</div><div>10:30-12:00</div></div><div><div>KCR</div></div></div> <div>[Free Paper Session 2]</div> <div>Grand Ballroom 105</div> <div><div>K</div></div>	
<div>Chairs</div> <div>Young Il Seo <i>(Hallym Univ., Korea)</i> Chung il Joung <i>(Konyang Univ., Korea)</i></div>	
KO-009	<div>Recovery and long-term renal outcome of patients with ANCA-associated vasculitis who are on dialysis at presentation</div> <div>Yeo-Jin Lee <i>(Asan Medical Center, Korea)</i></div>
KO-010	<div>Application of the 2022 ACR/EULAR classification criteria for ANCA-associated vasculitis to patients with polymyositis and dermatomyositis presenting clinical manifestations suggestive of small- and medium-vessels vasculitis</div> <div>Jangwoo Ha <i>(Severance Hosp., Korea)</i></div>
KO-011	<div>Non-alcoholic fatty liver disease fibrosis score is a useful index for predicting all-cause mortality during the follow-up in patients with antineutrophil cytoplasmic antibody-associated vasculitis</div> <div>Pil Gyu Park <i>(Nat'l Health Insurance Service Ilsan Hosp., Korea)</i></div>
KO-012	<div>Regional cardiovascular risk in gout patients: A nationwide cohort study in Korea</div> <div>Byeongzu Ghang <i>(Jeju Nat'l Univ., Korea)</i></div>
KO-013	<div>Comparative risk of retinal vascular complications in patients with gout initiating febuxostat versus allopurinol: A population-based cohort study</div> <div>Min Jung Kim <i>(Seoul Nat'l Univ., Korea)</i></div>
KO-014	<div>Adherence and persistence with urate-lowering therapies among patients with gout : A 6-years prospective observational study</div> <div>Min Wook So <i>(Pusan Nat'l Univ., Korea)</i></div>
KO-015	<div>Analysis of appropriate duration of colchicine prophylaxis to maximize the persistence of xanthine oxidase inhibitors as the first-line urate lowering therapy in patients with gout using HIRA database</div> <div>Seung-Geun Lee <i>(Pusan Nat'l Univ., Korea)</i></div>

<div><div><div>🕒</div><div>11:00-12:00</div></div><div><div>LUPUS</div></div></div> <div>[Special Lecture]</div> <div>Grand Ballroom 102</div> <div><div>E</div></div>	
<div>Chairs</div> <div>Nathalie Costedoat-Chalumeau <i>(Cochin Hosp., France)</i> Han Joo Baek <i>(Gachon Univ., Korea)</i></div>	
11:00-11:30	<div>Autoimmunity, COVID-19, post-COVID-19, and SLE</div> <div>Yehuda Shoenfeld <i>(Zabludowicz Center of Autoimmunity, Sheba Medical Center, Israel)</i></div>
11:30-12:00	<div>COVID-19 and Lupus: Unraveling the mystery from real world data</div> <div>Wen-Nan Huang <i>(Taichung Veterans General Hosp., Taiwan)</i></div>

<div><div><div>🕒</div><div>12:00-13:00</div></div><div><div>LUPUS</div><div>KCR</div></div></div> <div>[Luncheon Symposium 5 - Astellas]</div> <div>Grand Ballroom 101+102</div> <div><div>E</div></div>	
<div>Chair</div> <div>Young Ho Lee <i>(Korea Univ., Korea)</i></div>	
12:00-12:40	<div>Multi-target therapy in patients with lupus nephritis</div> <div>Keiju Hiromura <i>(Gunma Univ., Japan)</i></div>

<div><div>🕒</div><div>12:00-13:00</div></div> <div>[Luncheon Symposium 6 - Lilly]</div> <div>Grand Ballroom 103</div>	
<div><div>LUPUS</div><div>KCR</div><div>Spotlight on JAKi to Making the Right Decision for your Patients with RA</div><div>E</div></div>	
Chair	Wan-Uk Kim <i>(The Catholic Univ. of Korea, Korea)</i>
12:00-12:40	Shared decision making for patients with RA based on the evidence of Baricitinib Kei Ikeda <i>(Dokkyo Medical Univ., Japan)</i>

<div><div>🕒</div><div>12:00-13:00</div></div> <div>[Luncheon Symposium 7 - Novartis]</div> <div>Grand Ballroom 104</div>	
<div><div>LUPUS</div><div>KCR</div><div>Luncheon Symposium 7</div><div>K</div></div>	
Chair	Tae-Hwan Kim <i>(Hanyang Univ., Korea)</i>
12:00-12:40	Cosentyx as standard of care for axSpA in the era of Biologics Eun Young Lee <i>(Seoul Nat’l Univ., Korea)</i>

<div><div>🕒</div><div>12:00-13:00</div></div> <div>[Luncheon Symposium 8 - AbbVie]</div> <div>Grand Ballroom 105</div>	
<div><div>LUPUS</div><div>KCR</div><div>Optimizing Care to Improve Treatment Outcomes in Ankylosing Spondylitis</div><div>K</div></div>	
Chair	Hoon-Suk Cha <i>(Sungkyunkwan Univ., Korea)</i>
12:00-12:40	Exploring a new treatment option for active ankylosing spondylitis Sang-Hoon Lee <i>(Kyung Hee Univ., Korea)</i>

<div><div>🕒</div><div>13:00-14:30</div></div> <div>[Concurrent Session 5]</div> <div>Auditorium</div>	
<div><div>LUPUS</div><div>Comorbidities</div><div>E</div></div>	
Chairs	Dafna Gladman <i>(Univ. of Toronto, Canada)</i> Hye-Soon Lee <i>(Hanyang Univ., Korea)</i>
13:00-13:20	Update in cardiovascular lupus Michelle Petri <i>(Johns Hopkins Univ., USA)</i>
13:20-13:40	Malignancy in SLE Sasha Bernatsky <i>(Research Institute of the McGill Univ. Health Centre, Canada)</i>
13:40-14:00	Infection in SLE Chang-Hee Suh <i>(Ajou Univ., Korea)</i>
LO-018	Effect of COVID-19 infection on disease flares and herpes zoster reactivation in patients with SLE : A case-control study Chi-Chiu Mok <i>(Tuen Mun Hosp., Hong Kong)</i>
LO-019	Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus : Results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study Julius Lindblom <i>(Karolinska Institutet, Sweden)</i>
LO-020	Association between corticosteroid use and risk of avascular necrosis in patients with systemic lupus erythematosus: A nested case-control study Jongmin Lee <i>(Chung-Ang Univ., Korea)</i>

<div><div>🕒</div><div>13:00-14:30</div></div> <div>[Concurrent Session 6]</div> <div>Grand Ballroom 101</div>	
<div><div>LUPUS</div><div>New Treatments</div><div>E</div></div>	
Chairs	Richard Furie <i>(Northwell Health, USA)</i> Hoon-Suk Cha <i>(Sungkyunkwan Univ., Korea)</i>
13:00-13:20	Precision medicine for lupus: Big problems but greater rewards Joan Merrill <i>(Oklahoma Medical Research Foundation, USA)</i>
13:20-13:40	Type I interferon targeted therapy Ronald Van Vollenhoven <i>(Amsterdam UMC, Netherlands)</i>
13:40-14:00	Targeting B cells/plasma cells in SLE Richard Furie <i>(Northwell Health, USA)</i>
LO-021	Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE) Shin-Seok Lee <i>(Chonnam Nat’l Univ., Korea)</i>
LO-022	Modulation of inflammation in systemic lupus erythematosus utilizing mesenchymal stem cell-derived secretome Sung Soo Ahn <i>(Yonsei Univ., Korea)</i>
LO-043	Single-cell RNA sequencing reveals the dynamics of circulating immune cells in SLE patients treated with Belimumab Christine Suh-Yun Joh <i>(Seoul Nat’l Univ., Korea)</i>

<div><div>🕒</div><div>13:00-14:30</div></div> <div>[Alliance Session 3]</div> <div>Grand Ballroom 102</div>	
<div><div>LUPUS</div><div>Global Collaboration to Overcome Health Care Disparities</div><div>A가E</div></div>	
Chairs	Sung Sam Lim <i>(Emory Univ., USA)</i> Chan-Bum Choi <i>(Hanyang Univ., Korea)</i>
13:00-13:20	Latin Americans: A population at risk of severe lupus Guillermo Pons-Estel <i>(Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)</i>
13:20-13:40	Social determinants of health in lupus Sung Sam Lim <i>(Emory Univ., USA)</i>
13:40-14:00	Strategies to end health disparities in SLE Matthew H Liang <i>(Harvard Medical School, USA)</i>
14:00-14:30	Panel Discussion

<div><div><div>🕒</div><div>13:00-14:30</div></div><div><div>KCR</div></div></div> <div>[International Symposium 4]</div> <div>Grand Ballroom 103</div> <div><div>E</div></div>	
<div>Chairs</div> <div>Hyo-Jin Choi <i>(Gachon Univ., Korea)</i> Jung Soo Song <i>(Chung-Ang Univ., Korea)</i></div>	
13:00-13:30	<div>Cardiovascular safety of urate lowering therapies</div> <div>Eun Ha Kang <i>(Seoul Nat'l Univ., Korea)</i></div>
13:30-14:00	<div>The role of hyperuricemia in the progression of chronic kidney disease</div> <div>Daniel I. Feig <i>(Univ. of Alabama, USA)</i></div>
KIO-006	<div>Adherence to urate-lowering therapy affects the risk of cardiovascular events in patients with gout</div> <div>Min Jung Kim <i>(Seoul Nat'l., Korea)</i></div>
KIO-007	<div>Major adverse cardiovascular events with subclinical atherosclerosis in gouty arthritis patients</div> <div>Yu Wang <i>(First Hosp. of Peking Univ., China)</i></div>

<div><div><div>🕒</div><div>13:00-14:30</div></div><div><div>KCR</div></div></div> <div>[Free Paper Session 3]</div> <div>Grand Ballroom 104</div> <div><div>K</div></div>	
<div>Chairs</div> <div>Tae-Hwan Kim <i>(Hanyang Univ., Korea)</i> Myeung Su Lee <i>(Wonkwang Univ., Korea)</i></div>	
KO-016	<div>Dissociation of serum IL-23 and IL-17 levels in patients with spondyloarthritis according to radiographic stage</div> <div>Jina Yeo <i>(Gachon Univ., Korea)</i></div>
KO-017	<div>Clonorchis sinensis-excretory/secretory protein ameliorates inflammation in ankylosing spondylitis</div> <div>Moon-Ju Kim <i>(Chonnam Nat'l Univ., Korea)</i></div>
KO-018	<div>The expression of alpha7 nicotinic acetylcholine receptor and the effect of smoking in curdlan-administered SKG Mice</div> <div>Young Eun Kim <i>(Univ. of Ulsan, Korea)</i></div>
KO-019	<div>Inferring metabolic pathway activity levels of bone formation from RNA-Seq data of TgA86 mouse model of Spondyloarthritis</div> <div>Man S Kim <i>(Kyung Hee Univ., Korea)</i></div>
KO-020	<div>The complement factor H-related protein-5 (FHR-5) exacerbates pathological bone formation of ankylosing spondylitis</div> <div>Jihyun Lee <i>(Eulji Univ., Korea)</i></div>
KO-021	<div>The emerging mechanism of IL-17A/WNT5a/ROR2 axis in pathological bone formation of ankylosing spondylitis</div> <div>Sungsin Jo <i>(Hanyang Univ., Korea)</i></div>
KO-022	<div>Microtrauma exacerbates arthritis and enthesitis in curdlan-administered SKG mice by inducing FGF16 expression</div> <div>Seung Hoon Lee <i>(Hanyang Univ., Korea)</i></div>

<div><div><div>🕒</div><div>13:00-14:30</div></div><div><div>KCR</div></div></div> <div>[Free Paper Session 4]</div> <div>Grand Ballroom 105</div> <div><div>E</div><div>K</div></div>	
<div>Chairs</div> <div>Soo-Kyung Cho <i>(Hanyang Univ., Korea)</i> Sung Won Lee <i>(Dong-A Univ., Korea)</i></div>	
KO-023	<div>Withdrawn</div>
KO-024	<div>Mortality-related health metrics in rheumatic and musculoskeletal diseases: an epidemiological analysis of a nationwide register-based cohort</div> <div>Muong Li <i>(Peking Union Medical College Hosp., China)</i></div>
KO-025	<div>Risk of cancer, cardiovascular disease, thromboembolism, and mortality in rheumatoid arthritis with janus kinase inhibitors: Data from Korean health insurance data</div> <div>Hong Ki Min <i>(Konkuk Univ., Korea)</i></div>
KO-026	<div>Risk of major adverse cardiovascular events following targeted therapy according to cardiovascular disease history in patients with rheumatoid arthritis</div> <div>Seung-Hun You <i>(Chung-Ang Univ., Korea)</i></div>
KO-027	<div>Risk of infections between JAK inhibitors and TNF inhibitors among patients with rheumatoid arthritis</div> <div>Se Rim Choi <i>(Seoul Nat'l Univ., Korea)</i></div>
KO-028	<div>Risk-benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab</div> <div>Jun Won Park <i>(Seoul Nat'l Univ., Korea)</i></div>

<div><div><div>🕒</div><div>14:30-15:30</div></div><div><div>KCR</div></div></div> <div>[Meet the Mentor]</div> <div>Conference Room 209A</div> <div><div>K</div></div>	
<div>Facilitator</div> <div>Sang-Heon Lee <i>(Konkuk Univ., Korea)</i></div>	
14:30-15:30	<div>Meet the Mentor 2 - Prof. Ho-Youn Kim</div> <div>Ho-Youn Kim <i>(Ho Youn Kim's Clinics for Arthritis Rheumatism, Korea)</i></div>

<div><div><div>🕒</div><div>14:30-15:30</div></div><div><div>KCR</div></div></div> <div>[Meet the Mentor]</div> <div>Conference Room 209B</div> <div><div>E</div></div>	
<div>Facilitator</div> <div>Jason Jungsik Song <i>(Yonsei Univ., Korea)</i></div>	
14:30-15:30	<div>Meet the Mentor 3 - Prof. Mary Crow</div> <div>Mary Crow <i>(Hosp. for Special Surgery, USA)</i></div>

🕒 14:30-15:30 [Short Oral Prsentation] Auditorium Meeting Room A	
LUPUS SLE Etiology & Pathogenesis 2 E	
Chair Youn-soo Choi (Seoul Nat'l Univ., Korea)	
LSO-037	STING/TMEM173 mutation in systemic lupus erythematosus : From animal model to intrinsic human genetics Prapaporn Pisitkun (Mahidol Univ., Thailand)
LSO-038	Nlrp12 deficiency mice present severer lupus nephritis in lupus prone model and pristane-induced lupus like model Yen Po Tsao (Taipei Veterans General Hosp., Taiwan)
LSO-039	Proteomic analysis of cutaneous lupus erythematosus and dermatomyositis dermal infiltrate reveals differentially expressed canonical pathways Aliisa Häyry (Karolinska Institutet, Sweden)
LSO-040	Mitochondria promotes autoimmune plasmablasts generation in lupus Sung Hoon Jang (Yonsei Univ., Korea)
LSO-041	Loss-of-function NADPH oxidase variants promote lupus pathogenesis by modulating B cell-intrinsic TLR signals Shaun Jackson (Seattle Children's Research Institute, USA)
LSO-042	The treatment effect of STING inhibitor (ISD-017) on lupus phenotypes in the Fcgr2b-deficient mice Isara Alee (Chulalongkorn Univ., Thailand)
LSO-101	A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells. Shaun Jackson (Seattle Children's Research Institute, USA)

🕒 14:30-15:30 [Short Oral Prsentation] Conference Room 206 A+B	
LUPUS SLE Biomarkers 2 E	
Chair Seokchan Hong (Univ. of Ulsan, Korea)	
LSO-043	Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus Ji-Hyouon Kang (Chonnam Nat'l Univ., Korea)
LSO-044	Sphingolipids are potential diagnostic biomarkers for Korean patients with systemic lupus erythematosus Ji-Won Kim (Ajou Univ., Korea)
LSO-045	Multiple molecular biomarkers that predict response to treatment in lupus nephritis Dae Jin Park (Yonsei Univ., Korea)
LSO-046	Metabolomic analysis for the unique profile and novel biomarkers of neuropsychiatric systemic lupus erythematosus Xiaolin Sun (Peking Univ. People's Hosp., China)
LSO-047	Utility of autoantibody against an UCH-L1 epitope as a serum diagnostic marker for neuropsychiatric systemic lupus erythematosus Xiaolin Sun (Peking Univ. People's Hosp., China)
LSO-102	The correlation between interleukin-6(il-6) and the development of systemic lupus erythematosus(SLE) in Universiti Sains Malaysia(USM) Mohamed Shafi Mahboob Ali (Univ. Sains Malaysia(USM), Malaysia)

🕒 14:30-15:30 [Short Oral Prsentation] Auditorium Meeting Room C	
LUPUS SLE Epidemiology and Public Health 2 E	
Chair Yeon-Ah Lee (Kyung Hee Univ., Korea)	
LSO-048	Incidence, prevalence, and burden of systemic lupus erythematosus in urban China, 2013-2017 : A nationwide population-based study Mucong Li (Peking Union Medical College Hosp., China)
LSO-049	Greater social vulnerability associated with greater glucocorticoid use in patients with SLE Alfred Kim (Washington Univ., USA)
LSO-050	Mortality-rate in juvenile-onset systemic lupus erythematosus in perspective : Results from a population-based cohort study in Norway Sigrid Reppe Moe (Oslo Univ. Hosp., Norway)
LSO-051	Smoking at onset of systemic lupus erythematosus compared with age-matched controls Anniken Orre (Drammen Hosp. Trust, Norway)
LSO-052	Comparative cardiovascular risk in patients with older-onset systemic lupus erythematosus : A nationwide retrospective cohort study in Korea Jungyong Han (Hanyang univ., Korea)
LSO-103	Childhood-onset systemic lupus erythematosus : Long-term outcomes in a large multi-ethnic Ontario cohort Ha-Seul Jeoung (ICES, Canada)


🕒 14:30-15:30 [Short Oral Prsentation] Auditorium Meeting Room B	
LUPUS SLE Genetics & Omics E	
Chair Kwangwoo Kim (Kyung Hee Univ., Korea)	
LSO-053	Elevated expression of sa_circ_0000479 in neutrophils correlates with features of systemic lupus erythematosus Ranran Yao (Peking Univ. People's Hosp., China)
LSO-054	Genetic fine mapping of independent variants in MHC region associated with predisposition and clinical feature of systemic lupus erythematosus in Han Chinese population Ke Xue (China Japan Friendship hosp., China)
LSO-055	Genetic contributions to neuropsychiatric systemic lupus erythematosus Soojin Cha (Hanyang Univ., Korea)
LSO-056	Impaired function of neutrophil cytosolic factor 2 (NCF2) may participates in lupus from multiple pathways Ang Li (Peking Union Medical College and Chinese Academy of Medical Sciences, China)
LSO-057	Association between TNFSF13B gene polymorphism and serum BAFF Levels with disease activity in SLE patients Nadia Gita Ghassani (Lupus Study Group, Study Center of Immunology, Indonesia)


<div><div>🕒 14:30-15:30</div><div>LUPUS</div></div> <div>[Short Oral Presentation]</div> <div>Conference Room 205 A</div> <div>E</div>	
Chair <div>Seung Min Jung <i>(The Catholic Univ. of Korea, Korea)</i></div>	
LSO-058	Changes in clinical features and mortality of early (1998-2007) and late cohort (2008-2017) of systemic lupus erythematosus: a prospective inception cohort study <i>Young Bin Joo (Hanyang Univ., Korea)</i>
LSO-059	Systemic lupus erythematosus (SLE) patients in Auckland : Epidemiology and attainment of Lupus Low Disease Activity State (LLDAS) <i>Nisha Prashar (Te Whatu Ora Aotearoa, New Zealand)</i>
LSO-060	Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus. <i>Manuel Ugarte-gil (Universidad Científica del Sur, Peru)</i>
LSO-061	Withdrawn
LSO-062	Worse outcomes linked to ethnicity for the early treatment of refractory SLE : Results from the BILAG-BR <i>Ian Bruce (The Univ. of Manchester, UK)</i>
LSO-063	Prediction of mortality using clusters based on clinical and lab parameters : Data from 2072 patients from INSPIRE cohort <i>Chengappa Kavadiachanda (JIMPER, India)</i>
LSO-104	Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage iv or worse) in lupus nephritis <i>Dafna Gladman (Univ. of Toronto, Canada)</i>

<div><div>🕒 14:30-15:30</div><div>LUPUS</div></div> <div>[Short Oral Prsentation]</div> <div>Conference Room 205B</div> <div>E</div>	
Chair <div>Su-Jin Moon <i>(The Catholic Univ. of Korea, Korea)</i></div>	
LSO-064	Disease -modifying effect and long-term safety data of belimumab in patients with SLE : A single centre retrospective analysis <i>Takehiro Nakai (St. Luke's Int'l Hosp., Japan)</i>
LSO-065	Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: Results from four randomised clinical trials <i>Alvaro Gomez (Karolinska Institutet, Sweden)</i>
LSO-066	Spanish national registry of belimumab in patients with systemic lupus erythematosus <i>Vicente Aldasoro (Hosp. Universitario de Navarra, Spain)</i>
LSO-067	Withdrawn
LSO-068	Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity Index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-Fatigue scores in patients with SLE <i>Wen-Hung Chen (GSK, UK)</i>
LSO-069	Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice <i>Beatriz Frade-Sosa (Hosp. Clinic of Barcelona, Spain)</i>
LSO-105	D-ALW nanoparticles ameliorate lupus nephritis in MRL/lpr mice <i>Yumin Xia (The Second Affiliated Hosp. of Xi'an Jiaotong Univ., China)</i>

<div><div>🕒 15:30-17:00</div><div>LUPUS</div></div> <div>[Plenary Session 4]</div> <div>Auditorium</div> <div>E</div>	
Chairs <div>Joan Merrill <i>(Oklahoma Medical Research Foundation, USA)</i> Yong-Beom Park <i>(Yonsei Univ., Korea)</i></div>	
15:30-16:00	Sequential vs combination in lupus nephritis treatment <i>Chi-Chiu Mok (Tuen Mun Hosp., Hong Kong)</i>
16:00-16:30	How do we minimise the risk of damage when managing SLE patients? <i>Ian Bruce (The Univ. of Manchester, UK)</i>
LO-023	Remission of lupus nephritis: The trajectory of histologic response in successfully treated patients <i>Ana Malvar (Hosp. Fernández, USA)</i>
LO-024	Association between severe non-adherence to hydroxychloroquine and SLE flares, damage, and mortality in 660 patients from the SLICC inception cohort <i>Nathalie Costedoat-Chalumeau (Cochin Hosp., France)</i>



<div><div>🕒 15:30-17:00</div><div>KCR</div></div> <div>[International Symposium 5]</div> <div>Grand Ballroom 103</div> <div>E</div>	
Chairs <div>Shin-Seok Lee <i>(Chonnam Nat'l Univ., Korea)</i> Yun Jong Lee <i>(Seoul Nat'l Univ., Korea)</i></div>	
15:30-16:00	Labial minor salivary gland biopsy <i>Benjamin Fisher (Univ. of Birmingham, UK)</i>
16:00-16:30	Salivary gland ultrasonography for stratification of pSS patients <i>Hong Ki Min (Konkuk Univ., Korea)</i>
KIO-008	Interstitial lung disease in Sjögren's syndrome: Prevalence, patterns, treatment, and prognosis <i>Jung Hee Koh (The Catholic Univ. of Korea, Korea)</i>
KIO-009	Clinical significance of MerTK and Tyro3 levels in the minor salivary glands of patients with Sjögren's syndrome <i>Sung-Eun Choi (Chonnam Nat'l Univ., Korea)</i>
KIO-010	Synthetic glabridin derivatives improves Sjögren's syndrome by inducing salivary secretion and salivary gland regeneration <i>Jin-Sil Park (The Catholic Univ. of Korea, Korea)</i>

 15:30-16:30



[Free Paper Session 5]

Grand Ballroom 104




Rheumatoid Arthritis – Clinical Research 1

Chairs

Bin Yoo *(Univ. of Ulsan, Korea)*
Jinseok Kim *(Jeju Nat’l Univ., Korea)*

KO-029	Identification of a novel salivary diagnostic biomarker in rheumatoid arthritis <i>Mi Song Kim (Kyung Hee Univ., Korea)</i>
KO-031	Risk of acute myocardial infarction and stroke associated with anti-rheumatic drugs in patients with rheumatoid arthritis: A nationwide population-based study <i>Soo Min Ahn (Univ. of Ulsan, Korea)</i>
KO-032	Are disease-modifying antirheumatic drugs for rheumatoid arthritis associated with a lower risk of dementia? A systematic review with meta-analysis <i>Wenhui Xie (Peking Univ. First Hosp., China)</i>
KO-033	New-onset atrial fibrillation in seropositive rheumatoid arthritis: Association with disease-modifying anti-rheumatic drugs treatment <i>Sung Soo Ahn (Yonsei Univ., Korea)</i>
KO-034	Effect of rheumatoid arthritis on total knee arthroplasty <i>Wooseong Jeong (Jeju Nat’l Univ., Korea)</i>
KO-030	Salivary microbiome: As a diagnostic biomarker of seronegative rheumatoid arthritis <i>Hyesu Jo (Kyung Hee Univ., Korea)</i>

16:30-17:30

KCR

[Free Paper Session 6]

Grand Ballroom 104

E


K


Rheumatoid Arthritis – Clinical Research 2

Chairs

Gwan Gyu Song *(Korea Univ., Korea)*
Ki-Jo Kim *(The Catholic Univ. of Korea, Korea)*

KO-035	<div>Clinical characteristics and treatment outcomes of patients with difficult-to-treat rheumatoid arthritis : From the KOBIO registry</div> <div>Hyoun-Ah Kim <i>(Ajou Univ., Korea)</i></div>
KO-036	<div>Identifying HLA-DRB1 haplotypes that predict better response to abatacept than to TNF inhibitors in patients with rheumatoid arthritis</div> <div>Soojin Cha <i>(Hanyang Univ., Korea)</i></div>
KO-066	<div>Efficacy of subcutaneous vs intravenous infliximab in rheumatoid arthritis: A post-hoc analysis of a randomised phase III trial</div> <div>Dae Hyun Yoo <i>(Hanyang Univ., Korea)</i></div>
KO-037	<div>Effect of JAK1 inhibition on erosion repair in rheumatoid arthritis: A pilot HR-pQCT study</div> <div>Ho So <i>(The Chinese Univ. of Hong Kong, Hong Kong)</i></div>
KO-067	<div>Real-world utilisation and switching between Janus kinase inhibitors in patients with rheumatoid arthritis in the Australian OPAL dataset</div> <div>Young in Eom <i>(Lilly Korea Ltd., Korea)</i></div>

<div><div> 15:30-17:30</div><div>KCR</div></div> <div>[Symposium]</div> <div>Grand Ballroom 105</div> <div><div>K</div></div>		Medical Humanities Program	
Chairs		Sang-Hyon Kim <i>(Keimyung Univ., Korea)</i> Choong-Ki Lee <i>(Yeungnam Univ., Korea)</i>	
15:30-16:30	Prevention is the best solution to medical disputes Seung-Jae Hong <i>(Kyung Hee Univ., Korea)</i>		
16:30-17:30	Changes in the medical environment and ethics according to changes in Korea’s population Hyekyung Woo <i>(Kongju Nat’l Univ., Korea)</i>		

17:00-18:30

LUPUS

[Concurrent Session 7]

Auditorium

E

Chairs

Angela Tincani (ASST-Spedali Civili and Univ. of Brescia, Italy)
Jisoo Lee (Ewha Womans Univ., Korea)

17:00-17:20	Use of SLE therapies in the pre-conceptual and pregnant SLE patient Ian Bruce (The Univ. of Manchester, UK)
17:20-17:40	Will my baby be healthy? The long term outcome of children from patients with SLE Angela Tincani (ASST-Spedali Civili and Univ. of Brescia, Italy)
17:40-18:00	Burden of SLE on women of childbearing age Jisoo Lee (Ewha Womans Univ., Korea)
LO-025	Increasing pre-eclampsia knowledge and higher prevalence of aspirin use in SLE with a specific educational tool: Interim analyses of a randomized controlled trial Joo-Young (Esther) Lee (Research Institute of McGill Univ. Health Centre, Canada)
LO-026	Hydroxychloroquine use in pregnant women with systemic lupus erythematosus and major congenital malformations in the offspring Viet Ngoc Nguyen (Karolinska Institutet, Sweden)
LO-027	COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus Ioannis Parodis (Karolinska Institutet, Sweden)

<div><div>🕒</div><div>17:00-18:30</div></div> <div><div>LUPUS</div></div> <div>[Concurrent Session 8]</div> <div>Grand Ballroom 101</div> <div><div>E</div></div>	
<div>Chairs</div> <div>Peter E. Lipsky <i>(AMPEL BioSolutions, USA)</i> Kwangwoo Kim <i>(Kyung Hee Univ., Korea)</i></div>	
17:00-17:20	<div>Lupus autoimmunity and Epstein-Barr virus informs other idiopathic diseases</div> <div>John Harley <i>(Cincinnati Education and Research for Veterans Foundation, USA)</i></div>
17:20-17:40	<div>New insights into SLE from machine learning of transcriptomic data</div> <div>Peter E. Lipsky <i>(AMPEL BioSolutions, USA)</i></div>
17:40-18:00	<div>Neuroimaging and single cell RNAseq</div> <div>Betty Diamond <i>(The Feinstein Institutes for Medical Research, USA)</i></div>
LO-028	<div>Functional dissection of dysregulated enhancers influencing SLE critical gene expression</div> <div>Guojun Hou <i>(Shanghai Jiao Tong Univ., China)</i></div>
LO-029	<div>Longitudinal single-cell transcriptomic analysis of peripheral blood in lupus nephritis reveals different immune cell gene signatures depending on treatment response</div> <div>Woo-Joong Kim <i>(KAIST, Korea)</i></div>
LO-030	<div>Functional characterization of 2p22.3 locus identifies PARP-1 as an allele-specific interactor at rs13385731 which mechanistically regulates rasgrp3 expression in contributing SLE susceptibility</div> <div>Swapan Nath <i>(Oklahoma Medical Research Foundation, USA)</i></div>

<div><div>🕒</div><div>17:00-18:30</div></div> <div><div>LUPUS</div></div> <div>[Alliance Session 4]</div> <div>Grand Ballroom 102</div> <div><div>E</div></div>	
<div>Chairs</div> <div>George Tsokos <i>(Harvard Medical School, USA)</i> Joe Craft <i>(Yale Univ., USA)</i></div>	
17:00-17:30	<div>Grants and funding-National Institute of Arthritis and Musculoskeletal and Skin Diseases</div> <div>Lindsey Criswell <i>(Nat'l Institutes of Health, USA)</i></div>
17:30-18:00	<div>Grants and funding-Lupus Research Alliance</div> <div>Teodora Staeva <i>(Lupus Research Alliance, USA)</i></div>
18:00-18:30	<div>Panel Discussion</div>

<div><div>🕒</div><div>17:00-18:30</div></div> <div><div>LUPUS</div></div> <div>[Patient Session 2]</div> <div>Room 205A+B</div> <div><div>A가E</div><div>K</div></div>	
<div>Chairs</div> <div>Seung Cheol Shim <i>(Chungnam Nat'l Univ., Korea)</i> So-Young Bang <i>(Hanyang Univ., Korea)</i></div>	
17:00-17:20	<div>Living with lupus</div> <div>Jin Hye Kim <i>(Korea Lupus Support Group, Korea)</i></div>
17:20-17:40	<div>Coping with lupus</div> <div>Seonghoon Park <i>(Daegu Catholic Univ., Korea)</i></div>
17:40-17:45	<div>KSSR introduction</div> <div>Seung Cheol Shim <i>(Chungnam Nat'l Univ., Korea)</i></div>
17:45-17:50	<div>Korea Lupus Support Group introduction</div> <div>Jin Hye Kim <i>(Korea Lupus Support Group, Korea)</i></div>
17:50-18:00	<div>APLAR-SIG patient empowerment project introduction</div> <div>Laniyati Hamijoyo <i>(Univ. of Padjadjaran, Indonesia)</i></div>
18:00-18:20	<div>Discussion Forum</div>

<div><div>🕒</div><div>19:00-21:00</div></div> <div><div>LUPUS</div><div>KCR</div></div> <div>[Social Program]</div> <div>InterContinental Seoul COEX Harmony Ballroom</div> <div><div>E</div></div>	
<div>Gala Dinner</div>	

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



DAY 04

Program

 May 20 (Sat)



🕒

08:00-09:00

[Breakfast Symposium 9 - Novartis]

Grand Ballroom 101+102

LUPUS

KCR

Breakfast Symposium 9

E

Chair	Thomas Dörner (Charité Universitätsmedizin Berlin, Germany)
08:00-08:40	Evolution of therapeutic B cell depletion in lupus Stephen Oliver (Novartis AG, Switzerland)

🕒

08:00-09:00

[Breakfast Symposium 10 - Amgen]

Grand Ballroom 103

LUPUS

KCR

Building Strong Bones for Life: Strategies for Long-Term Osteoporosis Treatment

E

Chair	Jung Soo Song (Chung-Ang Univ., Korea)
08:00-08:40	Building strong bones for life: Strategies for long-term osteoporosis treatment Kichul Shin (Seoul Nat'l Univ., Korea)

🕒

08:00-09:00

[Breakfast Symposium 11 - Lilly]

Grand Ballroom 104

LUPUS

KCR

Improving Outcomes for the Patients with AxSpA

K

Chair	Yong-Beom Park (Yonsei Univ., Korea)
08:00-08:40	Exploring the impact of Ixekizumab in treatment for biologics-naive patients with Spondyloarthritis Yun-Hong Cheon (Gyeongsang Nat'l Univ., Korea)

🕒

08:00-09:00

[Breakfast Symposium 12 - Kezar Life Science]

Grand Ballroom 105

LUPUS

KCR

Zetomipzomib: A Novel Approach in Lupus Nephritis

E

Chair	Eric Morand (Monash Univ., Australia)
08:00-08:40	Selective immunoproteasome inhibition with Zetomipzomib for the treatment of lupus nephritis : Review of the open-label mission study results Richard Furie (Northwell Health, USA)

🕒

09:00-10:00

[Special Lecture]

Grand Ballroom 103+104+105

KCR

Keynote Lecture 2

K

Chairs	Sang-Cheol Bae (Hanyang Univ., Korea)
09:00-10:00	Synthetic biology and next-generation biomedicine Byung-Kwan Cho (KAIST, Korea)

🕒

09:15-10:00

[Meet the Professor 7]

Grand Ballroom 101

LUPUS

Musculoskeletal Diseases in SLE

E

Facilitator	Eun Young Lee (Seoul Nat'l Univ., Korea)
09:15-09:45	Musculoskeletal diseases in SLE Chak-Sing Lau (Univ. of Hong Kong, Hong Kong)
09:45-10:00	Q&A

🕒

09:15-10:00

[Meet the Professor 8]

Grand Ballroom 102

LUPUS

Lupus Nephritis

E

Facilitator	Seokchan Hong (Univ. of Ulsan, Korea)
09:15-09:45	Lupus nephritis Tak Mao Chan (Univ. of Hong Kong, Hong Kong)
09:45-10:00	Q&A

🕒

09:15-10:00

[Meet the Professor 9]

Room 205A+B

LUPUS

Pulmonary Hypertension

E

Facilitator	Hyun-Sook Kim (Soonchunhyang Univ., Korea)
09:15-09:45	Pulmonary hypertension Mandana Nikpour (The Univ. of Melbourne, Australia)
09:45-10:00	Q&A

🕒

10:30-12:00

[Plenary Session 5]

Auditorium


LUPUS


Clinical Challenges: Diagnosis and Outcome Measures


E


Chairs	Andrea Doria (Univ. of Padua, Italy) Young Ho Lee (Korea Univ., Korea)
10:30-11:00	Diagnostic challenges in SLE David Isenberg (Univ. College London, UK)
11:00-11:30	Challenges in measuring clinical outcomes in SLE Eric Morand (Monash Univ., Australia)
LO-031	Working towards a core minimal dataset for systemic lupus erythematosus studies Ian Bruce (The Univ. of Manchester, UK)
LO-032	Increased IFITM gene-signatures in age-associated B and plasma cells define non-response to mycophenolate mofetil in systemic lupus erythematosus Daniel Toro-domínguez (Centre for Genomics and Oncological Research, Spain)
LO-033	Towards a novel clinical outcome assessment for systemic lupus erythematosus trials - first outcomes of an international consensus process Eric Morand (Monash Univ., Australia)

 10:30-12:00		[International Symposium 6]	Grand Ballroom 103
		The Evolution of Fibromyalgia, its Concepts, and Treatment 	
Chairs		Geun-Tae Kim (<i>Kosin Univ., Korea</i>) Hyung-In Yang (<i>Kyung Hee Univ., Korea</i>)	
10:30-11:00	Fibromyalgia, how stress becomes neuropathic pain Manuel Martinez-Lavin (<i>Nat'l Institute of Cardiology Mexico, Mexico</i>)		
11:00-11:30	What role for neuroinflammation and small fiber neuropathy in fibromyalgia? Jeeyoung Oh (<i>Konkuk Univ., Korea</i>)		
11:30-12:00	New insights into the pathophysiology of fibromyalgia Jiwon Hwang (<i>Sungkyunkwan Univ., Korea</i>)		

 10:30-12:00	[Free Paper Session 7]	Grand Ballroom 104 <div> <div>E</div> <div>K</div> </div>
Chairs	Seung-Ki Kwok (<i>The Catholic Univ. of Korea, Korea</i>) Yong-Wook Park (<i>Chonnam Nat'l Univ., Korea</i>)	
KO-038	A novel therapeutic target for arthritis pain Kevin Lee (<i>Univ. of Melbourne, Australia</i>)	
KO-039	AMP-activated protein kinase modulates the migration of fibroblast-like synoviocytes via SLC7A11-NOX4-ROS signaling in patients with rheumatoid arthritis Ha-Reum Lee (<i>Chungnam Nat'l Univ., Korea</i>)	
KO-040	Exosome-based delivery of super-repressor IκB ameliorates inflammation in rheumatoid arthritis Hae-in Lee (<i>Chonnam Nat'l Univ., Korea</i>)	
KO-041	Low-dose radiotherapy attenuates experimental autoimmune arthritis by inducing lymphocyte apoptosis Bo-Gyu Kim (<i>Gyeongsang Nat'l Univ., Korea</i>)	
KO-042	Identification of three novel susceptibility loci for rheumatoid arthritis in a large-scale genome-wide association study in the Korean population Ayeong Kwon (<i>Kyung Hee Univ., Korea</i>)	
KO-043	The effect of treatment with TIP-1 and MIP-2 through blocking TLRs in adult-onset Still's disease animal model Mi-Hyun Ahn (<i>Ajou Univ., Korea</i>)	
KO-068	Multi-tissue adaptive regeneration of musculoskeletal tissues by novel human musculoskeletal stem cells induced from hPSCs Sang-il Lee (<i>Gyeongsang Nat'l Univ., Korea</i>)	

 10:30-12:00 <div>KCR</div>	[Free Paper Session 8] Miscellaneous rheumatic disease and inflammatory disease	Grand Ballroom 105 <div>E K</div>
Chairs	Won Park (<i>Inha Univ., Korea</i>) Seong-Ho Kim (<i>Inje Univ., Korea</i>)	
KO-044	Use of Infliximab in 90 children with Kawasaki Disease : Experience from a tertiary care centre in North-West India Prabal Barman (<i>Post Graduate Institute of Medical Education and Research Chandigarh, India</i>)	
KO-045	A comparative study of pattern of paediatric uveitis in different subtypes of juvenile idiopathic arthritis : Experience from a tertiary care centre in North-West India Prabal Barman (<i>Post Graduate Institute of Medical Education and Research Chandigarh, India</i>)	
KO-046	Educational project for rheumatology through a self-paced online learning platform : 6 year update of applied rheumatology on the go Lisa Traboco (<i>St Luke's Medical Center, Philippines</i>)	
KO-047	Prediction of osteoporosis in patients with rheumatoid arthritis using machine learning Ki Won Moon (<i>Kangwon Nat'l Univ., Korea</i>)	
KO-048	Artificial intelligence for detection of inflammatory sacroiliitis in magnetic resonance imaging in patients with axial spondyloarthritis Seulkee Lee (<i>Sungkyunkwan Univ., Korea</i>)	
KO-049	Clinical factors associated with pneumocystis pneumonia despite its primary prophylaxis : A case-control study Ju Yeon Kim (<i>Seoul Nat'l Univ., Korea</i>)	
KO-050	Germanium telluride-polyvinylpyrrolidone nanosheets ameliorate inflammatory response in inflammatory disease model Jieun Han (<i>Yonsei Univ., Korea</i>)	

 12:00-13:00 [Luncheon Symposium 9 - Janssen] Grand Ballroom 101+102	
<div style="display: flex; justify-content: space-between; align-items: center;"> <div> <div style="background-color: #800040; color: white; padding: 5px 10px; border-radius: 10px;">LUPUS</div> <div style="background-color: #000080; color: white; padding: 5px 10px; border-radius: 10px;">KCR</div> </div> <div style="text-align: center;"> <h2 style="margin: 0;">Considerations in Patients with Systemic Lupus Erythematosus : Pulmonary Arterial Hypertension</h2> </div> <div style="background-color: #008080; color: white; padding: 5px 10px; border-radius: 10px; text-align: center; font-weight: bold;">E</div> </div>	
Chair Jae-Bum Jun (<i>Hanyang Univ., Korea</i>)	
12:00-12:40	Identification of risk factors of pulmonary arterial hypertension in patients with SLE & updates of 2022 ESC/ERS PH Guidelines Yeon-Ah Lee (<i>Kyung Hee Univ., Korea</i>)

<div><div> 12:00-13:00</div><div>[Luncheon Symposium 10 - Pfizer]</div><div>Grand Ballroom 103</div></div> <div><div><div>LUPUS</div><div>KCR</div></div><div>Role of the Tofacitinib in Rheumatology</div><div>E</div></div>	
Chair <div>Eun Bong Lee (Seoul Nat'l Univ., Korea)</div>	
12:00-12:40	<div>Review the clinical trial data for XELJANZ across RA, PsA, AS</div> <div>Uta Kiltz (Rheumazentrum Ruhrgebiet, Germany)</div>

<div><div>🕒 13:00-14:30</div><div>KCR</div></div> <div>[International Symposium 7]</div> <div>Grand Ballroom 103</div> <div>E</div>	
<div>Chairs</div> <div>Hyun Ah Kim <i>(Hallym Univ., Korea)</i> Gunwoo Kim <i>(Daegu Fatima Hosp., Korea)</i></div>	
13:00-13:30	<div>The role of metabolism in the pathogenesis of osteoarthritis</div> <div>Ali Mobasheri <i>(Univ. of Oulu, Finland)</i></div>
13:30-14:00	<div>Chondrocyte metabolisms, ROS and inflammation</div> <div>Seungwoo Han <i>(Kyungpook Nat'l Univ., Korea)</i></div>
KIO-011	<div>Enhancing oxidative phosphorylation through inhibition of PDK2 alleviates cartilage degradation in a surgical model of osteoarthritis</div> <div>Jin Han <i>(Kyungpook Nat'l Univ., Korea)</i></div>
KIO-012	<div>Genetic knockout of CXCR7 in articular chondrocyte has potential protective effect on advanced knee osteoarthritis in mouse model</div> <div>Junyong Park <i>(Dong-A Univ., Korea)</i></div>
KIO-013	<div>Effect of intra-articular injection of stigmasterol loaded nanoparticles in osteoarthritis rat model</div> <div>Jae Hyun Jung <i>(Korea Univ., Korea)</i></div>

<div><div>🕒 13:00-14:30</div><div>KCR</div></div> <div>[Free Paper Session 9]</div> <div>Grand Ballroom 104</div> <div>E K</div>	
<div>Chairs</div> <div>Mie Jin Lim <i>(Inha Univ., Korea)</i> Bo Young Yoon <i>(Inje Univ., Korea)</i></div>	
KO-051	<div>COVID-19 Infection in patients with rheumatic disease during Omicron outbreak in South Korea : A single-center prospective study</div> <div>Yun Kyu Kim <i>(Seoul Nat'l Univ., Korea)</i></div>
KO-052	<div>Effects of COVID-19 and influenza vaccination on rheumatic diseases : Results from a survey of patient-reported outcome after vaccination</div> <div>Ji-Won Kim <i>(Ajou Univ., Korea)</i></div>
KO-053	<div>Immune response and safety of COVID-19 vaccine in patients with autoimmune diseases</div> <div>Pichaya O-charoen <i>(Mahidol Univ., Thailand)</i></div>
KO-054	<div>Dynamic immune features revealed by single-cell RNA and single-cell TCR/BCR sequencing in patients with rheumatoid arthritis receiving SARS-CoV-2 booster vaccination</div> <div>Yong Fan <i>(Peking Univ. First Hosp., China)</i></div>
KO-055	<div>Modeling of antibody response to COVID-19 vaccinations in patients with rheumatoid arthritis</div> <div>Yun Kyu Kim <i>(Seoul Nat'l Univ., Korea)</i></div>
KO-056	<div>Withdrawn</div>
KO-057	<div>Immunologic response and effects of COVID-19 vaccines in patients with ANCA-associated vasculitis</div> <div>Hyunsue Do <i>(Yonsei Univ., Korea)</i></div>

<div><div>🕒 13:00-14:30</div><div>KCR</div></div> <div>[Free Paper Session 10]</div> <div>Grand Ballroom 105</div> <div>E K</div>	
<div>Chairs</div> <div>Seong Wook Kang <i>(Chungnam Nat'l Univ., Korea)</i> Jinhyun Kim <i>(Chungnam Nat'l Univ., Korea)</i></div>	
KO-058	<div>Longitudinal analysis and treatment response of pathogenic B cells in Sjögren's syndrome</div> <div>Joanne Reed <i>(Westmead Institute for Medical Research, Australia)</i></div>
KO-059	<div>Binding of CXCL13 with heparan sulfate of syndecan-1 plays an important role in pathogenesis of Sjögren's syndrome</div> <div>Jiae Jang <i>(Daegu Fatima Hosp., Korea)</i></div>
KO-060	<div>Kynurenine pathway can be a potential biomarker of fatigue in primary Sjögren's syndrome</div> <div>Youngjae Park <i>(The Catholic Univ. of Korea, Korea)</i></div>
KO-061	<div>High dimensional cartography of lymphocytes using single-cell mass cytometry differentiates systemic lupus erythematosus and primary Sjögren's syndrome</div> <div>Franziska Szelinski <i>(Charité, Germany)</i></div>
KO-062	<div>Risk of incident psoriasis in patients with systemic sclerosis: A nationwide cohort study</div> <div>Oh Chan Kwon <i>(Yonsei Univ., Korea)</i></div>
KO-063	<div>All-cause mortality and risk factors for death in a large multi-center prospective registry cohort of idiopathic inflammatory myositis in China</div> <div>Liyong Peng <i>(Peking Union Medical College Hosp., China)</i></div>
KO-064	<div>Serial imaging changes in skeletal muscle composition and their association with clinical outcomes in idiopathic inflammatory myopathies (IIM)</div> <div>Mamatha Gorijavolu <i>(Jawaharlal Institute of Postgraduate Medical Education and Research, India)</i></div>
KO-065	<div>The expression and regulation of Nox4 in damaged myoblasts in inflammatory myopathy</div> <div>Hae Rim Kang <i>(Seoul Nat'l Univ., Korea)</i></div>

<div><div>🕒 14:30-15:30</div><div>KCR</div></div> <div>[Meet the Mentor]</div> <div>Conference Room 209A</div> <div>K</div>	
<div>Facilitator</div> <div>Tae-Hwan Kim <i>(Hanyang Univ., Korea)</i></div>	
14:30-15:30	<div>Meet the Mentor 4 - Prof. SeongYoon Kim</div> <div>SeongYoon Kim <i>(KIMSEONGYOON Clinic, Korea)</i></div>

<div><div>🕒 14:30-15:30</div><div>LUPUS</div></div> <div>[Short Oral Presentation]</div> <div>Auditorium Meeting Room B</div> <div>E</div>	
Miscellaneous Conditions Associated with SLE	
ChairSeonghoon Park (Daegu Catholic Univ., Korea)	
LSO-093	Gut microbiota analysis in Korean patients with systemic lupus erythematosus Ji-Won Kim (Ajou Univ., Korea)
LSO-094	Analysis of microbiota in patients with systemic lupus erythematosus Toshihiro Nanki (Toho Univ., Japan)
LSO-095	Withdrawn
LSO-096	Analyzing the shared and specific genetic signals among 15 autoimmune diseases shed new light on the underlying causal genes and molecular mechanisms Xiao Dang (The Univ. of Hong Kong, Hong Kong)
LSO-097	Captopril preventing blood brain barrier breach by Anti-Smith Antibody Yoshiyuki Arinuma (Kitasato Univ., Japan)
LSO-108	Ambulatory blood pressure in patients with systemic lupus erythematosus Brygida Przywara-Chowaniec (Medical Univ. of Silesia, Poland)
LSO-109	Characteristics associated with poor COVID-19 outcomes in people with rheumatic disease : Data from one single center from China Haihong Yao (Peking Univ. People's Hosp., China)
LSO-072	Comparison of COVID-19 vaccination with Influenza vaccination in Korean patients with systemic lupus erythematosus: Perception, adverse events, and flares from the CIVIL study Seonghoon Park (Daegu Catholic Univ., Korea)

<div><div>🕒 15:30-17:00</div><div>LUPUS</div></div> <div>[LUPUS 2023 Congress Highlights]</div> <div>Auditorium</div> <div>E</div>	
LUPUS 2023 Congress Highlights	
ChairsSang-Cheol Bae (Hanyang Univ., Korea) Yeonseok Chung (Seoul Nat'l Univ., Korea)	
15:30-16:00	Basic research Seung Cheol Shim (Chungnam Nat'l Univ., Korea)
16:00-16:30	Clinical research Sung Hwan Park (The Catholic Univ. of Korea, Korea)

<div><div>🕒 15:30-17:00</div><div>KCR</div></div> <div>[International Symposium 8]</div> <div>Grand Ballroom 103</div> <div>E</div>	
Managing Spondyloarthritis: Where are We Now	
ChairsSeong R. Kwon (Inha Univ., Korea) Min-Chan Park (Yonsei Univ., Korea)	
15:30-16:00	ASAS health index and spondyloarthritis treatment Uta Kiltz (Rheumazentrum Ruhrgebiet, Germany)
16:00-16:30	The epidemiology and treatment of ankylosing spondylitis in Korea Seong R. Kwon (Inha Univ., Korea)
KIO-014	Time-dependent csDMARDs use and inflammatory burden can predict cardiovascular risk in patients with ankylosing spondylitis: A population-based study Jenny Lin-Hong Shi (The Chinese Univ. of Hong Kong, China)
KIO-015	Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis Ji-Won Kim (Daegu Catholic Univ., Korea)

<div><div>🕒 15:30-17:00</div><div>KCR</div></div> <div>[Workshop]</div> <div>Grand Ballroom 104</div> <div>K</div>	
Editorial Committee Workshop	
ChairsSeong-Kyu Kim (Daegu Catholic Univ., Korea) Joong Kyong Ahn (Sungkyunkwan Univ., Korea)	
15:30-16:00	How to write effective peer review comments Yunhee Whang (Compecs Inc., Korea)
16:00-16:30	Creating effective scientific figures for publication Hyunjoo Kang (MEDART, Korea)
16:30 - 17:00	Appropriateness of study design in biomedical journal Changsoo Kim (Yonsei Univ., Korea)

<div><div>🕒 15:30-17:00</div><div>KCR</div></div> <div>[Symposium]</div> <div>Grand Ballroom 105</div> <div>K</div>	
Coding and Insurance Guideline in Rheumatic Disease	
ChairsSeung-Jae Hong (Kyung Hee Univ., Korea) Sung-Soo Kim (Univ. of Ulsan, Korea)	
15:30-16:00	Functional responsibility of insurance and policy committee Bong-Seog Kim (Innovative Drug Research Center, Boryung Co. LTD., Korea)
16:00-16:30	Practical tips from HIRA Eunmi Koh (Sungkyunkwan Univ., Korea)
16:30-17:00	Rheumatic diseases and Korean version of International Classification of Diseases (ICD)-11 Bo Young Yoon (Inje Univ., Korea)

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



Short Oral Presentation



May 18 (Thu) 14:30 – 15:30 Auditorium Meeting Room A	
SLE Etiology & Pathogenesis 1	
Chair	Yoontae Lee (Pohang Univ. of Science and Technology, Korea)
LSO-001	Modulating T-bet-promoted energy metabolism in pathogenic age/autoimmune-associated B cells ameliorates lupus autoimmunity Dai Dai (Shanghai Jiaotong Univ., China)
LSO-002	The transcriptional factor Pbx1 adjusts peripheral B cell homeostasis to constrain lupus autoimmunity Dai Dai (Shanghai Jiaotong Univ. School of Medicine, China)
LSO-003	Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice Young Eun Kim (Univ. of Ulsan, Korea)
LSO-004	cGAS deficiency enhances inflammasome activation in macrophages and inflammatory pathology in pristane-induced lupus Sarinya Kumpunya (Center of Excellence in Systems Biology, Thailand)
LSO-005	Type I interferon affects Th22 cell differentiation participated in the pathogenesis of lupus nephritis Haojie Xu (Peking Union Medical College Hosp., China)
LSO-006	Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders Jerome Boyd-Kirkup (Hummingbird Bioscience, Singapore)
LSO-007	Trimeric oligonucleotides ameliorate disease in a mouse model of CLE-like inflammatory skin disease Mary Speir (Hudson Institute of Medical Research, Australia)
LSO-098	Decreased Natural Killer T-like Cells Correlated To Disease Activity In Systemic Lupus Erythematosus Yingni Li (Peking Univ. people's Hosp., China)

May 18 (Thu) 14:30 – 15:30 Auditorium Meeting Room B	
Antiphospholipid Syndrome	
Chair	Hae-Rim Kim (Konkuk Univ., Korea)
LSO-008	Precipitating Factors Of Catastrophic Antiphospholipid Syndrome: The Role Of Anticoagulant Treatment In A Series Of 112 Patients Romain Stammers (Cochin Hosp., France)
LSO-009	The impact of high-risk antiphospholipid antibodies profile on major organ damage progression in systemic lupus erythematosus: CSTAR multiple prospective cohort study. Yufang Ding (Peking Union Medical College Hosp., China)
LSO-010	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibodies associated adverse pregnancy outcomes: a based on a 13-year longitudinal cohort study Yin Long (Peking Union Medical College Hosp., China)
LSO-011	Withdrawn
LSO-012	Withdrawn
LSO-013	Metabolomics analysis identifies biomarkers for APS and suggests potential new pathway for APS pathogenesis Yongjing Luo (Peking Univ. People's Hosp., China)

May 18 (Thu) 14:30 – 15:30 Conference Room 206 A+B	
SLE Biomarkers 1	
Chair	Jason Jungsik Song (Yonsei Univ., Korea)
LSO-014	Clinico-pathological association of serum CD44 level in lupus nephritis patients Susan Yung (The Univ. of Hong Kong, Hong Kong)
LSO-015	Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study IanM. Catlett (Bristol Myers Squibb, USA)
LSO-016	Activated leukocyte cell adhesion molecule, hemopexin, and peroxiredoxin 6 as a potential urine biomarker for Korean patients with systemic lupus erythematosus Ji-Won Kim (Ajou Univ., Korea)
LSO-017	Anti-TCP1 antibody is the potential biomarker of systemic lupus erythematosus (SLE) Sang-Won Lee (Ajou Univ., Korea)
LSO-018	iC3b/C3 ratios more strongly correlate with SLE disease activity in African- Americans compared with Whites Alfred Kim (Washington Univ., USA)
LSO-099	The neutrophil-to-C3 ratio (NC3R) was an inflammatory marker in the assessment of lupus nephritis and ocular vessel density in systemic lupus erythematosus patients Shuilian Yu (The Second Affiliated Hosp. of Guangzhou Medical Univ., China)

May 18 (Thu) 14:30 – 15:30 Auditorium Meeting Room C	
SLE Epidemiology and Public Health 1	
Chair	Chan Hong Jeon (Soonchunhyang Univ., Korea)
LSO-019	Effect of air pollutant exposure on disease activity of systemic lupus erythematosus: A prospective longitudinal study from Korea Ji-Hyoun Kang (Chonnam National Univ., Korea)
LSO-020	Intervention to improve medication adherence among patients with systemic lupus erythematosus Kai Sun (Duke Univ., USA)
LSO-021	Epidemiology and survival of SLE in the last decade: data from a large population-based study in northeastern Italy Margherita Zen (Univ. of Padua, Italy)
LSO-022	Adverse childhood experiences and disease activity: The role of trauma in the black women’s experiences living with lupus (bewell) study Kara W Chung (Tulane School of Public Health and Tropical Medicine, USA)
LSO-023	Clinical characteristics of SARS-CoV-2 infection in patients with systemic lupus erythematosus in Argentina : Data from the SAR-COVID national registry Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
LSO-024	Comparison of clinical characteristics and outcomes in patients with systemic lupus erythematosus : A cross-national study Sung Sam Lim (Emory Univ., USA)

May 18 (Thu) 14:30 – 15:30 Grand Ball Room 101	
Lupus Nephritis	
Chair	Seung-Geun Lee (Pusan Nat’l Univ., Korea)
LSO-025	Comparison between add-on pulse methylprednisolone versus medium to high dose glucocorticoids alone in Thai patients with proliferative lupus nephritis receiving monthly pulse intravenous cyclophosphamide Porntip Intapiboon (Prince of Songkla Univ., Thailand)
LSO-026	Sirolimus versus mycophenolate mofetil for the treatment of lupus nephritis: Results from a real-world CSTAR cohort Wei Bai (Peking Union Medical College Hosp., China)
LSO-027	Predictors of long-term renal survival and mortality in patients with biopsy-proven lupus nephritis: A prospective cohort Jung-Min Shin (Eulji Univ., Kore)
LSO-028	Predictors of de novo renal flares in systemic lupus erythematosus – time to revisit belimumab dose for extra-renal disease? Results from five phase III clinical trials of belimumab Ioannis Parodis (Karolinska Institutet, Sweden)
LSO-029	Predictors of renal relapse in Korean patients with lupus nephritis : Over a 35-year period at a single center Howook Jeon (Uijeongbu St. Mary’s Hosp., Korea)
LSO-030	Predictors of renal flares in systemic lupus erythematosus : A post-Hoc analysis of four phase III clinical trials of belimumab Alvaro Gomez (Karolinska Institutet, Sweden)
LSO-100	Does early complete remission preclude adverse outcomes in lupus nephritis? Dafna Gladman (Univ. of Toronto, Canada)

May 18 (Thu) 14:30 – 15:30 Grand Ballroom 102	
SLE Diagnosis and Manifestations	
Chair	Chang-Nam Son (Eulji Univ., Korea)
LSO-031	Association of serologic and clinical low disease activity states with outcomes in a large multi-national lupus cohort Yanjie Hao (The Univ. of Melbourne, Ausrtalia)
LSO-032	Predictors of first hospitalizations due to disease activity and infections in systemic lupus erythematosus patients Bernardo A. Pons-Estel (Regional Center for Autoimmune and Rheumatic Diseases, Argentina)
LSO-033	Comparison of the systemic lupus international collaborating clinics frailty index (SLICC-FI) and the FRAIL scale for identifying frailty among individuals with systemic lupus erythematosus Alexandra Legge (Dalhousie Univ., Canada)
LSO-034	Association of latent tuberculosis infection with clinical and serological parameters in systemic lupus erytematosus - a prospective observational study Gayathri Ms (Jawaharlal Institute of Postgraduate Medical Education and Research, India)
LSO-035	Withdrawn
LSO-036	Cluster analysis and subphenotype stratification in lupus erythematosus based on data from the Asia Pacific Lupus Collaboration cohort (APLC-CASTLE) Shirley Chiu Wai Chan (Univ. of Hong Kong, Hong Kong)

May 19 (Fri) 14:30 – 15:30 Auditorium Meeting Room A	
SLE Etiology & Pathogenesis 2	
Chair	Youn-soo Choi (Seoul Nat’l Univ., Korea)
LSO-037	STING/TMEM173 mutation in systemic lupus erythematosus: From animal model to intrinsic human genetics Prapaporn Pisitkun (Mahidol Univ., Thailand)
LSO-038	Nlrp12 deficiency mice present severer lupus nephritis in lupus prone model and pristane-induced lupus like model Yen Po Tsao (Taipei Veterans General Hosp., Taiwan)
LSO-039	Proteomic analysis of cutaneous lupus erythematosus and dermatomyositis dermal infiltrate reveals differentially expressed canonical pathways Aliisa Häyry (Karolinska Institutet, Sweden)
LSO-040	Mitochondria promotes autoimmune plasmablasts generation in lupus Sung Hoon Jang (Yonsei Univ., Korea)
LSO-041	Loss-of-function NADPH oxidase variants promote lupus pathogenesis by modulating B cell-intrinsic TLR signals Shaun Jackson (Seattle Children’s Research Institute, USA)
LSO-042	The treatment effect of STING inhibitor (ISD-017) on lupus phenotypes in the Fcgr2b-deficient mice Isara Alee (Chulalongkorn Univ., Thailand)
LSO-101	A spatially-resolved single cell resolution atlas of pediatric lupus nephritis uncovers complex interactions between stromal and infiltrating immune cells. Shaun Jackson (Seattle Children’s Research Institute, USA)

May 19 (Fri) 14:30 – 15:30 Conference Room 206 A+B	
SLE Biomarkers 2	
Chair	Seokchan Hong <i>(Univ. of Ulsan, Korea)</i>
LSO-043	Urinary neutrophil gelatinase-associated lipocalin (NGAL) as a mediator of the association between particulate matter exposure and disease activity in systemic lupus erythematosus <i>Ji-Hyoun Kang (Chonnam Nat'l Univ., Korea)</i>
LSO-044	Sphingolipids are potential diagnostic biomarkers for Korean patients with systemic lupus erythematosus <i>Ji-Won Kim (Ajou Univ., Korea)</i>
LSO-045	Multiple molecular biomarkers that predict response to treatment in lupus nephritis <i>Dae Jin Park (Yonsei Univ., Korea)</i>
LSO-046	Metabolomic analysis for the unique profile and novel biomarkers of neuropsychiatric systemic lupus erythematosus <i>Xiaolin Sun (Peking Univ. People's Hosp., China)</i>
LSO-047	Utility of autoantibody against an UCH-L1 epitope as a serum diagnostic marker for neuropsychiatric systemic lupus erythematosus <i>Xiaolin Sun (Peking Univ. People's Hosp., China)</i>
LSO-102	The correlation between interleukin-6(il-6) and the development of systemic lupus erythematosus(SLE) in Universiti Sains Malaysia(USM) <i>Mohamed Shafi Mahboob Ali (Universiti Sains Malaysia, Malaysia)</i>

May 19 (Fri) 14:30 – 15:30 Auditorium Meeting Room C	
SLE Epidemiology and Public Health 2	
Chair	Yeon-Ah Lee <i>(Kyung Hee Univ., Korea)</i>
LSO-048	Incidence, prevalence, and burden of systemic lupus erythematosus in urban China, 2013-2017 : A nationwide population-based study <i>Mucong Li (Peking Union Medical College Hosp., China)</i>
LSO-049	Greater social vulnerability associated with greater glucocorticoid use in patients with SLE <i>Alfred Kim (Washington Univ., USA)</i>
LSO-050	Mortality-rate in juvenile-onset systemic lupus erythematosus in perspective: Results from a population-based cohort study in Norway <i>Sigrid Reppe Moe (Oslo Univ. Hosp., Norway)</i>
LSO-051	Smoking at onset of systemic lupus erythematosus compared with age-matched controls <i>Anniken Orre (Drammen Hosp. Trust, Norway)</i>
LSO-052	Comparative cardiovascular risk in patients with older-onset systemic lupus erythematosus: A nationwide retrospective cohort study in Korea <i>Jungyong Han (Hanyang Univ., Korea)</i>
LSO-103	Childhood-onset systemic lupus erythematosus: Long-term outcomes in a large multi-ethnic Ontario cohort <i>Ha-Seul Jeoung (ICES, Canada)</i>

May 19 (Fri) 14:30 – 15:30 Auditorium Meeting Room B	
SLE Genetics & Omics	
Chair	Kwangwoo Kim <i>(Kyung Hee Univ., Korea)</i>
LSO-053	Elevated expression of sa_circ_0000479 in neutrophils correlates with features of systemic lupus erythematosus <i>Ranran Yao (Peking Univ. People's Hosp., China)</i>
LSO-054	Genetic fine mapping of independent variants in MHC region associated with predisposition and clinical feature of systemic lupus erythematosus in Han Chinese population <i>Ke Xue (China Japan Friendship Hosp., China)</i>
LSO-055	Genetic contributions to neuropsychiatric systemic lupus erythematosus <i>Soojin Cha (Hanyang Univ., Korea)</i>
LSO-056	Impaired function of neutrophil cytosolic factor 2 (NCF2) may participates in lupus from multiple pathways <i>Ang Li (Peking Union Medical College and Chinese Academy of Medical Sciences, China)</i>
LSO-057	Association between TNFSF13B gene polymorphism and serum BAFF Levels with disease activity in SLE patients <i>Nadia Gita Ghassani (Universitas Padjadjaran, Indonesia)</i>

May 19 (Fri) 14:30 – 15:30 Conference Room 205 A	
SLE Outcomes and Prognosis	
Chair	Seung Min Jung <i>(The Catholic Univ. of Korea, Korea)</i>
LSO-058	Changes in clinical features and mortality of early (1998-2007) and late cohort (2008-2017) of systemic lupus erythematosus: A prospective inception cohort study <i>Young Bin Joo (Hanyang Univ., Korea)</i>
LSO-059	Systemic lupus erythematosus (SLE) patients in Auckland: Epidemiology and attainment of Lupus Low Disease Activity State (LLDAS) <i>Nisha Prashar (Te Whatu Ora Aotearoa, New Zealand)</i>
LSO-060	Self-efficacy is associated with a lower probability of damage accrual in patients with systemic lupus erythematosus. <i>Manuel Ugarte-gil (Universidad Cientifica del Sur, Peru)</i>
LSO-061	Withdrawn
LSO-062	Worse outcomes linked to ethnicity for the early treatment of refractory SLE: Results from the BILAG-BR <i>Ian Bruce (The Univ. of Manchester, UK)</i>
LSO-063	Prediction of mortality using clusters based on clinical and lab parameters: Data from 2072 patients from INSPIRE cohort <i>Chengappa Kavadichanda (JIMPER, India)</i>
LSO-104	Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage iv or worse) in lupus nephritis <i>Dafna Gladman (Univ. of Toronto, Canada)</i>

May 19 (Fri) 14:30 – 15:30 Conference Room 205B	
SLE Treatment 1	
Chair	Su-Jin Moon <i>(The Catholic Univ. of Korea, Korea)</i>
LSO-064	Disease -modifying effect and long-term safety data of belimumab in patients with SLE: A single centre retrospective analysis Takehiro Nakai <i>(St. Luke's Int'l Hosp., Japan)</i>
LSO-065	Belimumab in combination with antimalarial agents prevent renal flares in patients with systemic lupus erythematosus and moderate-to-high extra-renal activity: Results from four randomised clinical trials Alvaro Gomez <i>(Karolinska Institutet, Sweden)</i>
LSO-066	Spanish national registry of belimumab in patients with systemic lupus erythematosus Vicente Aldasoro <i>(Hosp. Universitario de Navarra, Spain)</i>
LSO-067	Withdrawn
LSO-068	Association between organ-specific safety of estrogens in lupus erythematosus national assessment-systemic lupus erythematosus (SLE) disease activity index (SELENA-SLEDAI) response to belimumab and SF-36v2 and FACIT-Fatigue scores in patients with SLE Wen-Hung Chen <i>(GSK, UK)</i>
LSO-069	Satisfaction and effectiveness of switching from intravenous to subcutaneous belimumab treatment in daily clinical practice Beatriz Frade-sosa <i>(Hosp. Clinic of Barcelona, Spain)</i>
LSO-105	D-ALW nanoparticles ameliorate lupus nephritis in MRL/lpr mice Yumin Xia <i>(The Second Affiliated Hosp. of Xi'an Jiaotong Univ., China)</i>

May 20 (Sat) 14:30 – 15:30 Conference Room 206 A+B	
SLE Comorbidities	
Chair	Sang Youn Jung <i>(CHA Univ., Korea)</i>
LSO-070	CHA2DS2-VASc score for prediction of ischemic stroke in patients with systemic lupus erythematosus without atrial fibrillation-RISK of risk scores in the era of artificial intelligence Wei Syun Hu <i>(China Medical Univ. Hosp., Taiwan)</i>
LSO-071	Correlation of traditional and SLE related risk factors with carotid intima media thickness as early MACEs predictor in SLE patients: A systematic review and meta-analysis Sandra Surya Rini <i>(North Lombok Regional Hosp., Indonesia)</i>
LSO-073	Improvements and challenges of systemic lupus erythematosus associated pulmonary arterial hypertension : A 10-year multicenter cohort study Xingbei Dong <i>(Peking Union Medical College Hosp., China)</i>
LSO-074	All-cause mortality and the incidence of cancer in patients with moderate-to-severe SLE : Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR) Ian Bruce <i>(The Univ. of Manchester, UK)</i>
LSO-075	Performance of conventional cardiovascular risk scores in identifying subclinical atherosclerosis in systemic lupus erythematosus Gayathri Ms <i>(Jawaharlal Institute of Postgraduate Medical Education and Research, India)</i>
LSO-106	Risk factors associated with the development of cardiovascular events in a multiethnic Asian systemic lupus erythematosus cohort Hwee Siew Howe <i>(Tan Tock Seng Hosp., Singapore)</i>
LSO-107	Association of hypertension with higher chronicity index scores among patients with lupus nephritis Peter Paolo Daleon <i>(Univ. of Santo Tomas Hosp., Philippines)</i>

May 20 (Sat) 14:30 – 15:30 Auditorium Meeting Room A	
SLE Precision Medicine	
Chair	So-Young Bang <i>(Hanyang Univ., Korea)</i>
LSO-076	Understanding the genetic architecture of SLE from the perspective of associations from 14 other autoimmune diseases Wanling Yang <i>(Univ. of Hong Kong, Hong Kong)</i>
LSO-077	Identification of an interferon 5-gene signature score as a pharmacodynamic and potential predictive biomarker for deucravacitinib treatment in a phase 2 trial in patients with systemic lupus erythematosus Chun Wu <i>(Bristol Myers Squibb, USA)</i>
LSO-078	Clinical characteristics and genetic variants in a large cohort of monogenic lupus patients: Emerging or fading frontiers? Sulaiman Al-mayouf <i>(King Faisal Specialist Hosp. & Research Center, Saudi Arabia)</i>
LSO-079	Dynamic changes of immune cells in systemic lupus erythematosus with nephritis using longitudinal peripheral blood single-cell RNA-seq Seung-Jun Park <i>(Ajou Univ., Korea)</i>
LSO-080	Machine-learning approach on lupus low disease activity prediction Nick Faelnar <i>(Univ. of the Philippines, Philippines)</i>
LSO-081	Genomic prediction model using machine Learning techniques that can distinguish autoimmune diseases (RA or SLE) from healthy controls Young Bin Joo <i>(Hanyang Univ., Korea)</i>

May 20 (Sat) 14:30 – 15:30 Conference Room 205A	
SLE Pregnancy and Reproductive Health	
Chair	Sung Hae Chang <i>(Soonchunhyang Univ., Korea)</i>
LSO-082	Withdrawn
LSO-083	“Systemic lupus erythematosus Women with lupus nephritis In pregnancy Therapeutic CHallenge (SWITCH)” : The systemic lupus international collaborating clinics experience Joo-Young (Esther) Lee <i>(Research Institute of McGill Univ. Health Centre, Canada)</i>
LSO-084	Pregnancy outcomes in patients with systemic lupus erythematosus (SLE), anti-phospholipid antibody syndrome (APL), scleroderma (SSc) and rheumatoid arthritis (RA) at the Kenyatta national hospital, Nairobi, Kenya. Paul Etau Ekwom <i>(KNH, Kenya)</i>
LSO-085	Nationwide patterns and factors associated with adverse pregnancy outcomes in women with systemic lupus erythematosus Yu-Seon Jung <i>(Chung-Ang Univ., Korea)</i>
LSO-086	Pregnancy outcomes in systemic lupus erythematosus: Data from a multiethnic, multinational latin american cohort Guillermo Pons-estel <i>(Centro Rgional de Enfermedades Autoinmunes y Reumáticas, Argentina)</i>

May 20 (Sat) 14:30 – 15:30 Conference Room 205 B	
SLE Treatment 2	
Chair	Dong-Jin Park (<i>Chonnam Nat'l Univ., Korea</i>)
LSO-087	Sub-optimal use of anti-malarial therapy for SLE In the Asia Pacific Region; Observations from the Asia Pacific lupus cohort Rangi Kandane-Rathnayake (<i>Monash Univ., Australia</i>)
LSO-088	Ld-IL2 synthesis with belimumab in the treatment of systemic lupus erythematosus patients Ruiling Feng (<i>Peking Univ. People's Hosp., China</i>)
LSO-089	Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort Irene Altabás-gonzález (<i>Complejo Hospitalario Universitario de Vigo, Spain</i>)
LSO-090	A placebo-controlled phase 1 study in healthy adult volunteers of the safety, tolerability, pharmacokinetics, and pharmacodynamics of povetacicept, a potent dual BAFF/APRIL antagonist, for the treatment of systemic lupus erythematosus Stacey Dillon (<i>Alpine Immune Sciences, USA</i>)
LSO-091	Study design of ENERGY: A phase 2/3 trial to assess the efficacy and safety of nipocalimab in warm autoimmune hemolytic anemia YoungJa Lee (<i>Janssen Asia Pacific, Korea</i>)
LSO-092	Safety, efficacy and pharmacodynamics of cenerimod in patients with systemic lupus erythematosus : Two randomised, double-blind phase 2 clinical trials Sandra Navarra (<i>Univ. of Santo Tomas, Philippines</i>)

May 20 (Sat) 14:30 – 15:30 Auditorium Meeting Room B	
Miscellaneous Conditions Associated with SLE	
Chair	Seonghoon Park (<i>Daegu Catholic Univ., Korea</i>)
LSO-093	Gut microbiota analysis in Korean patients with systemic lupus erythematosus Ji-Won Kim (<i>Ajou Univ., Korea</i>)
LSO-094	Analysis of microbiota in patients with systemic lupus erythematosus Toshihiro Nanki (<i>Toho Univ, Japan</i>)
LSO-095	Withdrawn
LSO-096	Analyzing the shared and specific genetic signals among 15 autoimmune diseases shed new light on the underlying causal genes and molecular mechanisms Xiao Dang (<i>The Univ. of Hong Kong, Hong Kong</i>)
LSO-097	Captopril preventing blood brain barrier breach by anti-smith antibody Yoshiyuki Arinuma (<i>Kitasato Univ., Japan</i>)
LSO-108	Ambulatory blood pressure in patients with systemic lupus erythematosus Brygida Przywara-Chowaniec (<i>Medical Univ. of Silesia, Poland</i>)
LSO-109	Characteristics associated with poor COVID-19 outcomes in people with rheumatic disease : Data from one single center from China Haihong Yao (<i>Peking Univ. People's Hosp., China</i>)
LSO-072	Comparison of COVID-19 vaccination with Influenza vaccination in Korean patients with systemic lupus erythematosus : Perception, adverse events, and flares from the CIVIL study Seonghoon Park (<i>Daegu Catholic Univ., Korea</i>)

LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium



E-poster Presentation



Antiphospholipid syndrome		
No.	Title	Presenter
LP-001	Antiphospholipid syndrome in Juvenile systemic lupus erythematosus : The Malaysian experience	La Reina Sangaran (Selayang Hosp., Malaysia)
LP-002	Immunomagnetic anti-cardiolipin antibody sorption in SLE-associated APS using magnetic polyacrylamide carrier	Maria Mamus (Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Russian Federation)
LP-003	Antiphospholipid antibodies and recurrent thrombosis in primary antiphospholipid syndrome	Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-004	Serum calprotectin could be a novel marker of microangiopathy in antiphospholipid syndrome patients	Yuan Zhao (Peking Union Medical College Hosp., China)
LP-005	Withdrawn	
LP-006	Hemorrhage complications in obstetric antiphospholipid syndrome : Risk factors and the association with adverse pregnancy outcomes	Yongjing Luo (Peking Univ. People's Hosp., China)
LP-007	Cytokine profiles in antiphospholipid syndrome	Xiangjun Liu (Peking Univ. People's Hosp., China)

SLE Biomarkers		
No.	Title	Presenter
LP-008	Genetic analysis auto-antigen biomarkers for lupus	Ramlah Ramlah (Universitas Sulawesi Barat, Indonesia)
LP-009	Immunoglobulin Gamma-3 subclass is a potential biomarker in seruma, saliva, and urine of patients with systemic lupus erythematosus	Ji-Won Kim (Ajou Univ., Korea)
LP-010	Analytical performance of improved Anti-DNase I ELISA test for SLE diagnostics	Maria Mamus (Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Russian Federation)
LP-011	Role of naïve and memory CD8 T cells in predicting the risk of pneumonia among systemic lupus erythematosus patients	Mirza Zaka Pratama (Universitas Brawijaya, Indonesia)
LP-012	Patients with systemic lupus erythematosus and hyperproduction of antibodies to anti-U1RNP	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-013	Autoantibody trajectories associate with classification and treatment response in lupus nephritis	Andrea Fava (Johns Hopkins Univ., USA)
LP-014	Gas and liquid chromatography-based urine metabolomics reveals a distinctive signature in patients with lupus nephritis	Lisandro Pacheco (Universidad Simón Bolívar, Colombia)
LP-015	Exploring the Lupus Risk Index (LRI) as a biomarker in patients with lupus nephritis	Cynthia Aranow (Feinstein Institutes for Medical Research, USA)
LP-016	Anti-histone and anti-nucleosome antibodies, rather than anti-dsDNA antibodies are associated with interferon-induced biomarkers in Sudanese and Swedish SLE patients	Johan Rönnelid (Uppsala Univ., Sweden)
LP-017	Double-stranded DNA breaks are a marker of the inflammatory activity of systemic lupus erythematosus	Anastasia Avdeeva (V.A. Nasonova Research Institute of Rheumatology, Russia)
LP-203	The new markers of systemic lupus erythematosus activity: focus on interleukin (IL)-1b and soluble IL-2 receptor	Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

SLE Comorbidities		
No.	Title	Presenter
LP-018	Risk factors for moderate to severe COVID-19 infection in systemic lupus erythematosus	Wendell Oliver Española (UST Hosp., Philippines)
LP-019	Social maladjustment and anxiety-depressive spectrum disorders in system lupus erythematosus and primary antiphospholipid syndrome patients	Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-020	Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease complicated with systematic lupus erythematosus	Naidi Wang (Peking Univ. People's Hosp., China)
LP-021	Problem In management of systemic lupus erythematosus in pregnancy with anti-phospholipid syndrome and congenital heart block as comorbidities	Gede Arya Dwipayana (Udayana Univ., Indonesia)
LP-022	Preference and efficacy of zoledronate for the treatment of glucocorticoid-induced osteoporosis in patients with autoimmune disease including systemic lupus erythematosus	Ji-Won Kim (Ajou Univ, Korea)
LP-023	Systemic lupus erythematosus concomitant with atopic dermatitis, A case series report	Seon Young Song (Hanyang Univ., Korea)
LP-024	Colorectal duplication cyst with recto-vesica fistule in systemic lupus erythematosus patient	Gede Perdana Putera (RSUP Dr. Sardjito, Indonesia)
LP-025	Lipid spectrum and cholesterol content in circulating immune complexes in the blood of SLE patients	Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)
LP-026	Obesity, hyperleptinemia and insulin resistance in women with systemic lupus erythematosus and rheumatoid arthritis	Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)
LP-027	Overweight and obesity phenotypes based on body mass index and insulin resistance in women with systemic lupus erythematosus	Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russia)
LP-028	Ileal perforation occuring at the beginning of anti-tuberculosis treatment in a 19-year old with disseminated tuberculosis and systemic lupus erythematosus	Bryan Leonard Quizon (Nat'l Kidney and Transplant Institute, Philippines)

SLE Diagnosis and Manifestations		
No.	Title	Presenter
LP-029	Pediatric lupus erythematosus-an interdisciplinary challenge	Rodica Olteanu (Colentina Clinical Hosp., Romania)
LP-030	Diffuse alveolar hemorrhage: A rare fatal complication of systemic lupus erythematosus (a report of two cases)	Kenzle Denise Monsanto (Univ. of the Philippines, Philippines)
LP-031	Autoimmune hepatitis in a 28 year-old female with lupus nephritis: A case report	Ronald Ramirez (Valenzuela Medical Center, Philippines)
LP-032	Protein losing enteropathy as a manifestation of lupus in a 19-year-old Filipino female : A case report	Alyssa Nelle Dacapias (Baguio General Hosp. and Medical Center, Philippines)
LP-033	A study of treatment satisfaction in the patients with rheumatoid arthritis and systemic lupus erythematosus	Hyo-Jin Choi (Gachon Univ. Gil Medical Center)
LP-034	Factors associated with health-related quality of life in lupus nephritis	Hajar Ellassas (CHU Mohammed VI, Morocco)
LP-037	A case of systemic lupus erythematosus after SARS-CoV-2 vaccination and review of literatures	Eric Ranniel Guevarra (Univ. of Santo Tomas Hosp., Philippines)
LP-038	Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage : A potential key to improve outcomes	Muong Li (Peking Union Medical College Hosp., China)
LP-039	Long-term outcome related with initial clinical parameters in juvenile systemic lupus erythematosus: Retrospective study	Dae Chul Jeong (The Catholic Univ. of Korea, Korea)
LP-040	Comparison of clinical and serological features in juvenile and adult-onset systemic lupus erythematosus in a tertiary care center in pakistan	Anum Khan (Fauji Foundation Hosp. Rawalpindi, Pakistan)
LP-041	Successful management of myasthenia gravis in crisis as an initial presentation of systemic lupus erythematosus: A case report	Geode Allan Diansuy (Zamboanga City Medical Center, Philippines)
LP-042	Cardiac tamponade: Uncommon manifestation in systemic lupus erythematosus	Eli Novi (Andalas Univ., Indonesia)
LP-043	Gastrointestinal manifestations in systemic lupus erythematosus are associated with high disease activity and mortality: A nationwide cohort study from India	Pankti Mehta (King George's Medical Univ., India)
LP-044	A comparative study on the effect of high-dose dexamethasone pulse therapy versus methylprednisolone pulse therapy in systemic lupus erythematosus patients admitted at Bicol Medical Center	Aileen Billones (Bicol Medical Center, Philippines)
LP-045	Withdrawn	
LP-046	Refractory immune thrombocytopenia in a patient with lupus nephritis and anti-phospholipid syndrome on treatment for disseminated tuberculosis	Eric Ranniel Guevarra (Univ. of Santo Tomas Hosp., Philippines)
LP-047	Bilateral pallidal lesions in a patient with neuropsychiatric lupus patient: A case report	Chien-Sheng Wu (Far Eastern Memorial Hosp., Taiwan)
LP-048	Characteristics and clinical outcome of incomplete systemic lupus erythematosus	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
LP-049	Influence of activity and clinical features of systemic lupus erythematosus on serum anti-elastin antibody levels	Maria Mamus (Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Russian Federation)
LP-050	Recurrent seizures as a wake-up call for SLE diagnosis in a limited resource setting	Radhiyatam Mardhiyah (RSUP Fatmawati, Indonesia)

No.	Title	Presenter
LP-051	Sleep quality of patients with systemic lupus erythematosus at East avenue medical center	Ramar John Bangayan (East Avenue Medical Center, Philippines)
LP-052	A rare case of chronic tophaceous gout and systemic lupus erythematosus in a female Filipino patient	Ramar John Bangayan (East Avenue Medical Center, Philippines)
LP-053	Dietary and life-style habits of patients with gastrointestinal involvement of systemic lupus erythematosus	Haojie Xu (Peking Union Medical College Hosp., China)
LP-054	Serious infections among Thai patients with systemic lupus erythematosus : Data from the LUCRA cohort	Rattapol Pakchotanon (Phramongkutklao College of Medicine, Thailand)
LP-055	The effect of different remission definitions in patients with systemic lupus erythematosus on damage accrual: Data from the LUCRA cohort	Rattapol Pakchotanon (Phramongkutklao College of Medicine, Thailand)
LP-056	Pseudo-pseudo Meigs Syndrome or Tjalma Syndrome : An initial presentation in a young female with systemic lupus erythematosus	Chad Kevin Fernandez (Davao Regional Medical Center, Philippines)
LP-057	Psychological problems of women with systemic lupus eryhematosus	Ardela Iga Pratiwi (Alumnus Universitas Gadjah Mada, Indonesia)
LP-058	The involvement of scalp and nails in cutaneous lupus erythematosus patients : A retrospective study	Jin Hyun Jang (Hanyang Univ., Korea)
LP-059	Association of seasonal vitamin D levels and disease activity in patients with systemic lupus erythematosus	Ji-Won Kim (Ajou Univ., Korea)
LP-060	Extracellular vesicular proteins in plasma from patients with cutaneous lupus correlate with disease activity.	Mariko Momohara (Nagoya Univ., Japan)
LP-061	Male sex and disease activity at diagnosis are predictors of severe hemolytic anemia in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort	Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
LP-062	Two-year outcomes by belimumab additive on standard of care in patients with systemic lupus erythematosus: A single center retrospective cohort study	Yoshiyuki Arinuma (Kitasato Univ., Japan)
LP-063	Clinical characteristics and outcomes of Libman Sacks endocarditis in patients with systemic lupus erythematosus	Eunsong Kang (Asan Medical Center, Korea)
LP-064	Effect of osteoporosis on major adverse cardiovascular events (MACEs) in systemic lupus erythematosus (SLE): A longitudinal study	Chi-Chiu Mok (Tuen Mun Hosp., Hong Kong)
LP-065	Prevalence and risk factors of fragility fractures in systemic lupus erythematosus (SLE) : A longitudinal study over 12 years	Chi-Chiu Mok (Tuen Mun Hosp., Hong Kong)
LP-066	Severe systemic lupus erythematosus with manifestation of lupus nephritis and pericardial effusion: A case report	Arief Nurudhin (Sebelas Maret Univ., Indonesia)
LP-067	Analysis of hospital length of stay in systemic lupus erythematosus patients hospitalised with infection	Alberta Hoi (Monash Health, Australia)
LP-201	Withdrawn	
LP-202	Volvulus of the proximal sigmoid colon as a manifestation of systemic lupus erythematosus : A case report	Kristopher Paul Quitiquit (East Avenue Medical Center, Philippines)
LP-204	Chilblain lupus erythematosus-a rare encounter	Mohaned Shafi Mahboob Ali (Universiti Sains Malaysia, Malaysia)
LP-206	ANA-negative lupus presenting with segmental hyalinizing vasculitis and valvular heart disease - a rare case report	Widya Inarah Nadhilah Hamid (Hasanuddin Univ., Indonesia)

SLE Epidemiology and Public Health		
No.	Title	Presenter
LP-068	The challenges in the management of systemic lupus erythematosus during the 3rd wave of COVID19 pandemic in Sri Lanka: A single-centre experience	Chathurika Dandeniya (Univ. of Peradeniya, Sri Lanka)
LP-069	Update of the epidemiology and mortality of juvenile onset SLE and pediatric SLE in Italy	Margherita Zen (Univ. of Padua, Italy)
LP-070	Medication compliance in systemic lupus erythematosus: Community-based study in surakarta, Indonesia	Indrayana Sunarso (Sebelas Maret Univ., Indonesia)
LP-071	Accuracy of disease-specific ICD-10 code for incident systemic lupus erythematosus; Results from a population-based cohort study set in Norway	Sigrid Reppe Moe (Oslo Univ. Hosp., Norway)
LP-072	Validity of a claim-based algorithm for SLE disease severity to clinical SLE Disease Activity Index in Korean patients with SLE	Hyoungyoung Kim (Hanyang Univ., Korea)
LP-073	Identification of systemic lupus erythematosus classification criteria attributes in a regional medical record data network	Rosalind Ramsey-goldman (Northwestern Univ., USA)
LP-074	Cost-of-Illness changes before and after diagnosis of systemic lupus erythematosus : A nationwide population-based cohort study in Korea	Hyoungyoung Kim (Hanyang Univ., Korea)
LP-075	The effect of religiosity and spirituality on quality of life among moslem patients with systemic lupus erythematosus in Indonesia: A qualitative study	Anindya Amanda Damayanti (Islamic Univ. of Indonesia, Indonesia)
LP-076	The correlation between sociodemographic factors and health-related quality of life (HRQOL) among patients with systemic lupus erythematosus (SLE) in Indonesia	Nisrina Nabila (Universitas Islam Indonesia, Indonesia)
LP-077	The role of social support on mood improvement and remission of systemic lupus erythematosus (SLE) patients: A case study in Bandung	Nazala Safira (Universitas Islam Indonesia, Indonesia)
LP-078	Characterization of a cohort of patients with a diagnosis of systemic lupus erythematosus followed-up in the city of Cali, Colombia	Carlos Toro (Centro de Referencia en Osteoporosis, Colombia)

SLE Etiology & Pathogenesis		
No.	Title	Presenter
LP-079	Lactobacillus paracasei GMNL-32 exerts a therapeutic effect on cardiac abnormalities in NZB/W F1 mice	Wei Syun Hu (China Medical Univ. Hosp., Taiwan)
LP-080	Transplantation of mesenchymal stem cells increases expression of antioxidant proteins and ameliorates GP91/ROS/inflammasome signaling in lupus cardiomyopathy	Wei Syun Hu (China Medical Univ. Hosp., Taiwan)
LP-081	TRIM21 as a regulator of UVB-driven IFN responses in lupus	Richard Moore (Cedars-Sinai, USA)
LP-082	Effects of rosuvastatin for the treatment in lupus-prone mice	Wook-Young Baek (Ajou Univ., Korea)
LP-083	Phorbol ester activates human mesenchymal stem cells to inhibit B cells and ameliorate lupus symptoms in MRL.Faslpr mice	Hong Kyung Lee (Bioengineering Institute, Corestem Inc., Korea)
LP-084	Single cell genomics of self-reactive B cells in systemic lupus erythematosus	Joanne Reed (Westmead Institute for Medical Research, Australia)
LP-085	Investigating the therapeutic potential of achatina fulica snail mucus on pristane-induced lupus nephritis in mice	Arief Nurudhin (Sebelas Maret Univ., Indonesia)
LP-086	Dexamethasone-incorporated immunomodulatory PDMAEMA-PLGA nanoparticles potentially induced tolerogenic dendritic cells and ameliorated lupus disease by mediating antigen-specific immune tolerance	Phuriwat Khiewkamrop (Graduate Program in Medical Microbiology, Thailand)
LP-087	LILRA3 plays a protective role in MAS-like disease	Yundi Tang (Peking Univ. People's Hosp., China)
LP-088	IL-21 regulating age-associated b cells (ABCs) drive autoimmune disease phenotype in aged mice	Jeein Oh (Seoul Nat'l Univ., Korea)
LP-089	Role of inflammatory cytokines, IL-6 and the correlation with ratio of IL-6 and IL-17 serum cytokines in active systemic lupus erythematosus patients.	Dwitya Elvira (Universitas Andalas, Indonesia)
LP-090	Correlation between serum interleukin-1 with glomerular filtration rate in systemic lupus erythematosus	Gede Arya Dwipayana (Udayana Univ., Indonesia)
LP-091	Neutrophil extracellular traps in APS and SLE	Tatiana Reshetnyak (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-092	Interferon stimulated genes in CD4 T cells are associated with pyroptosis pathways in patients with lupus	Sang Jin Lee (Kyungpook Nat'l Univ., Korea)
LP-093	Role of Leukocyte Immunoglobulin-Like Receptor A3 (LILRA3) in the pathogenesis of lupus-like disease	Yundi Tang (Peking Univ. People's Hosp., China)
LP-094	Repression of Id3 aggravates lupus phenotypes in murine models via aberrant B cell differentiation	Youngjae Park (The Catholic Univ. of Korea, Korea)
LP-095	Macrophage activation in untreated patients with systemic lupus erythematosus (preliminary data)	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
LP-096	Plasmablast-like antigen-experienced CXCR5- CD19low B cells are expanded in systemic lupus erythematosus	Franziska Szelinski (Charité-Univ.Medicine Berlin, Germany)
LP-097	Degranulating PR3+ myeloid cells characterize proliferative lupus nephritis	Andrea Fava (Johns Hopkins Univ., USA)
LP-098	Proteomic analysis of histological lesions in lupus nephritis identifies an inflammatory signature of fibrous crescents	Andrea Fava (Johns Hopkins Univ., USA)
LP-210	Peripheral blood B-cell subsets in patients with systemic lupus erythematosus	Tatyana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

SLE Genetics & Omics		
No.	Title	Presenter
LP-099	High genetic risk loads increase the risk of lupus nephritis in Koreans	So-Young Bang (Hanyang Univ., Korea)
LP-100	Association of the TNFα rs1800629 and STAT4 rs7574865 polymorphisms with systemic lupus erythematosus susceptibility	Mohammad Safiqui Islam (Noakhali Science and Technology Univ., Bangladesh)
LP-101	LINC01420 inhibit inflammation through MAPK pathway in systemic lupus erythematosus	Keke Li (Hunan Children's Hosp., China)
LP-102	Understanding human disease mutations through gene editing and genome-wide next generation investigations	Hye Kyung Lee (Nat'l Institutes of Health, USA)
LP-103	Annotation of cell-type specific differences in the function of the SLE-associated gene IKZF2, using ChIP-Seq	Deborah Cunnihame Graham (King's College London, UK)
LP-104	The Association between CD40 rs1883832 polymorphism and susceptibility of systemic lupus erythematosus : Systematic review and meta analysis	Rizki Febriawan (Univ. of Indonesia, Indonesia)
LP-105	Synergistic effect of extra X chromosome in the development of systemic lupus erythematosus in Klinefelter syndrome karyotype 47, XXY and karyotype 47, XXX females	Irene J. Tan (Einstein Medical Center Philadelphia, USA)
LP-106	Multi-omics integrated analysis characterizing OAS1 variant in systemic lupus erythematosus	Jingkai Xu (China-Japan Friendship Hosp., China)
LP-107	A meta-analytic approach to explore the association between complement gene polymorphisms and systemic lupus erythematosus	Md Abdullah Al Maruf (The Hong Kong Polytechnic Univ., Hong Kong)
LP-108	The distribution of gene variants in Yakut children with SLE	Mikhail Kostik (Saint Petersburg State Pediatric Medical Univ., Russian Federation)
LP-109	Genetic study of children with familial lupus: Preliminary results	Rinat Raupov (Saint Petersburg State Pediatric Medical Univ., Russian Federation)
LP-110	Development of GSTA1, CYP2C19, and CYP2B6 gene polymorphism detection methods on the response of cyclophosphamide therapy for lupus nephritis patients	Yen Yen Ari Indrawijaya (Institut Teknologi Bandung, Indonesia)

Miscellaneous Conditions Associated with SLE		
No.	Title	Presenter
LP-111	Autoimmune hepatitis with SLE on a 28 year old female presenting as liver cirrhosis : A case report	Rica Kezia King (St. Lukes Medical Center, Philippines)
LP-112	A case of macrophage activation syndrome in neonatal lupus	Jung-Woo Rhim (The Catholic Univ. of Korea, Korea)
LP-113	Systemic lupus erythematosus induced by experimental therapy with a combination of monoclonal antibodies against the SARS-CoV-2 surface s-protein	Tatiana Popkova, (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-114	Lupus and multiple sclerosis may share an initiating pathogenesis : The anti- EBNA1 heuristic conjecture	John B. Harley (Cincinnati Education and Research Foundation for Veterans, USA)
LP-115	Mask and vaccinated: New-onset systemic lupus erythematosus after mRNA SARS-COV-2 vaccination	Fayanne Patricia Lim (San Pedro Hosp., Philippines)
LP-116	To get, or not to get: Risk and benefit of COVID-19 vaccine in Korean patients with systemic lupus erythematosus	Seonghoon Park (Daegu Catholic Univ., Korea)
LP-117	A case report of a 22 year old Filipino male diagnosed SLE who was infected with HIV-AIDS and COVID 19 moderate disease	Petersian Alcazaren (West Visayas State Univ. Medical Center, Philippines)
LP-118	Assessment of systemic lupus erythematosus activity and remission: SLEDAI-2k or SLE-DAS – which to choose?	Tatiana Reshetnyak (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
LP-119	Thalassemia traits in systemic lupus erythematosus patients with anemia	Laniyati Hamijoyo (Univ. Padjadjaran, Indonesia)
LP-120	Antecedent COVID-19 vaccine in 4 patients with new-onset severe lupus nephritis : Possible causality?	Vincent Luceño (Univ. of Santo Tomas Hosp., Philippines)
LP-121	Disseminated tuberculosis with associated vitamin D deficiency in a male patient with systemic lupus erythematosus	Eloisa Trina Generoso (Makati Medical Center, Philippines)

SLE Genetics & Omics		
No.	Title	Presenter
LP-122	Lupus nephritis presenting as a renal hematoma in a Filipino female patient: A case report	Ronald Ramirez (Valenzuela Medical Center, Philippines)
LP-123	Calcineurin inhibitors as induction treatment for proliferative lupus nephritis: A systematic review and meta-analysis	Wendell Oliver Española (UST Hosp., Philippines)
LP-124	Childhood-onset lupus nephritis: Real world long-term outcome data from a single center	Jiwon Jung (Asan Medical Center Children's Hosp., Korea)
LP-125	Glomerulonephritis in systemic lupus erythematosus: “Not everything is Lupus” a case series	Diana Michelle Paez Galindo (Guatemalan Social Security Institute, Guatemala)
LP-126	The infectious complication in multitarget therapy of class v lupus nephritis: A case report	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
LP-127	Tacrolimus is effective treatment in patients with refractory lupus nephritis	Ji-Won Kim (Ajou Univ., Korea)
LP-128	Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and azathioprine as maintenance therapies for lupus nephritis: A network meta-analysis	Young Ho Lee (Korea Univ. Medicine, Korea)
LP-129	Lupus low disease activity state as an attainable and complementary target for lupus nephritis	Chak Kwan Cheung (Queen Mary Hosp. and the Univ. of Hong Kong, Hong Kong)
LP-130	Effect of renin-angiotensin system inhibitors on renal remission in lupus nephritis: A real-world single-center study	Xiaohui Zhang (Peking Univ. First Hosp., China)
LP-131	Serum uric acid and the risk of renal involvement in premenopausal female systemic lupus erythematosus patients	Su Jin Choi (Ulsan Univ., Korea)
LP-132	Comparison in efficacy and safety of mycophenolate mofetil and cyclophosphamide in lupus nephritis: Evidence from a real-world study	Xiaohui Zhang (Peking Univ. First Hosp., China)
LP-133	Baseline clinical characteristics of SLE patients compared to those with Lupus nephritis and on renal replacement treatment (RRT) including Kidney transplantation	Rajaie Namas (Cleveland Clinic Abu Dhabi, United Arab Emirates)
LP-134	Withdrawn	
LP-207	Impact of time to remission, flares and time on immunosuppressives on the estimated glomerular filtration rate in lupus nephritis	Dafna Gladman (Univ. of Toronto, Canada)
LP-208	Mesangial lupus nephritis: Long term outcomes	Dafna Gladman (Univ. of Toronto, Canada)

SLE Outcomes and Prognosis		
No.	Title	Presenter
LP-135	High neutrophil-to-lymphocyte ratio is a risk factor for chronic kidney disease in patients with lupus nephritis	Dong-Jin Park (Chonnam Nat'l Univ., Korea)
LP-136	A 52 year old female with abdominal pain and diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy and probable systemic lupus erythematosus: A case report	Kimberly Yu (Far Eastern Univ. - Nicanor Reyes Medical Foundation Medical Center, Philippines)
LP-137	Benefits of ANA screening for NPSLE in patients admitted to the department of psychiatry	Yeo-Jin Lee (Asan Medical Center, Korea)
LP-138	Predictors for future development of systemic lupus erythematosus in Korean Sjögren’s syndrome patients	Bong-Woo Lee (The Catholic Univ. of Korea, Korea)
LP-139	Baseline characteristics of a longitudinal, multinational, multiethnic study of lupus patients, with or without lupus nephritis	Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
LP-140	Application of supervised machine learning algorithms in classification of systemic lupus erythematosus versus other antinuclear antibody positive autoimmune rheumatic diseases	Prudhvi Krishna Manyam (Amrita Institute of Medical Sciences, India)

No.	Title	Presenter
LP-141	Delay to diagnosis of systemic lupus erythematosus and its impact on cumulative damage and mortality: Data from a Multiethnic Latin American Cohort	Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
LP-142	The use of childhood LLDAS: First results in a real-life longitudinal childhood lupus cohort shows good feasibility but difficult attainment	Sandy Bergkamp (Amsterdam UMC, Emma Children’s Hosp., Netherlands)
LP-143	A case of systemic lupus erythematosus in a male patient presenting with mouth bleeding and cutaneous manifestation	Mariam Amanda Kostansia Mauko (Prof. Dr. W.Z.Johanes Kupang General Hosp., Indonesia)
LP-144	Cytosolic localization of antibodies in monocytes is positively associated with disease activity of the patients with systemic lupus erythematosus	Minjae Kim (Ajou Univ., Korea)
LP-145	Case report: A 43-year-old Filipino with lupus myocarditis as initial presentation of systemic lupus erythematosus	Mark Ledge Gerona (FEU-NRMF, Philippines)
LP-146	Thrombotic thrombocytopenic purpura as initial presentation of systemic lupus erythematosus: A case report	Noreen Marie Garcia-pedro (Makati Medical Center, Philippines)
LP-147	Multiple opportunistic infection in a male with systemic lupus erythematosus and concomitant human immunodeficiency virus infection	Joseph Peter T. Lim (Makati Medical Center, Philippines)
LP-148	Acute myositis: A rare manifestation of systemic lupus erythematosus	Noreen Marie Garcia-pedro (Makati Medical Center, Philippines)
LP-149	Latin-American systemic lupus erythematosus clusters	Guillermo Pons-Estel (Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina)
LP-150	Outcomes of serologically active clinically quiescent (SACQ) versus serologically and clinically quiescent (SQCQ) statuses in patients with systemic lupus erythematosus	Rattapol Pakchotanon (Phramongkutklao College of Medicine, Thailand)
LP-151	Cluster analysis of serious infections in SLE predicts subsets susceptible to recurrent intracellular and bacterial infections.	Rudrarpan Chatterjee (Sanjay Gandhi Postgraduate Institute of Medical Sciences, India)
LP-152	Sinus node dysfunction (tachycardia-bradycardia syndrome) and acute transverse myelitis as initial presentation of systemic lupus erythematosus in a 55-year-old female: A case report	Rio May Llanes (Chong Hua Hosp., Philippines)
LP-153	The potential role of serum cytoskeleton-associated protein 4 as a novel biomarker to monitor disease activity in systemic lupus erythematosus	Yuki Kudo (Hokkaido Univ., Japan)
LP-154	Peripheral gangrene in systemic lupus erythematosus – a rare case report	Nurul Fadhilah (Hasanuddin Univ., Indonesia)
LP-155	Psychosis as an early manifestation of neuropsychiatric systemic lupus erythematosus – a case report	Widya Wirasasmita Mirsan (Hasanuddin Univ., Indonesia)
LP-156	OPTIMISE - Validation of the SLEDAI-P self-questionnaire completed by the patient to measure the activity of the systemic lupus	Marc Scherlinger (Centre Hospitalier Universitaire de Strasbourg, France)
LP-157	Progressive discoid lupus related severe vasculitis - A rare case report	Ika Saputri Burhanuddin (Hasanuddin Univ., Indonesia)
LP-158	Macrophage activation syndrome in 10 children with systemic lupus erythematosus : The retrospective cohort observation study	Mikhail Kostik (Saint Petersburg State Pediatric Medical Univ., Russian Federation)
LP-159	Studying the disease activity and the degree of internal organ damage in systemic lupus erythematosus patients in the Kazakh population	Gulzhan Alibekova (NISC Astana Medical Univ., Kazakhstan)
LP-160	Characteristics of patients with seronegative lupus erythematosus	Jairo Cajamarca-Baron (Fundación Universitaria de ciencias de la salud (FUCS) Hosp. San Jose, Colombia)
LP-161	Tjalma syndrome (Pseudo-pseudo Meigs Syndrome): Polyserositis with increased CA-125 in patients with systemic lupus erythematosus	Dinar Faricy yaddin (Padjadjaran Univ., Indonesia)
LP-162	Prognostic factors for the chronic thrombocytopenia in systemic lupus erythematosus	Soo Min Ahn (Univ. of Ulsan, Korea)
LP-163	The correlation between depression and fatigue in patient with systemic lupus erythematosus (SLE) in Indonesia	Zavia Putri Salsabila (Universitas Islam Indonesia, Indonesia)
LP-164	Urinary N-acetyl-beta-D-glucosaminidase, a marker of lupus nephritis activity	A S M Julfekar Helal (Lab Aid Specialized Hosp., Bangladesh)

No.	Title	Presenter
LP-165	Co-existence of systemic lupus erythematosus and Hansen’s disease in a young adult Filipino female	Kathleen Faye Rayos (Region 1 Medical Center, Philippines)
LP-166	Withdrawn	
LP-167	Uncommon initial presentations of SLE – A case series	Madusha Jayasinghe (Rheumatology and Rehabilitation Hosp., Sri Lanka)
LP-168	Prevalence and association of autoantibodies with latent tuberculosis in first-degree relatives of patients with systemic lupus erythematosus	Gayathri Ms (Jawaharlal Institute of Postgraduate Medical Education and Research, India)
LP-169	Alpha thalassemia in SLE: A case report from the Philippines	Nicola Malko (Region 1 Medical Center, Philippines)
LP-170	Predictors of neuropsychiatric flares in patients with systemic lupus erythematosus: Results from five phase III clinical trials of belimumab	Julius Lindblom (Karolinska Institutet, Sweden)
LP-171	Fibromyalgia and glucocorticoids use drives self-perceived depression in systemic lupus erythematosus: Insights from a large prospective and multicenter study using RELESSERPROS register’s database.	Jose María Pego-Reigosa (Complejo Hospitalario Universitario de Vigo, Spain)
LP-172	Validation of the lupus impact tracker in Argentina	Pablo David Ibañez Peña (HIGA San Martin De La Plata, Argentina)
LP-173	Systemic lupus erythematosus and associated pulmonary arterial hypertension : Discussion of own data	Natalia Yudkina (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-174	Factors affecting SLICC damage index score in systemic lupus erythematosus patients in Hasan Sadikin General Hospital, Indonesia	Hans Albertus (Universitas Padjadjaran, Indonesia)
LP-175	Frequencies, clinical characteristics and prognosis of patients with neuropsychiatric systemic lupus erythematosus	Shirley Chiu Wai Chan (Univ. of Hong Kong, Hong Kong)
LP-176	SARS-CoV-2 antibody formation after COVID-19 vaccination in SLE patients treated with belimumab: Single-center prospective observational study	Eunsong Kang (Univ. of Ulsan, Korea)
LP-211	Disease manifestations and outcomes in juvenile and adult onset SLE - a nested case control study within a singapore cohort	Hwee Siew Howe (Tan Tock Seng Hosp., Singapore)

SLE Pregnancy and Reproductive Health

No.	Title	Presenter
LP-177	Intravenous immunoglobulin in pregnant women with severe active lupus: A case series	Jairo Cajamarca-Baron (Fundación Universitaria de ciencias de la salud (FUCS) Hosp. San Jose, Colombia)
LP-178	Association between systemic lupus erythematosus (SLE) and abnormal uterine bleeding (AUB) among reproductive-age women	Zulfania Rahmah (Universitas Islam Indonesia, Indonesia)
LP-200	Relapsing polychondritis and systemic lupus erythematosus overlap in a 26 year old G2P1 pregnant mother with successful pregnancy outcome	Adel Taradji (Zamboanga City Medical Center, Philippines)

SLE Treatment

No.	Title	Presenter
LP-179	Design of 2 phase 3, double-blind, placebo-controlled, global trials of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus	Cristina Arriens (Oklahoma Medical Research Foundation, USA)
LP-180	Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosus	Victoria P. Werth (Univ. of Pennsylvania and the Michael J. Crescenz VA Medical Center)

No.	Title	Presenter
LP-181	Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus	Masato Okada (SLIH, Japan)
LP-182	Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus	Takafumi Ide (Bristol Myers Squibb, USA)
LP-183	Enpatoran: Preclinical evidence supporting glucocorticoid dose reduction and phase II study eesign in patients with SLE and/or CLE (WILLOW)	Eric Morand (Monash Univ., Australia)
LP-184	Rationale and design of two phase 3, randomized, double-blind, placebo-controlled studies of the efficacy and safety of Litifilimab in adults with active systemic lupus erythematosus: TOPAZ-1 and TOPAZ-2	Ronald F Van Vollenhoven (Amsterdam Univ. Medical Centers, Netherlands)
LP-185	Treatment of cutaneous lupus erythematosus with energy based devices	Jin Hyun Jang (Hanyang Univ., Korea)
LP-186	Initial experience with belimumab In SE Asian lupus patients - A report of 6 patients	Yoon Kam Hon (El Shaddai Arthritis & Rheumatism Specialist Medical Centre, Singapore)
LP-187	Deucravacitinib, an oral, allosteric, tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus: patient-reported outcomes in a phase 2 trial	Laurent Arnaud (Univ. Hosp. of Strasbourg, France)
LP-188	Glucocorticoids withdrawn in systemic lupus erythematosus patients with serologically active clinically quiescent state: A desirable goal.	Yufang Ding (Peking Union Medical College Hosp., China)
LP-189	Effect of belimumab in patients with systemic lupus erythematosus treated with minimal or no steroid	Yeo-Jin Lee (Asan Medical Center, Korea)
LP-190	Successful treatment of rituximab and bortezomib in refractory systemic lupus erythematosus: A case report	Yundi Tang (Peking Univ. People’s Hosp., China)
LP-191	Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort	Irene Altabás-gonzález (Complejo Hospitalario Universitario de Vigo, Spain)
LP-192	Low-dose IL-2 as a possible immune-modulating therapy to manage systemic lupus erythematosus during pregnancy: a retrospective study	Xian Xiao (Peking Univ. People’s Hosp., China)
LP-193	A therapeutic challenge of a patient with Systemic Lupus Erythematosus and Anti-phospholipid Syndrome	Lucia Manfredi (Azienda Ospedaliero Universitaria delle Marche, Italy)
LP-194	Comparative analysis of the results of treatment of a 12-month course of rituximab BCD020 biosimilar in systemic lupus erythematosus in children with early and late administration of the drug.	Mikhail Kostik (Saint Petersburg State Pediatric Medical Univ., Russian Federation)
LP-195	Design of a phase 2 study evaluating the efficacy and safety of nipocalimab in adult patients with active systemic lupus erythematosus	YoungJa Lee (Janssen Asia Pacific, Korea)
LP-196	Low-dose IL-2 therapy in SLE: Efficacy on organ involvement, response predictors and synergistic effects with glucocorticoid treatment	Xiaolin Sun (Peking Univ. People’s Hosp., China)
LP-197	Association between steroid therapy and IGRA result in systemic lupus erythematosus	Naurah Alzena Hana Dhea (Universitas Padjadjaran, Indonesia)
LP-198	Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): A post hoc analysis from clinical trial data	Joan T Merrill (Oklahoma Medical Research Foundation, USA)
LP-199	Medications given to patients with incomplete systemic lupus erythematosus	Tatiana Popkova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
LP-205	Belimumab shows promise in neuropsychiatric lupus: Another challenge to find the offender	Shuilian Yu (The Second Affiliated Hosp. of Guangzhou Medical Univ., China)
LP-209	Methotrexate induced cutaneous ulceration : A systematic review of cases	Rizki Audita (Andalas Univ., Indonesia)
LP-212	SLE overlap with psoriatic arthritis successfully treated with secukinumab	Athina Theodoridou (Hippokrateion Hosp. Thessaloniki, Greece)

Basic science and immunology related to rheumatic disease		
No.	Title	Presenter
KP-001	Design and discovery of novel 1,3,5-triazines-thiazole (TT-05) as potent NF-κB inhibitor against rheumatoid arthritis	Udaya Pratap Singh (Sam Higginbottom Univ. of Agriculture, Technology and Sciences, India)
KP-002	APEX1 suppresses the inflammation of fibroblast-like synoviocytes via TNF-α/IL-17 induced matrix metalloproteinase 3 regulation in patients with rheumatoid arthritis	Ha-Reum Lee (Chungnam Nat'l Univ., Korea)
KP-003	Liver X receptor regulates GSK3β-TCF-1 axis in T cells	Jiyeon Kim (Seoul Nat'l Univ., Korea)
KP-004	Interleukin-18 binding protein regulates the apoptosis and necroptosis of fibroblast-like synoviocytes and chondrocytes in rheumatoid arthritis	Hong Ki Min (Konkuk Univ., Korea)
KP-005	Formation of extracellular traps by blood monocytes and neutrophils in rheumatoid arthritis	Maria Mamus (Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky, Russian Federation)
KP-006	25-hydroxycholesterol in the pathogenesis of rheumatoid arthritis	Hong Huang (Peking Univ. First Hosp., China)
KP-007	Body composition by dual-energy X-ray absorptiometry (DXA) in patients with early RA on different therapeutic regimens.	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
KP-008	Dual inhibition of TNF-α and OX40L in osteoclastogenesis	Hee Sung Kwon (Seoul Nat'l Univ., Korea)
KP-009	Exploration of long-noncoding RNAs implicated in rheumatoid arthritis and lncRNA target gene prediction	Ji-Min Kim (Keimyung Univ., Korea)
KP-010	Single-cell transcriptomics identified interferon response gene expression in ACPA-positive RA	Ho-Youn Kim (HOYUNKIM's Clinic for Arthritis Rheumatism, Korea)
KP-011	The anti-inflammatory effect of a marine-derived compound, sinulariolide, in collagen induced arthritis	Deng-Ho Yang (Taichung Armed Forces General Hosp., Taiwan)

RA-clinical aspects		
No.	Title	Presenter
KP-012	Falling and risk factors in osteoporotic patients with rheumatoid arthritis	Rajaa Assadi (Hassan II Univ., Morocco)
KP-013	Factors determining health related quality of life in patients with rheumatoid arthritis	Chathurika Dandeniya (Univ. of Peradeniya, Sri Lanka)
KP-014	Proteomic identification of salivary biomarkers for the diagnosis of seronegative RA	Hyesu Jo (Kyung Hee Univ., Korea)
KP-015	Effect of abatacept and conventional synthetic disease-modifying anti-rheumatic drugs on the progression and development of interstitial lung disease in patients with rheumatoid arthritis: A multicenter retrospective observational study	Kyung-Ann Lee (Soonchunhyang Univ., Korea)
KP-016	Bowel perforation following tocilizumab administration in a patient with rheumatoid arthritis in SARS-CoV-2 infection	Yunjung Choi (Jeonbuk Nat'l Univ., Korea)
KP-017	Comparison of cholesterol profile changes after treatment with biologics or Janus kinase inhibitors in patients with rheumatoid arthritis	Jung Hee Koh (The Catholic Univ. of Korea, Korea)
KP-018	Doing both RF and CCP antibodies for diagnosis of rheumatoid arthritis -what is the advantage	Velammal Petchiappan (PSG Institute Of Medical Sciences and Research Centre, India)
KP-019	Sarcopenic phenotype of body composition and nutritional status in rheumatoid arthritis patients	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

No.	Title	Presenter
KP-020	The frequency of osteoporosis and its relationship with nutritional status in patients with rheumatoid arthritis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-021	Impact of the presence of bronchiectasis on the disease activity in patients with rheumatoid arthritis	Soo-Kyung Cho (Hanyang Univ., Korea)
KP-022	Neovascularization of carotid atherosclerotic plaques in patients with rheumatoid arthritis	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
KP-023	Early rheumatoid arthritis: Obesity phenotypes.	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
KP-024	The influence of low-energy fractures and comorbid diseases on the disability of patients with rheumatoid arthritis (the result of a long-term follow-up)	Polina Postnikova (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-197	Risk factors for interstitial lung disease in rheumatoid arthritis: A prospective cohort study from the KOBIO registry	Hong Ki Min (Konkuk Univ., Korea)

RA-treatment		
No.	Title	Presenter
KP-025	Results of methotrexate therapy in patients with rheumatoid arthritis in groups with and without therapeutic drug monitoring	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-026	Dynamic characteristics and predictive profile of glucocorticoids withdrawal in rheumatoid arthritis patients commencing glucocorticoids with csDMARD: A real-world experience	Wenhui Xie (Peking Univ. First Hosp., China)
KP-027	Prediction of flare following glucocorticoids withdrawal in rheumatoid arthritis patients receiving csDMARDs: A prospective real-life study	Wenhui Xie (Peking Univ. First Hosp., China)
KP-028	Effect of tocilizumab therapy on lipid levels in patients with rheumatoid arthritis : A meta-analysis	Ida Mae Tan (Luke's Medical Center, Philippines)
KP-029	The efficacy and safety of tofacitinib in the treatment of DMARDs naive rheumatoid arthritis patients (EASTERN study)	Juan Zhao (Peking Univ. First Hosp., China)
KP-030	Clinical equivalence of generic and branded tofacitinib in real-world: A prospective longitudinal cohort study in rheumatoid arthritis patients	Juan Zhao (Peking Univ. First Hosp., China)
KP-031	Impact of tofacitinib on lipid metabolism in patients with rheumatoid arthritis: A real-world study	Hong Huang (Peking Univ. First Hosp., China)
KP-032	Drug retention and patterns of discontinuation of tofacitinib in Malaysian patients with rheumatoid arthritis	Sivakami Janahiraman (International Medical Univ., Malaysia)
KP-033	Consensus recommendations on the use of biosimilars in the treatment of inflammatory rheumatic joint diseases in the gulf countries	Khalid A. Alnaqbi (Tawam Hosp., United Arab Emirates)
KP-034	Tofacitinib in rheumatoid arthritis: A well tolerated drug with less severe adverse events	Naga Prabu (Sakthi Rheumatology Centre, India)
KP-035	Drug retention of biologic and targeted synthetic DMARDs in Korean Seropositive Rheumatoid arthritis (RA) patients: A real-world single-center retrospective study	Bong-Woo Lee (The Catholic Univ. of Korea, Korea)
KP-036	Single-cell transcriptomic profiling reveals immunological perturbation in response to Abatacept in patients with rheumatoid arthritis	Eunji Ha (Kyung Hee Univ., Korea)
KP-037	Effect of abatacept on clinical response and radiological progression in patients with rheumatoid arthritis	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-038	Association of different biomarkers with clinical response of abatacept therapy	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-039	Comparative effectiveness of abatacept treatment in different groups of patients with rheumatoid arthritis	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

No.	Title	Presenter
KP-040	Dynamics of traditional modifiable risk factors, and structural changes of carotid arteries in patients with rheumatoid arthritis on long-term interleukin-6 receptor antagonist treatment	Tatiana Popkova (V.A.Nasonova Research Institute of Rheumatology, Russian Federation)
KP-041	Tofacitinib in halting radiographic progression - evidence from 2 cases	Naga Prabu (Sakthi Rheumatology Centre, India)
KP-198	How the caregiver status could increase the quality of life among rheumatoid arthritis elderly with dementia status?	Rosinta Hotmaida Pebrianti Purba (Bappenas, Indonesia)
KP-199	How religiosity have positive association with mental health and derive prolonged survival in rheumatoid arthritis patients: A systematic review	Lintong Hottua Simbolon (Alumnus of Univ. of Lampung, Indonesia)
KP-200	Differential drug retention rates between tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis subgroups defined by simple laboratory tests	Jung Gon Kim (Inje Univ., Korea)

Osteoarthritis		
No.	Title	Presenter
KP-042	Withdrawn	
KP-043	Quantitative analysis of efficacy and associated factors of platelet rich plasma treatment for osteoarthritis	Ying Cao (Southern Medical Univ., China)
KP-044	Quantitative analysis of efficacy and associated factors of therapeutic exercise and education on symptoms in osteoarthritis	Zhaohua Zhu (Southern Medical Univ., China)
KP-045	Efficacy of metformin and ibuprofen joint treatment in patients with knee osteoarthritis and metabolic syndrome	Jamol Uzokov (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan)
KP-046	Circulating exosomal microrna expression in patients with knee osteoarthritis and metabolic syndrome	Zumrad Ubaydullaeva (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan)
KP-047	Influence of metabolic syndrome components in patients with hip osteoarthritis	Jamol Uzokov (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan)
KP-048	Factorial validity of the PHQ-9 in individuals with osteoarthritis. Results from the 2020 Korea National Health and Nutrition Examination Survey (KNHANES)	Patrick Brzoska (Witten/Herdecke Univ., Germany)
KP-049	The effect of nerve growth factor on in vitro chondrogenesis using induced pluripotent stem cells	Jung Sein (The Catholic Univ. of Korea, Korea)
KP-201	Therapeutic role of Wharton's jelly mesenchymal stem cells (WJ-MSCs) to the MIA-induced osteoarthritis model	Eryati Darwin (Medical Faculty Universitas Andalas, Indonesia)

Systemic sclerosis and Raynaud’s phenomenon		
No.	Title	Presenter
KP-050	The clinical characteristics, management, and immunological features in patients with mixed connective tissue disease	Aran Kim (Pusan Nat'l Univ., Korea)
KP-051	Mortality and prognostic factors in connective tissue disease associated pulmonary arterial hypertension patients complicated with right heart failure	Xiaoyue Deng (Peking Union Medical College Hosp., China)
KP-052	Anti-fibrotic effect of Ginkgo biloba extract on skin fibrosis in bleomycin-induced systemic sclerosis mouse model	Seung-Geun Lee (Pusan Nat'l Univ., Korea)
KP-053	The comorbidity burden in interstitial lung disease associated with systemic sclerosis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-054	Body composition in women with systemic sclerosis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-055	Osteoporosis in premenopausal women with systemic sclerosis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-056	Systemic sclerosis in men: Focus on osteoporosis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-057	Changes of acute-phase reactants in systemic sclerosis during rituximab therapy	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-058	Cardiac involvement in systemic sclerosis and impact of rituximab therapy	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-059	Impact of systemic sclerosis subset on the efficacy of rituximab therapy	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-060	Association immunological parameters and pulmonary function parameters in patients with SSc and ILD over 5 year follow up study	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-061	The predictive intervals for patients with systemic sclerosis and interstitial lung disease using discriminant analysis	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-062	Evaluation of the clinical significance of the main radiological signs of interstitial lung disease in systemic sclerosis	Olga Koneva (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-063	To study the influence of a variety of clinical, laboratory and instrumental parameters on the results of treatment of patients with systemic sclerosis and interstitial lung disease	Olga Koneva (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-064	Study of the traditional basic drugs and anti-B-cell therapy effect on systemic sclerosis skin and pulmonological manifestations.	Olga Koneva (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-065	Rituximab in the treatment of patients with systemic sclerosis: influence of the renal function	Mayya Starovoytova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-066	Vascular manifestations of systemic sclerosis in patients with pulmonary arterial hypertension	Natalia Yudkina (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-067	Clinical characteristics of overlap-syndrome systemic sclerosis-systemic lupus erythematosus	Oxana Desinova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-068	Model for the detection of systemic sclerosis in patients with pulmonary arterial hypertension	Natalia Yudkina (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-069	Bifidobacterium longum RAPO ameliorates dermal and pulmonary fibrosis through the modulation of gut microbiota and immune response in bleomycin-induced systemic sclerosis in mice	Suhee Kim (Gyeongsang Nat'l Univ., Korea)

Idiopathic inflammatory myopathy		
No.	Title	Presenter
KP-070	High fatigue scores in patients with idiopathic inflammatory myopathies: A multigroup comparative study from the COVAD e-survey	Lisa Traboco (Univ. of the Philippines, Philippines)
KP-071	Performance of cut-offs adjusted with positive control band intensity in line-blot assays for myositis-specific antibodies	Se Rim Choi (Seoul Nat'l Univ., Korea)
KP-072	Anti HMGR positive necrotizing myopathy after statin use in a 77 year old male : A case report	Rica Kezia King (St. Luke's, Philippines)
KP-073	Challenging treatment of anti-synthetase syndrome complicated by severe immunodeficiency	Suzy Maria (Universitas Indonesia, Indonesia)
KP-074	Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies : Results from the COVAD study	Chou Luan Tan (Hosp. Putrajaya, Malaysia)
KP-075	Complete remission of severe anti-MDA5 dermatomyositis with combination sequential immunosuppressive and antifibrotic therapy	Yoon Kam Hon (El Shaddai Arthritis & Rheumatism Specialist Medical Centre, Singapore)
KP-076	Anti-hydroxy-3-methylglutaryl-coenzyme a reductase myopathy with new onset diabetes: A case report	Marivic Bolando (Univ. of Santo Tomas Hosp., Philippines)

Sjögren's syndrome		
No.	Title	Presenter
KP-077	Chronic sclerosing sialadenitis, is it a Sjögren's syndrome or not?	Eui-Jong Kwon (The Catholic Univ. of Korea, Korea)
KP-078	EULAR Sjögren's syndrome patient index (ESSPRI) and other patient-reported outcomes in assessment of glandular dysfunction in Sjögren's syndrome	Hirut Yadeta Ture (Kyungpook Nat'l Univ., Korea)
KP-079	The clinical characteristics of Korean primary Sjögren's syndrome (pSS) patients with positive anti-double-stranded DNA (anti-dsDNA) antibody by the Farr method	Bong-Woo Lee (The Catholic Univ. of Korea, Korea)
KP-080	Design of a phase 2, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy and safety of nipocalimab in adults with primary Sjögren's syndrome	YoungJa Lee (Janssen Asia Pacific, Korea)
KP-081	Deep learning based assessment of salivary gland ultrasonography images for supporting the diagnosis of Primary Sjögren's syndrome	Yan Geng (Peking Univ. First Hosp., China)
KP-202	A study of clinical characteristics and autoantibody clustering of Hypokalemic periodic palsy (HPP) in primary Sjögren syndrome (PSS) from India	Ritasman Baisya (Assistant Professor, India)
KP-203	Withdrawn	

Spondyloarthropathies and psoriatic arthritis		
No.	Title	Presenter
KP-082	Risk of cancer, tuberculosis, and serious infections in patients with ankylosing spondylitis, psoriatic arthritis, and psoriasis treated with IL-17 and TNF-α inhibitors : A nationwide nested case-control analysis	Sung Soo Ahn (Yonsei Univ., Korea)
KP-083	Proposal of simplified CT syndesmophyte score (sCTSS) and comparison with CTSS in patients with ankylosing spondylitis	Hong Ki Min (Konkuk Univ., Korea)
KP-084	The relationship between long-term use of nonsteroidal anti-inflammatory drugs and kidney function in patients with ankylosing spondylitis	Bon San Koo (Inje Univ., Korea)
KP-085	Prevalence of fall risk factors in patients followed for spondyloarthritis	Rajaa Assadi (Hassan II Univ., Morocco)

No.	Title	Presenter
KP-086	A case of difficult to treat psoriatic arthritis: Is there a hope with switching biologics?	Sasheela Ubhayasiri (Rheumatology and Rehabilitation Hosp. Ragama, Sri Lanka)
KP-087	Risks of cancers in patients with ankylosing spondylitis	Jihyoun Kim (Chungbuk Nat'l Univ., Korea)
KP-088	The development of axial spondyloarthritis after a COVID-19 infection.	Ekaterina Agafonova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-089	Relationship of x-ray progression and MRI changes in the hip joints in patients with axial spondyloarthritis	Ekaterina Agafonova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-090	The difference in disease activity score and treatment response according to gender in patients with axial spondyloarthritis	Seulkee Lee (Sungkyunkwan Univ., Korea)
KP-091	Association between triglyceride-glucose index and carotid atherosclerosis in patients with psoriatic arthritis: A cross-sectional study	Wenhui Xie (Peking Univ. First Hosp., China)
KP-092	Complete remission of severe erythrodermic psoriasis with combination ixekizumab and abrocitinib therapy	Yoon Kam Hon (El Shaddai Arthritis & Rheumatism Specialist Medical Centre, Singapore)
KP-093	Effects of TNF inhibitors on lipid profile in ankylosing spondylitis patients	Inbeom Kwon (Hanyang Univ., Korea)
KP-094	Mortality in patients with psoriatic arthritis: A systematic review and meta-analysis	Hong Huang (Peking Univ. First Hosp., China)
KP-095	Value of low-dose computed tomography for examination of sacroiliac joints in axial spondyloarthritis	In Woon Baek (Ewha Womans Univ., Korea)
KP-096	Renal safety of long term NSAID use in patients with ankylosing spondylitis	Young-Eun Kim (Univ. of Ulsan, Korea)
KP-097	Subchondral insufficiency fracture of the Femoral head in a Patient with Ankylosing spondylitis: Case report and literature review	Yeo-Jin Lee (Asan Medical Center, Korea)
KP-098	Oral administration with DPP4 inhibitor ameliorates pathological bone formation in curdlan-injected SKG mice	Sungsin Jo (Hanyang Univ., Korea)
KP-099	Withdrawn	
KP-100	Usefulness of MRI in patients without findings of sacroiliitis on X-rays	Yeo-Jin Lee (Asan Medical Center, Korea)
KP-101	Factors associated with cause-specific discontinuation of the first line anti-tumor necrosis factor agent in ankylosing spondylitis	Bora Nam (Hanyang Univ., Korea)
KP-102	Knowledge of disease among Filipin patients with spondyloarthritis	Kenzle Denise Monsanto (Univ. of the Philippines, Philippines)
KP-103	Impact of disease activity on functional impairment in patients with spondyloarthritis is different according to the degree of radiographic progression : Result from SNUH-AS cohort	Jiin Jung (Seoul Nat'l Univ., Korea)
KP-104	A case of IgA nephropathy developed during secukinumab treatment in a patient with ankylosing spondylitis	Seoung Wan Nam (Wonju Severance Christian Hosp., Korea)
KP-105	HIV Induced Spondyloarthropathy (SpA): An autoimmune disease in immunodeficiency state	Johanda Damanik (Cipto Mangunkusumo Nat'l Hosp., Indonesia)
KP-204	Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis	Young In Eom (Lilly Korea Ltd., Korea)

Behçet's disease & Vasculitis		
No.	Title	Presenter
KP-106	IgA vasculitis as an initial presentation of HIV in a young Filipino male: A case report	Antonio Lorenzo Quiambao (East Avenue Medical Center, Philippines)
KP-107	Eosinophilic granulomatous polyangiitis (EGPA) presenting as superior vena cava (SVC) syndrome-like in a Filipino female patient: A case report	Ronald Ramirez (Valenzuela Medical Center, Philippines)
KP-108	Thoracic endovascular aneurysm repair in a patient with Behçet's disease and thoracic aneurysm: A case report	Ronald Ramirez (Valenzuela Medical Center, Philippines)
KP-109	Association between interleukin-1 gene polymorphisms and behcet's disease susceptibility : Systematic review and meta-analysis	Steven Irving (Universitas Sebelas Maret, Indonesia)
KP-110	Behçet's disease: Demographic, social, clinical manifestations and ongoing therapy in Kazakhstan	Almas Amir (Almaty City Rheumatology Center, Kazakhstan)
KP-111	Clinical characteristics and courses of Korean patients with giant cell arteritis : A multi-center retrospective study	Jeein Lee (Seoul Nat'l Univ., Korea)
KP-112	Polyarteritis nodosa: A Rare cause of severe abdominal pain in an elderly filipina	Goldee Meir Rosaurio (VSMC, Philippines)
KP-113	Systemic immune-inflammation index in Behçet's disease	Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-114	Neutrophil reactivity in Behçet's disease	Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-115	Inflammatory markers in Behçet's disease activity	Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-116	Neutrophil extracellular traps (NETs) in Behçet's disease	Tatiana Reshetnyak (Nasonova Research Institute of Rheumatology, Russian Federation)
KP-117	Haemostatic abnormalities in patients with Behçet's disease and antiphospholipid syndrome before anticoagulants treatment	Nataliya Seredavkina (Scientific Research Institute of Rheumatology named after V.A. Nasonova, Russian Federation)
KP-118	Eosinophilic granulomatosis with polyangiitis in a 56-year-old female presenting with hoarseness: A case report	Leandro Jose Dado (St. Luke's Medical Center, Philippines)
KP-119	Eosinophilic granulomatosis with polyangiitis in a patient with discoid lupus	Charysse Vergel de Dios (St. Luke's Medical Center, Philippines)
KP-120	Indian data on patients with Behçet's disease : Single centre experience	Sehaj Roop Kaur (AIIMS, India)
KP-121	An analysis of hospital discharge coding for Giant Cell Arteritis shows high proportion of patients meeting the rACR criteria, but one-third do not have GCA	Andrew Dermawan (Royal Perth Hosp., Australia)
KP-205	Acute transverse myelitis and leptomeningitis in an adolescent female: A dramatical presentation leading to neurobehcet's disease diagnosis	Rachid Smaili (Universitary Hosp. of Tangier, France)

Osteoporosis and metabolic bone diseases		
No.	Title	Presenter
KP-122	Association and correlation between bone mineral density and osteoporosis with blood pressure indices, hypertension and body mass index	Javad Alizargar (Nat'l Taipei Univ. of Nursing and Health Sciences, Taiwan)
KP-123	Bisphosphonates therapy for osteoporosis in women with breast cancer : A 6-year follow up	Rajaa Assadi (Hassan II Univ., Morocco)
KP-124	Poly medication and risk of falling	Rajaa Assadi (Hassan II Univ., Morocco)
KP-125	Correlation between vitamin D and falling: About 425 Moroccan patients	Rajaa Assadi (Hassan II Univ., Morocco)
KP-126	Falling and vitamin D status in osteoporotic patients	Rajaa Assadi (Hassan II Univ., Morocco)
KP-127	Biochemical evaluation of plant based diet and its preventive effects against osteoporosis and other bone related disorder	Muhammad Sajid Arshad (Government College Univ. Faisalaba, Pakistan)
KP-128	Variations in free vitamin D and vitamin D binding protein in patients with acute and chronic upper limb injuries	Ji Sup Hwang (Seoul Nat'l Univ., Korea)
KP-129	Case reports: Primary hypertrophic osteoarthropathy identified by gene mutation of slco2a1 in Vietnam	Trang Do Thi Huyen (Hanoi Medical Univ. Hosp., Vietnam)
KP-130	Genetic association between mild osteogenesis imperfecta(OI) and postmenopausal osteoporosis	Eiman Shahrour (Tishreen Univ., Syria)
KP-131	Coccydenia -A Covid era pain ailment and role of vitamin D	Suresh Gemawat (Madan Mohan Medical and Counselling Centre, India)
KP-132	Osteogenesis imperfecta, osteoporosis and rheumatoid arthritis in the era of biologic therapies. Do we have the right solutions?	Bogdan Ion Gavrilă (Univ. of Medicine and Pharmacy "Carol Davila", Romania)
KP-206	Withdrawn	

Fibromyalgia and soft tissue disorders		
No.	Title	Presenter
KP-133	Fibromyalgia and cataract: Friend or foe	Wei Syun Hu (China Medical Univ. Hosp., Taiwan)
KP-134	The impact of personality trait on the comorbidity of fibromyalgia in patients with rheumatoid arthritis	Ji Hyun Lee (Maryknoll General Hosp., Korea)
KP-135	Withdrawn	

Crystal induced arthropathies		
No.	Title	Presenter
KP-136	Febuxostat dose adjustment according to renal function to attain target serum urate level: A retrospective cohort study	Young Eun Kim (Univ. of Ulsan, Korea)
KP-137	Axial form of gout: Difficulties in differential diagnosis.	Ekaterina Agafonova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-138	The drug retention rates of urate-lowering agents in Korean patients with gout	Hye Jin Jeong (Keimyung Univ., Korea)
KP-139	The inverted J-shaped relationship between serum uric acid level and abdominal muscle mass in Korean male population: A single-center study of 5114 cases	Sungwon Ko (Univ. of Ulsan, Korea)
KP-140	Chronic tophaceous gout in an 70 year-old female presenting as posterior ankle impingement syndrome	Leandro Jose Dado (St. Luke's Medical Center, Philippines)

Pediatric rheumatology		
No.	Title	Presenter
KP-141	Juvenile gout in a Filipino male: A rare and aggressive disease	Eric Ranniel Guevarra (Univ. of Santo Tomas Hosp., Philippines)
KP-142	Withdrawn	
KP-143	Perception of multiple components towards an ideal model of transition care for autoimmune rheumatic patients in Cipto Mangunkusumo national general hospital (RSCM)	Cindy Oey (Univ. of Indonesia, Indonesia)
KP-144	Refractory juvenile takayasu arteritis managed sucessfully with adalimumab	Viknesh Raj (Coimbatore Medical College, India)
KP-207	Withdrawn	

Orthopedics & Rehabilitation		
No.	Title	Presenter
KP-145	Validation study of hand grip strength measured using jamar dynamometer and aneroid sphygmanometer as a diagnostic tool for sarcopenia	Eric Ranniel Guevarra (Univ. of Santo Tomas Hosp., Philippines)
KP-146	The effectiveness of exercise on physical performance for long covid symptoms in people with rheumatic conditions	Rachel Lai Chu Kwan (Tung Wah College, Hong Kong)
KP-147	Arthroscopic synovectomy due to untypical synovial chondromatosis performed to patient with diagnosed ankylosing spondylitis	Sergey Maglevaniy (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-148	Local complication after large joint of lower limb arthroplasty in patients with systemic lupus erythematosus.	Alexander Khramov (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-149	Correlation of activity of rheumatoid arthritis and infectious/wound complications after total hip and knee arthroplasty	Alexander Khramov (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-150	Arthroscopic wrist synovectomy in patients with rheumatoid arthritis : Short-term outcomes	Sergey Maglevaniy (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-151	Surgical treatment of tibialis posterior tendon disfunction in patients with rheumatoid arthritis	Alexey Rybnikov (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

Epidemiology & Public health		
No.	Title	Presenter
KP-152	Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF-inhibitor therapy	Sung Soo Ahn (Yonsei Univ., Korea)
KP-153	Comparisons of protective efficacy between Artemisia herba extract, proton pump inhibitor and rebapamide against non-steroidal anti-inflammatory drugs-induced gastrointestinal bleeding in patients with rheumatoid arthritis using HIRA database	Byung Wook Song (Pusan Nat'l Univ., Korea)
KP-154	Clinical features of the course of COVID-19 in patients with different rheumatic diseases	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-155	Hospitalization requirement and complications after COVID-19 in patients with rheumatic diseases	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-156	Disease flare-ups after SARS-COV -2 vaccination among patients with rheumatic and musculoskeletal diseases in a rheumatology specialized care center- Sri Lanka	Sasheela Ubhayasiri (Rheumatology and Rehabilitation Hosp. Ragama, Sri Lanka)
KP-157	Post covid syndrome in patients with various rheumatic diseases	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-158	Prevalence of myelodysplastic syndromes in patients with rheumatologic diseases : A retrospective cohort study	Young Eun Kim (Univ. of Ulsan, Korea)
KP-159	Reactivation of chronic viral hepatitis B: Frequency in patients with rheumatic diseases	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-160	Burden of osteoarthritis in China from 1990 to 2019 and predictions of the burden in future 25 years: Findings from the Global Burden of Disease Study 2019	Haowei Chen (Southern Medical Univ., China)
KP-161	Association between hyperuricemia and hearing impairment: Results from the Korean National Health and Nutrition Examination Survey	Hyemin Jeong (Soonchunhyang Univ., Korea)
KP-162	Prevalence and associated factors of atlantoaxial subluxation in patients with rheumatoid arthritis: A single-center retrospective study	Yeo-Jin Song (Hanyang Univ., Korea)
KP-163	COVID-19 outcomes in Korean patients with gout	Min Jung Kim (Seoul Nat'l Univ., Korea)
KP-164	Causes of death in rheumatic and musculoskeletal diseases in a nationwide registry	Mucong Li (Peking Union Medical College Hosp., China)
KP-165	Tobacco smoking reduces the risk of knee replacement surgery in knee osteoarthritis patients	Junyong Park (Dong-A Univ., Korea)
KP-166	Pregnancy outcomes associated with biologic agent exposure in patients with immune-mediated inflammatory diseases	Soo Min Ahn (Asan Medical Center, Korea)
KP-167	Screening and treatment of latent tuberculosis infection and incidence of active tuberculosis in patients with rheumatoid arthritis receiving targeted therapy	Jeong-Yeon Kim (Chung-Ang Univ., Korea)
KP-168	Women with metabolic syndrome and negative life style factors are at a higher risk for hyperuricemia compared to men	Seonyoung Kang (Sungkyunkwan Univ., Korea)
KP-169	Autoimmune diseases and their association with TYK2 polymorphisms : An updated meta-analysis	Farhana Sultana Mitu (SnifVac Limited, Hong Kong)
KP-170	Safety & immUnogenicity of COVID-19 vaCcines in systEmic immUnE mediated inflammatory Diseases (SUCCEED): Preliminary results	Sasha Bernatsky (Research Institute of the McGill Univ. Health Centre, Canada)
KP-171	Rate and causes of hesitancy in COVID-19 vaccination in Korean patients with autoimmune rheumatic diseases: A survey study	Byung Wook Song (Pusan Nat'l Univ., Korea)
KP-172	Analysis of the influence of socioeconomic factors, feeding rules and happiness on rheumatism sufferers	Putri Ayu (Andalas Univ., Indonesia)

Epidemiology & Public health		
No.	Title	Presenter
KP-173	A multi-country analysis of the uptake of anti-TNF biosimilars: Policies that matter	Aslam H. Anis (Providence Research, Canada)
KP-174	Better oral hygiene is associated with lower risk of late-onset ankylosing spondylitis : A nationwide cohort study	Min Kyung Chung (Ewha Womans Univ., Korea)
KP-175	Quality of life of rheumatic patients in Indonesia	Derizal Derizal (STP Trisakti, Indonesia)
KP-208	Utilization of community-based health centers (Puskesmas) to improve accessibility and early detection of health services for rheumatoid arthritis in older people	Lintong Hottua Simbolon (Alumnus of Univ. of Lampung, Indonesia)
KP-209	Myositis and Covid-19: A systematic review of case reports and series	Stephanie Palacios (West Visayas State Univ. Medical Center, Philippines)
KP-210	COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune rheumatic diseases: Results from the COVAD study	Sheila Marie Reyes (St. Luke's Medical Center, Philippines)
KP-211	Limbic encephalitis associated with severe Sars-CoV2 infection in a patient with autoimmune myositis	Rachid Smaili (Universitary Hosp. of Tangier, Morocco)

Innovative medical research		
No.	Title	Presenter
KP-176	Telerheumatology experience for a service department of a tertiary hospital : Rheum for improvement?	Lisa Traboco (St. Luke's Medical Center, Philippines)
KP-177	Early detection of osteoporosis based on machine learning using neuro-fuzzy system algorithm	Rifaldy Fajar (Univ. of LAquila, Italy)
KP-178	Using convolutional neural networks (CNN) to scoring hand joints on X-ray of patients with rheumatoid arthritis	Polina Postnikova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)

Miscellaneous rheumatic and inflammatory diseases		
No.	Title	Presenter
KP-179	Autoimmune reactions associated with various types of SARS-COV-2 vaccines among rheumatic disease patients: A case series	Vincent Luceño (Univ. of Santo Tomas Hosp., Philippines)
KP-180	Successful treatment of refractory thrombocytopenia with Rituximab plus Eltrombopag in a post-splenectomy lupus patient: A case report	Joy Buccat (Baguio General Hosp. and Medical Center, Philippines)
KP-181	Interspinous bursitis is not the origin of spinal pain in Polymyalgia rheumatica : A retrospective study of Sixty-two PMR patients in a single center	Yoonju Na (Samsung Medical Center, Korea)
KP-182	The correlation between total cholesterol level and serum uric acid level in the rats (Rattus norvegicus) after the intervention with quail egg yolks	Rafik Prabowo (Universitas Islam Indonesia, Indonesia)
KP-183	Post-COVID acute sarcoidosis-a case report	Subbarayudu Boda (NRI Institute of Medical Sciences, India)
KP-184	A case report of IgA vasculitis following coronavac vaccination in a Filipino patient	Ramar John Bangayan (East Avenue Medical Center, Philippines)
KP-185	Eosinophilic cellulitis (Wells syndrome) associated with mixed connective tissue disease	Yunkyoung Kim (Kosin Univ., Korea)
KP-186	Otologic manifestations among adults with autoimmune diseases at the Kenyatta national hospital	Paul Etau Ekwom (KNH, Kenya)
KP-187	New-onset retroperitoneal fibrosis following COVID-19 mRNA vaccination: Coincidental or vaccine-induced phenomenon?	Hirut Yadeta Ture (Kyungpook Nat'l Univ., Korea)
KP-188	The effect of social media on healthcare utilization and medical information acquisition in patients with rheumatic diseases who visited a tertiary hospital: A survey study	Dong-Hyuk Moon (Pusan Nat'l Univ., Korea)
KP-189	COVID-19 vaccination status and adverse events following SARS-COV-2 vaccine in autoimmune inflammatory rheumatic disease (AIRD) patients: A single center experience	Vincent Luceño (Univ. of Santo Tomas Hosp., Philippines)
KP-190	A first case report of Schnitzler syndrome presenting with acropachy	Xiaoying Sun (Peking Univ. First Hosp., China)
KP-191	Applying standard classification criteria excludes up to a half of all patients from connective tissue diseases (CTD) clinical trials	Ian Bruce (Manchester Univ. Hosp. NHS Foundation Trust, Manchester Academic Health Science Centre, UK)
KP-192	The role of ultrasound lung in rheumatic disease	Rushana Shayakhmetova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)
KP-193	A case of post Coronavirus Disease 2019 (COVID-19) Multisystem Inflammatory Syndrome in Adults (MIS-A) presenting as fever and seizures	Eloisa Trina Generoso (Makati Medical Center, Philippines)
KP-194	Description of a case of postcovid complications as a trigger for the onset of autoimmune diseases	Sairan Kozhakanova (Astana Medical Univ., Kazakhstan)
KP-195	An occurrence of immune-mediated necrotizing myopathy following treatment of polymyositis in a Filipino female: A case report	Patricia Danielle Cervantes (St. Luke's Medical Center, Philippines)
KP-196	Withdrawn	
KP-212	B cell subset characteristics in adult-onset Still's disease	Xiangyu Fang (Peking Univ. People's Hosp., China)

LUPUS & KCR 2023 Steering Committee

LUPUS

President	Sang-Cheol Bae (<i>Hanyang University</i>)
Secretary General	Seung-Cheol Shim (<i>Chungnam National University</i>)
Deputy Secretary General	Chan-Bum Choi (<i>Hanyang University</i>)
Scientific Committee Chair	Jisoo Lee (<i>Ewha Womans University</i>)
Scientific Committee Vice Chair	Chang-Hee Suh (<i>Ajou University</i>)

KCR

President	Sang-Cheol Bae (<i>Hanyang University</i>)
Chairman of the Board	Shin-Seok Lee (<i>Chonnam National University</i>)
Director of Planning	Hoon-Suk Cha (<i>Sungkyunkwan University</i>)
	Wan-Uk Kim (<i>The Catholic University of Korea</i>)
Director of General Affairs	Seung-Ki Kwok (<i>The Catholic University of Korea</i>)
Director of Finance	Yong-Beom Park (<i>Yonsei University</i>)
Director of Academic Affairs	Yoon-Kyoung Sung (<i>Hanyang University</i>)

LUPUS Organizing Committee

Local Organizing Committee

President	Secretary General
Sang-Cheol Bae (<i>Hanyang University</i>)	Seung-Cheol Shim (<i>Chungnam National University</i>)
Deputy Secretary General	Scientific Committee Chair
Chan-Bum Choi (<i>Hanyang University</i>)	Jisoo Lee (<i>Ewha Womans University</i>)
Scientific Committee Vice Chair	
Chang Hee Suh (<i>Ajou University</i>)	
Member	
Hoon-Suk Cha (<i>Sungkyunkwan University</i>)	Shin-Seok Lee (<i>Chonnam National University</i>)
Yeonseok Chung (<i>Seoul National University</i>)	Young Ho Lee (<i>Korea University</i>)
Seung Hyeok Han (<i>Yonsei University</i>)	Seonghoon Park (<i>Daegu Catholic University</i>)
Seung-ki Kwok (<i>The Catholic University of Korea</i>)	Sung Hwan Park (<i>The Catholic University of Korea</i>)
Chang-Keun Lee (<i>University of Ulsan</i>)	Yong-Beom Park (<i>Yonsei University</i>)
Hye-Soon Lee (<i>Hanyang University</i>)	Yoon-Kyoung Sung (<i>Hanyang University</i>)

Scientific Committee

Scientific Committee Chair	Scientific Committee Vice Chair
Jisoo Lee (<i>Ewha Womans University</i>)	Chang Hee Suh (<i>Ajou University</i>)
Basic	Clinical
Soyoung Bang (<i>Hanyang University</i>)	Sung Hae Chang (<i>Soonchunhyang University</i>)
Seokchan Hong (<i>University of Ulsan</i>)	Sangtae Choi (<i>Chung-Ang University</i>)
Ki-Jo Kim (<i>The Catholic University of Korea</i>)	Eun Ha Kang (<i>Seoul National University</i>)
Kwangwoo Kim (<i>Kyung Hee University</i>)	Geun-Tae Kim (<i>Kosin University</i>)
Seungki Kwok (<i>The Catholic University of Korea</i>)	Hae-Rim Kim (<i>Konkuk University</i>)
Youn-soo Choi (<i>Seoul National University</i>)	Yong-Gil Kim (<i>University of Ulsan</i>)
Yoontae Lee (<i>POSTECH</i>)	Jin Kyun Park (<i>Seoul National University</i>)
Su-Jin Moon (<i>The Catholic University of Korea</i>)	Seonghoon Park (<i>Daegu Catholic University</i>)
Yong-wook Park (<i>Chonnam National University</i>)	Yoon-Kyoung Sung (<i>Hanyang University</i>)

LUPUS Organizing Committee

International Organizing Committee	
No.	Affiliation
Olufemi Adelowo	Lagos State University Teaching Hospital, Nigeria
Tatsuya Atsumi	Hokkaido University, Japan
Sasha Bernatsky	Research Institute of the McGill University Health Centre, Canada
Marina Botto	Imperial College London, UK
Ian Bruce	The University of Manchester, UK
Tak Mao Chan	University of Hong Kong, Hong Kong
Nathalie Costedoat-Chalumeau	Cochin Hospital, France
Joe Craft	Yale University , USA
Lindsey Criswell	National Institutes of Health, USA
Mary Crow	Hospital for Special Surgery, USA
Yong Cui	China-Japan Friendship Hospital, China
Betty Diamond	The Feinstein Institutes for Medical Research, USA
Andrea Doria	University of Padua, Italy
Thomas Dörner	Charite Universitätsmedizin Berlin, Germany
John Esdaile	Arthritis Research Canada, The University of British Columbia, Canada
Paul Fortin	Université Laval, Canada
Richard Furie	Northwell Health, USA
Dafna Gladman	University of Toronto, Canada
Laniyati Hamijoyo	University of Padjadjaran, Indonesia
Masayoshi Harigai	Tokyo Women's Medical University, Japan
John Harley	Cincinnati Education and Research for Veterans Foundation, USA
Lothar Hennighausen	National Institutes of Health, USA
Wen-Nan Huang	Taichung Veterans General Hospital, Taiwan
David Isenberg	University College London, UK
Rangi Kandane-Rathnayake	Monash University, Australia
Mariana Kaplan	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH, USA
Munther Khamashta	Kings College London, UK
Uta Kitz	Rheumazentrum Ruhrgebiet, Germany
Chak-Sing Lau	University of Hong Kong, Hong Kong
Arnaud Laurent	Strasbourg University, France
Alexandra Legge	Dalhousie University, Canada
Mengtao Li	Peking Union Medical College Hospital, China
Matthew H Liang	Harvard Medical School, USA
Sung Sam Lim	Emory University, USA
Peter E. Lipsky	AMPEL BioSolutions, USA

LUPUS Organizing Committee

International Organizing Committee	
No.	Affiliation
Anselm Mak	National University of Singapore, Singapore
David McCann	Harvard University, USA
Joan Merrill	Oklahoma Medical Research Foundation, USA
Chandra Mohan	University of Houston, USA
Chi-Chiu Mok	Tuen Mun Hospital, Hong Kong
Eric Morand	Monash University, Australia
Sandra Navarra	University of Santo Tomas, Philippines
Mandana Nikpour	The University of Melbourne, Australia
Kenji Oku	Kitasato University, Japan
Michelle Petri	Johns Hopkins University, USA
Bernardo A. Pons-Estel	Regional Center for Autoimmune and Rheumatic Diseases, Argentina
Guillermo Pons-Estel	Centro Regional de Enfermedades Autoinmunes y Reumáticas, Argentina
Rosalind Ramsey-Goldman	Northwestern University, USA
Angelo Ravelli	IRCCS Istituto Giannina Gaslini, Italy
Boris Reizis	NYU Grossman School of Medicine, USA
Brad Rovin	The Ohio State University , USA
Ignacio Sanz	Emory University, USA
Matthias Schneider	Heinrich-Heine-Universität Düsseldorf, Germany
Nan Shen	Jiao Tong University, China
Yehuda Shoenfeld	Zabludowicz Center of Autoimmunity, Sheba Medical Center Israel, Israel
Koshiro Sonomoto	University of Occupational and Environmental Health, Japan
Teodora Staeva	Lupus Research Alliance, USA
Elisabet Svenungsson	Karolinska Institutet and Karolinska Univ. Hosp., Sweden
Tsutomu Takeuchi	Keio University, Japan
Lai Shan Tam	The Chinese University of Hong Kong, Hong Kong
Yoshiya Tanaka	University of Occupational and Environmental Health, Japan
Xinping Tian	Peking Union Medical College, China
Angela Tincani	ASST-Spedali Civili and University of Brescia, Italy
George Tsokos	Harvard Medical School, USA
Ronald Van Vollenhoven	Amsterdam UMC, Netherlands
Evelyne Vinet	McGill University Health Centre, Canada
Tim Vyse	King's College London, UK
Victoria Werth	University of Pennsylvania, USA
Pingting Yang	China Medical University,, China
Xiaofeng Zeng	Peking Union Medical College, China
Jiuliang Zhao	Peking Union Medical College, China

LUPUS Organizing Committee

Advisory Committee of Past Chairs

1st	Marvin J. Fritzler	Canada
	Eng M. Tan	USA
2nd	Pao-Hsii Feng †	Singapore
3rd	Graham R.V. Hughes	United Kingdom
4th	Yehuda Shoenfeld	Israel
5th	Donato Alarcon-Segovia †	Mexico
6th	Munther A. Khamashta	United Kingdom
7th	Robert G. Lahita	USA
8th	Shunle Chen †	China
9th	John M. Esdaile	Canada
10th	Bernardo A. Pons-Estel	Argentina
	Mary Carmen Amigo	Mexico
11th	Josef S. Smolen	Austria
12th	Eric F. Morand	Australia
13th	Lindsey A. Criswell	USA
14th	Andrea Doria	Italy

† Honorary member

KCR Organizing Committee

Organizing Committee

President Sang-Cheol Bae (<i>Hanyang University</i>)	Chairman of the Board of Directors Shin-Seok Lee (<i>Chonnam National University</i>)
Director of Planning Wan-Uk Kim (<i>The Catholic University of Korea</i>) Hoon-Suk Cha (<i>Sungkyunkwan University</i>)	Director of General Affairs Seung-Ki Kwok (<i>The Catholic University of Korea</i>)
Director of Finance Yong-Beom Park (<i>Yonsei University</i>)	Editor-in-Chief Seong-Kyu Kim (<i>Daegu Catholic University</i>)
Director of International Affairs Kichul Shin (<i>Seoul National University</i>)	Director of Health Insurance Bo Young Yoon (<i>Inje University</i>) Seung-Jae Hong (<i>Kyung Hee University</i>)
Director of Public Relations Myeung Su Lee (<i>Wonkwang University</i>)	Director of Education & Training Geun-Tae Kim (<i>Kosin University</i>)
Director of Research Yong-Gil Kim (<i>University of Ulsan</i>)	Director of Health Information Chan-Bum Choi (<i>Hanyang University</i>)
Director of Health Policy Chong-Hyeon Yoon (<i>The Catholic University of Korea</i>)	Director of Legislation & Ethics Sang-Hyon Kim (<i>Keimyung University</i>)
Director of Clinical Practice Guideline Eun Bong Lee (<i>Seoul National University</i>)	

Academic Affairs Committee

Director Yoon-Kyoung Sung (<i>Hanyang University</i>)	Executive Secretary Ki-Jo Kim (<i>The Catholic University of Korea</i>)
Member	
Joong Kyong Ahn (<i>Sungkyunkwan University</i>)	Seung-Geun Lee (<i>Pusan National University</i>)
Soo-Kyung Cho (<i>Hanyang University</i>)	Yeon-Ah Lee (<i>Kyung Hee University</i>)
Hyun Sik Gong (<i>Seoul National University</i>)	Hong Ki Min (<i>Konkuk University</i>)
Chan Hong Jeon (<i>Soonchunhyang University</i>)	Dong-Jin Park (<i>Chonnam National University</i>)
Hyoum-Ah Kim (<i>Ajou University</i>)	Jin Kyun Park (<i>Seoul National University</i>)
Jinhyun Kim (<i>Chungnam National University</i>)	Jung-Woo Rhim (<i>The Catholic University of Korea</i>)
Yong-Gil Kim (<i>University of Ulsan</i>)	Chang-Nam Son (<i>Eulji University</i>)
Oh Chan Kwon (<i>Yonsei University</i>)	

Diamond Sponsor



Platinum Sponsor



Gold Sponsor



Silver Sponsor



LUPUS & KCR 2023

The 15th International Congress on Systemic Lupus Erythematosus and
The 43rd KCR Annual Scientific Meeting & 17th International Symposium

Stairway to the End of the War

May 17 (Wed) - 20 (Sat), 2023 | Coex, Seoul, Korea





대한류마티스학회
Korean College of Rheumatology

Please contact the Secretariat of LUPUS & KCR 2023 if you have any further inquiry.
Please address all correspondence to :

Secretariat of LUPUS & KCR 2023

8F Geumcheok Tower, 460 Bongeunsa-ro, Gangnam-gu, Seoul, Korea
T. +82- 2-576-9945 | E. secretariat@lupus-kcr2023.org | info@kcr2023.com

Korean College of Rheumatology

Raemian Yongsan A Building 1917, 95 Hangang-daero, Yongsan-gu, Seoul, 04378, Korea
T. +82-2-794-2630 | F. +82-2-794- 2631
E. webmaster@rheum.or.kr